Page last updated: 2024-10-29

ifosfamide and Carcinoma, Epidermoid

ifosfamide has been researched along with Carcinoma, Epidermoid in 173 studies

Research Excerpts

Excerpt	Relevance	Reference
" A 49-year-old white male diagnosed with T3 N3 M0 Stage IIIB anal cancer was treated initially with surgical excision and adjuvant fluorouracil/cisplatin due unavailability of mitomycin."	7.81	Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab. ( Baxley, A; Khawandanah, M; Pant, S, 2015)
"Generalized and partial seizures with secondary generalization were observed during ifosfamide-mesna (IFO) treatment in a patient with lung epidermoid carcinoma."	7.69	[Epileptic seizures and treatment with ifosfamide-mesna]. ( Farisse, P; Somma-Mauvais, H; Viallat, JR, 1994)
"Fifty-three patients with inoperable non-small cell bronchial carcinoma were treated at four-weekly intervals with two cytostatic drugs, doxorubicin (50 mg/m2 on day 1) and ifosfamide (2000 mg/m2 on days 1-3)."	7.66	[Combined cytostatic chemotherapy of advanced non-small-cell bronchial carcinoma with doxorubicin and ifosfamide]. ( Göbel, D; Matthiessen, W; Stempinski, E; Thalmann, U, 1983)
"We have reported the results of a previous Phase II trial of two courses of neoadjuvant mitomycin (6 mg/m2), ifosfamide (3 g/m2) and cisplatin (50 mg/m2) (MIC) in squamous or anaplastic carcinoma of the oesophagus."	5.08	A phase II trial of four courses of preoperative chemotherapy in squamous or anaplastic carcinoma of the oesophagus. ( Cullen, MH; Darnton, SJ; Matthews, HR; McAleer, JA; McManus, KG; Steyn, RS, 1998)
" A 49-year-old white male diagnosed with T3 N3 M0 Stage IIIB anal cancer was treated initially with surgical excision and adjuvant fluorouracil/cisplatin due unavailability of mitomycin."	3.81	Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab. ( Baxley, A; Khawandanah, M; Pant, S, 2015)
"The stage-by-stage prognosis for cervical cancer patients has not improved in the past decades."	3.77	Neoadjuvant therapy for cervical cancer. ( Achterrath, W; Eiermann, W; Kuehnle, H; Meerpohl, HG, 1992)
" Three courses with cisplatin 75 mg/m(2), paclitaxel 175 mg/m(2) and ifosfamide 5 g/m(2) (epirubicin 80 mg/m(2) in adenocarcinoma) were followed by cold-knife conization and pelvic lymphadenectomy."	3.74	Neoadjuvant chemotherapy and conservative surgery for stage IB1 cervical cancer. ( Bonazzi, C; Chiari, S; Maneo, A; Mangioni, C, 2008)
"The multidrug resistance gene product P-glycoprotein (P-GP) was assessed immunohistochemically (by antibody JSB-1) in biopsy specimens from 27 oesophageal squamous carcinomas and 10 adenocarcinomas before treatment with mitomycin, ifosfamide and cisplatin (MIC)."	3.69	Lack of correlation of P-glycoprotein expression with response to MIC chemotherapy in oesophageal cancer. ( Darnton, SJ; Ferry, DR; Jenner, K; Matthews, HR; Steyn, RS, 1995)
"Generalized and partial seizures with secondary generalization were observed during ifosfamide-mesna (IFO) treatment in a patient with lung epidermoid carcinoma."	3.69	[Epileptic seizures and treatment with ifosfamide-mesna]. ( Farisse, P; Somma-Mauvais, H; Viallat, JR, 1994)
"Of 13 patients with adenocarcinoma treated with 5-fluorouracil, adriamycin, and mitomycin (FAM), nine showed minor histological changes compared with 14 control cases."	3.68	Histopathological findings in oesophageal carcinoma with and without preoperative chemotherapy. ( Allen, SM; Darnton, SJ; Edwards, CW; Matthews, HR, 1993)
"Fifty-three patients with inoperable non-small cell bronchial carcinoma were treated at four-weekly intervals with two cytostatic drugs, doxorubicin (50 mg/m2 on day 1) and ifosfamide (2000 mg/m2 on days 1-3)."	3.66	[Combined cytostatic chemotherapy of advanced non-small-cell bronchial carcinoma with doxorubicin and ifosfamide]. ( Göbel, D; Matthiessen, W; Stempinski, E; Thalmann, U, 1983)
"Men with penile squamous cell carcinoma and regional lymph node involvement have a low probability of survival with lymphadenectomy alone."	2.75	Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. ( Daliani, D; Kincaid, M; Osai, W; Pagliaro, LC; Pettaway, CA; Thall, PF; Wen, S; Williams, DL; Williams, MB, 2010)
"Grade 3/4 neutropenia was observed in 21 % of patients and grade 3/4 febrile neutropenia was seen in only one patient."	2.73	Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma. ( Ahn, JS; Ahn, MJ; Hwang, IG; Im, YH; Kang, WK; Lee, SC; Lim, HY; Park, BB; Park, K, 2008)
"Ifosfamide is an active alkylating agent used in the first-line treatment of NSCLC."	2.71	Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel. ( Chen, MC; Chen, YM; Lee, CS; Lin, WC; Perng, RP; Shih, JF; Tsai, CM, 2003)
" Haematological toxicity and dosage reductions were higher with SuperMIP, which was nevertheless associated with a significantly increased absolute dose intensity."	2.71	A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer. ( Berghmans, T; Corhay, JL; Efremidis, A; Giner, V; Koumakis, G; Lafitte, JJ; Lecomte, J; Lothaire, P; Mommen, P; Ninane, V; Paesmans, M; Richez, M; Sculier, JP; Thiriaux, J; Van Houtte, P; Wackenier, P, 2004)
"Twelve patients in stage IIIB cervical cancer were submitted to NAC and 12 (control group)--received standart pelvic radiation to whole pelvis--52 Gy."	2.71	[Effect of neoadjuvant chemotherapy in the treatment of patients with stage IIIB cervical cancer]. ( Gorchev, G; Kornovski, Ia, 2003)
"All of the patients had biopsy-proven squamous cell carcinoma of the uterine cervix."	2.71	Retrospective analysis of concurrent chemoradiation with the combination of bleomycin, ifosfamide and cisplatin (BIP) for uterine cervical cancer. ( Abe, Y; Aida, T; Akahira, J; Aoki, M; Ito, K; Katahira, A; Kitamura, T; Niikura, H; Okamura, C; Okamura, K; Otsuki, K; Saito, S; Sato, N; Takano, T; Utsunomiya, H; Yaegashi, N, 2004)
"Megestrol acetate 250 mg PO was administered throughout the duration of chemotherapy."	2.69	A brief intensive cisplatin-based outpatient chemotherapy regimen with filgrastim and megestrol acetate support for advanced non-small cell lung cancer: results of a phase II trial. ( Craffey, M; Dowlati, A; Levitan, N; MacKay, W; McKenney, J; Remick, SC; Tahsildar, H, 1998)
"Ifosfamide was given initially to 12 patients in combination with standard fixed doses of cisplatin and 5-fluorouracil, at 1,000 mg/m2 daily on days 2, 3, and 4."	2.69	Phase II clinical trial of cisplatin, 5-fluorouracil, and ifosfamide as treatment for advanced locoregional head and neck carcinoma. ( Abad, T; Alvárez, I; Churruca, C; Egana, L; Guimón, E; Lacasta, A; López de Argumedo, G; Paredes, A; Piera, JM; Sánchez Parra, M, 1999)
"A preliminary co-operative study by 7 institutes was conducted to determine the optimal dosage of the combination regimen with nedaplatin, bleomycin and ifosfamide, which is used in a phase III clinical study, to investigate its efficacy as neoadjuvant chemotherapy against advanced cervical cancer of the uterus."	2.68	[Combination chemotherapy with nedaplatin, bleomycin and ifosfamide for advanced cervical cancer of the uterus--a preliminary study for phase III clinical study]. ( Hatae, M; Hirabayashi, K; Kanazawa, K; Noda, K; Ozaki, M; Terashima, Y; Yakushiji, M, 1997)
"All patients were required to have squamous cell carcinoma of the head and neck that had recurred following surgery or radiotherapy or both."	2.68	A phase II study of ifosfamide in recurrent squamous cell carcinoma of the head and neck. ( Benner, SE; Dimery, IW; Dunnington, JS; Hong, WK; Huber, MH; Lippman, SM; Shirinian, M, 1996)
"Granulocytopenia was the dose-limiting toxicity."	2.68	Phase I study of paclitaxel, cisplatin, and ifosfamide in patients with recurrent or metastatic squamous cell cancer of the head and neck. ( Benner, SE; Hong, WK; Huber, MH; Lippman, SM, 1995)
"The early stages of bronchial carcinoma are still a domain of operative treatment."	2.68	[Neoadjuvant radiochemotherapy in locally advanced non-small cell bronchial carcinoma. Initial results of a prospective multicenter study]. ( Klinke, F; Micke, O; Rübe, C; von Eiff, M; Wagner, W; Willich, N, 1995)
"Thirty patients with advanced squamous cell carcinoma of the cervix were included in a phase II study with cisplatin (DDP) and ifosfamide (IF)/mesna."	2.68	Cisplatin and ifosfamide in patients with advanced squamous cell carcinoma of the uterine cervix. A phase II trial. ( Araujo, CE; Cervellino, JC; Miles, H; Nishihama, A; Sánchez, O, 1995)
"A total of 37 men with epidermoid head and neck cancer whose disease had recurred following primary treatment (surgery and/or radiotherapy) received first-line chemotherapy with ifosfamide at i."	2.67	Ifosfamide in advanced epidermoid head and neck cancer. ( Almenarez, J; Casado, A; Diaz-Rubio, E; Dominguez, S; González Larriba, JL; López-Vega, JM; Martín, M; Sastre, J, 1993)
"Neo-adjuvant therapy with MIC in squamous carcinoma of the oesophagus has shown encouraging early results, with acceptable toxicity."	2.67	A phase II study of mitomycin, ifosfamide and cisplatin in operable and inoperable squamous cell carcinoma of the oesophagus. ( Allen, SM; Cullen, MH; Darnton, SJ; Duffy, JP; Matthews, HR; Walker, SJ, 1994)
"Ifosfamide/mesna has activity in a wide range of gynecologic malignancies."	2.67	Gynecologic Oncology Group experience with ifosfamide. ( Berman, ML; Blessing, JA; Homesley, HD; Photopulos, G; Sutton, GP, 1990)
" The major dose-limiting toxic effect of CIA was leukopenia."	2.64	Protection against chemotherapy toxicity by IV hyperalimentation. ( Bodey, GP; Copeland, EW; Dudrick, SJ; Freireich, EJ; Issell, BF; Valdivieso, M; Zaren, HA, 1978)
"Ifosfamide (IFO) has demonstrated activity in recurrent/metastatic squamous cell head and neck carcinoma with an overall response rate of 24-26%."	2.42	Ifosfamide in the treatment of head and neck cancer. ( Airoldi, M; Bumma, C; Cortesina, G; Giordano, C; Pedani, F, 2003)
"Patients with advanced squamous cell head and neck cancer have a dismal long-term survival rate not only because of metastatic disease, but also primarily because of failure in local disease control."	2.41	Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions. ( Glisson, BS; Hong, WK; Khuri, FR; Lippman, SM; Shin, DM, 2000)
"Paclitaxel has been tested with interesting results in cervical cancer."	2.41	Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza. ( Fei, F; Mangioni, C; Zanetta, G, 2000)
" The Eastern Cooperative Oncology Group is currently evaluating high-dose (200 mg/m2) and low-dose (135 mg/m2) paclitaxel in combination with cisplatin to assess dose-response effects, toxicity, and efficacy."	2.39	Single-agent paclitaxel and paclitaxel plus ifosfamide in the treatment of head and neck cancer. ( Forastiere, AA; Urba, SG, 1995)
"We report a case of metastatic penile cancer refractory to TIP chemotherapy, with a dramatic treatment response to ipilimumab and nivolumab."	1.62	Metastatic penile squamous cell carcinoma with dramatic response to combined checkpoint blockade with ipilimumab and nivolumab. ( Baweja, A; Mar, N, 2021)
" In this study, we adjusted the dosage of the triplet regimen and introduced carboplatin in cisplatin-intolerable patients."	1.48	Response to Combination Chemotherapy With Paclitaxel/Ifosfamide/Platinum Versus Paclitaxel/Platinum for Patients With Metastatic, Recurrent, or Persistent Carcinoma of the Uterine Cervix: A Retrospective Analysis. ( Bae, DS; Choi, CH; Choi, HJ; Kim, BG; Kim, TJ; Lee, JW; Lee, YY; Paik, ES, 2018)
"Locally advanced cervical cancer (LACC) is one of the leading health problems of the developing countries."	1.42	Long follow-up of patients with locally advanced cervical cancer treated with concomitant chemobrachyradiotherapy with cisplatin and ifosfamide followed by consolidation chemotherapy. ( Boraska Jelavić, T; Hamm, W; Hrepić, D; Petrić Miše, B; Prskalo, T; Strikic, A; Tomić, K; Tomić, S; Vrdoljak, E, 2015)
"Standard treatment of cervical cancer FIGO stage IB1 is a radical hysterectomy with pelvic lymphadenectomy."	1.42	Neoadjuvant chemotherapy followed by large cone resection as fertility-sparing therapy in stage IB cervical cancer. ( Leunen, K; Moerman, P; Neven, P; Salihi, R; Van Limbergen, E; Vergote, I, 2015)
"Standard chemotherapy for advanced penile cancer has not been established because of its rarity."	1.42	[Dramatic response of penile cancer with inguinal lymph node metastases to neoadjuvant chemotherapy with paclitaxel, ifosfamide and cisplatin : a case report]. ( Arakawa, H; Deguchi, T; Horie, K; Kato, H; Kubota, Y; Matsuoka, K; Nagai, S; Nakano, M, 2015)
"Downstaging by NAC in IB1 and IB2 cervical cancer before fertility-sparing surgery is still an experimental procedure, but shows some promise."	1.40	Oncological and pregnancy outcomes after high-dose density neoadjuvant chemotherapy and fertility-sparing surgery in cervical cancer. ( Halaska, MJ; Lisy, J; Matecha, J; Pluta, M; Rob, L; Robova, H; Skapa, P, 2014)
"The management of advanced cervical cancer is challenging."	1.40	Robotic radical hysterectomy following neoadjuvant chemotherapy in FIGO stage IIIB cervical cancer: a case report. ( Siesto, G; Vitobello, D, 2014)
" Our patient was subsequently enrolled on a phase 1 clinical trial of a novel, orally bioavailable bromodomain and extra terminal inhibitor, GSK525762 (NCT01587703)."	1.39	NUT midline carcinoma: an aggressive intrathoracic neoplasm. ( Costello, BA; Dronca, RS; French, CA; Hilton, J; Marks, RS; Molina, JR; Nerby, CL; Parikh, SA; Peddareddigari, VG; Roden, AC; Shapiro, GI, 2013)
"The role of chemotherapy (CHX) in squamous cell carcinoma of the head and neck (SCCHN) has been expanding."	1.38	The anti-tumour effect of cisplatin and ifosfamide on xenografted squamous cell carcinoma of the head and neck is schedule-dependent. ( Ekblad, L; Kjellén, E; Mineta, H; Sasaki, Y; Wahlberg, P; Wennerberg, J, 2012)
"Pure primary squamous cell carcinoma (SCC) of the breast is rare and difficult to treat."	1.35	Primary squamous cell carcinoma of the breast: achieving long-term control with cisplatin-based chemotherapy. ( Bhatt, L; Fernando, I, 2009)
"In 20."	1.35	A retrospective study of patients with locally advanced cancer of the cervix treated with neoadjuvant chemotherapy followed by radical surgery. ( Doval, DC; Kumar, JV; Rao, R; Rawal, S, 2009)
"For patients with stage II to IV laryngeal cancer, radiation therapy (RT) either alone or with concurrent chemotherapy provides the highest rate of organ preservation but can be associated with functional impairment."	1.35	Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. ( Ark, N; Diaz, EM; El-Naggar, AK; Garden, AS; Gillenwater, AM; Ginsberg, LE; Glisson, BS; Holsinger, FC; Khuri, FR; Ki Hong, W; Kies, MS; Lee, JJ; Lewin, JS; Lin, HY; Shin, DM, 2009)
"The prognosis of recurrent metastatic cervical cancer is extremely poor."	1.34	Unexpected long-term survival without evidence of disease after salvage chemotherapy for recurrent metastatic cervical cancer: a case series. ( Abu-Rustum, NR; Aghajanian, C; Bowes, RJ; Jhamb, N; Khoury-Collado, F, 2007)
"Human-derived head-and-neck squamous cell carcinoma xenografts (implanted in nude mice/nine groups of 10 mice) were treated with various treatment modalities and combinations of them (radiation with 5 x 2 or 10 x 2 Gy, hyperthermia at 41 degrees C or 41."	1.31	Tumor oxygenation after radiotherapy, chemotherapy, and/or hyperthermia predicts tumor free survival. ( Feyerabend, T; Ressel, A; Weiss, C, 2001)
"43 patients with Stage IV squamous cell carcinoma of the head and neck have been treated neoadjuvantly with two cycles chemotherapy (ifosfamide 1."	1.31	[The value of qualitative regression grading as a prognostic factor for survival after preoperative radiochemotherapy in patients with advanced head and neck cancer]. ( Christoph, B; Esser, E; Hartlapp, J; Hermann, RM; Krech, R; Müller, MK; Wagner, W, 2001)
"The response rate was higher in squamous cell carcinomas (85%) than adenocarcinomas or adenosquamous carcinomas (67%)."	1.30	[Neoadjuvant chemotherapy for advanced cervical cancer]. ( Hongo, A; Ikuhashi, H; Kobashi, Y; Kodama, J; Kudo, T; Miyagi, Y; Mizutani, Y; Okuda, H; Yoshinouchi, M, 1999)
"Seven oesophageal squamous carcinomas, treated with pre-operative chemotherapy (mitomycin-C, ifosfamide and cisplatin-MIC), with a course finishing 21 days prior to resection, were examined by electronmicroscopy."	1.29	Effects of chemotherapy on ultrastructure of oesophageal squamous cell carcinoma. ( Antonakopoulos, GN; Darnton, SJ; Duffy, JP; Matthews, HR; Newman, J, 1994)
"Ifosfamide (IFX) has activity in a number of gynaecological malignancies and was selected for evaluation in this disease."	1.28	A phase II study of ifosfamide in endometrial cancer. ( Barton, C; Blackledge, G; Buxton, EJ; Meanwell, CA; Mould, JJ, 1990)
"Ifosfamide has shown promising single-agent activity in non-small cell lung cancer (NSCLC)."	1.28	Phase II study of cisplatin, ifosfamide with mesna, and etoposide (PIE) chemotherapy for advanced non-small cell lung cancer. ( Dhingra, HH; Greenberg, J; Hong, WK; Lee, JS; Shirinian, M, 1992)
"The authors report a case of pulmonary squamous cell carcinoma which occurred after chemotherapy of non-Hodgkin's lymphoma (NHL)."	1.28	[Elderly non-Hodgkin's lymphoma presenting with pulmonary squamous cell carcinoma as a complication of chemotherapy for malignant lymphoma]. ( Annoh, S; Arai, N; Kaneko, H; Shirai, T; Tsukahara, T; Umeda, M, 1992)
"Thirty-one patients with inoperable squamous cell carcinoma of the lung were treated with a combination of cis-platin (CDDP, 100 mg/m2 day 1), ifosfamide (IFX, 2 g/m2 day 1, 2, 3; with mesna) and vindesine (VDS, 3 mg/m2 day 1)."	1.28	[Cisplatin, ifosfamide and vindesine in the chemotherapy of squamous cell carcinoma of the lung]. ( Asakawa, M; Fujita, A; Honda, R; Inoue, Y; Nakajima, S; Sasaki, H; Sekine, K; Suzuki, A, 1991)
"Survival in patients with advanced cervical cancer (stage III B) treated by radical radiotherapy is low."	1.28	Cisplatin-ifosfamide as neoadjuvant chemotherapy in stage IIIB cervical uterine squamous-cell carcinoma. ( Garcia-Puche, JL; Lara, PC; Pedraza, V, 1990)
"The tumors included 5 squamous cell carcinomas (non keratinizing: 2, keratinizing: 3), two adenosquamous (including one glassy cell carcinoma), one adenocarcinoma (endometrioid type) and one argyrophil cell carcinoma."	1.28	Ifosfamide, adriamycin and cisplatin (IAP) plus bleomycin (B) combination chemotherapy in patients with recurrent cancer of the uterine cervix. ( Arimatsu, T; Izumi, S; Matsumura, T; Nagano, H; Nagasue, N; Nishida, T; Okura, N; Yakushiji, M, 1989)
"Thirty patients with advanced squamous carcinoma of the uterine cervix recurrent after radiotherapy or surgery and refractory to first-line chemotherapeutic agents were treated with ifosfamide in a dose of 1."	1.28	Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix. A Gynecologic Oncology Group study. ( Adcock, L; Blessing, JA; DeEulis, T; Sutton, GP; Webster, KD, 1989)
"Ifosfamide/mesna has activity in a wide range of gynecologic malignancies."	1.28	Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies. ( Berman, ML; Blessing, JA; Homesley, HD; Photopulos, G; Sutton, GP, 1989)
"The course of 72 patients (36 with squamous carcinoma, 25 with adenocarcinoma, two with alveolar-cell carcinoma and nine with large-cell carcinoma) could be evaluated."	1.27	[Chemotherapy of the non-small cell carcinoma of the lung with ifosfamide and cisplatin]. ( Abel, U; Dirks, HP; Drings, P; Grimm, V; Heinrich, S; Kleckow, M; Manke, HG; Queisser, W; Stiefel, P, 1984)
" Bone marrow suppression was the dose-limiting toxicity and led to dosage modification in 24 patients."	1.27	A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix. ( Coleman, RE; Gallagher, C; Harper, PG; Osborne, R; Rankin, EM; Silverstone, AC; Slevin, ML; Souhami, RL; Tobias, JS; Trask, CW, 1986)
"The most frequent histology was squamous cell carcinoma found in 20 patients."	1.27	[Chemotherapy with mitomycin C, vindesine and ifosfamide in the treatment of inoperable non-small cell bronchial carcinoma]. ( Gatzemeier, U; Hossfeld, DK; Radenbach, D; Zschaber, R, 1985)
"The etoposide combination was tolerated better."	1.27	Experience with ifosfamide combinations (etoposide or DDP) in non-small cell lung cancer. ( Abel, U; Bülzebruck, H; Drings, P; Kleckow, M; Manke, HG; Stiefel, P, 1986)
"Ifosfamide has minimal activity in esophageal cancer and causes severe myelosuppression."	1.27	Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpectant severe toxicity. ( Eisenberger, M; Kelsen, DP; Lipperman, R; Nanus, DM, 1988)
"Ifosfamide was administered to 21 patients with recurrent or disseminated lung cancer at a dose of 4."	1.26	Ifosfamide in the treatment of recurrent or disseminated lung cancer: a phase II study of two dose schedules. ( Costanzi, JJ; Gagliano, R; Hokanson, JA; Loukas, D; Panettiere, FJ, 1978)

Research

Studies (173)

Timeframe	Studies, this research(%)	All Research%
pre-1990	36 (20.81)	18.7374
1990's	58 (33.53)	18.2507
2000's	47 (27.17)	29.6817
2010's	31 (17.92)	24.3611
2020's	1 (0.58)	2.80

Authors

Authors	Studies
Baweja, A	1
Mar, N	1
Karageorgopoulou, S	1
Kostakis, ID	1
Gazouli, M	1
Markaki, S	1
Papadimitriou, M	1
Bournakis, E	1
Dimopoulos, MA	2
Papadimitriou, CA	1
Choi, HJ	1
Paik, ES	1
Choi, CH	1
Kim, TJ	1
Lee, YY	1
Lee, JW	1
Bae, DS	1
Kim, BG	1
Xu, J	1
Li, G	1
Zhu, SM	1
Cai, QL	1
Wang, Z	1
Yang, X	2
Zhang, HT	1
Niu, YJ	1
Pinkavova, I	1
Fischerova, D	1
Zikan, M	1
Burgetova, A	1
Slama, J	1
Svarovsky, J	1
Dundr, P	1
Dusek, L	1
Cibula, D	1
Siesto, G	2
Vitobello, D	2
Ozdemir, O	1
Ozdemir, P	1
Veral, A	1
Uluer, H	1
Ozhan, MH	1
Ma, K	1
Yang, YH	1
Feng, ZY	1
Liu, TY	1
Wen, HW	1
Liao, QP	1
Parikh, SA	1
French, CA	1
Costello, BA	1
Marks, RS	1
Dronca, RS	1
Nerby, CL	1
Roden, AC	1
Peddareddigari, VG	1
Hilton, J	1
Shapiro, GI	1
Molina, JR	1
Vizza, E	1
Corrado, G	1
Zanagnolo, V	2
Tomaselli, T	1
Cutillo, G	1
Mancini, E	1
Maggioni, A	2
Khawandanah, M	1
Baxley, A	1
Pant, S	1
Robova, H	1
Halaska, MJ	1
Pluta, M	1
Skapa, P	1
Matecha, J	1
Lisy, J	1
Rob, L	1
Petrić Miše, B	1
Boraska Jelavić, T	1
Strikic, A	1
Hrepić, D	1
Tomić, K	1
Hamm, W	3
Tomić, S	1
Prskalo, T	3
Vrdoljak, E	3
Kubota, Y	1
Nakano, M	1
Nagai, S	1
Matsuoka, K	1
Arakawa, H	1
Horie, K	1
Deguchi, T	1
Kato, H	1
Scandurra, G	1
Scibilia, G	1
Banna, GL	1
D'Agate, G	1
Lipari, H	1
Gieri, S	1
Scollo, P	2
Gakis, G	1
Morgan, TM	1
Daneshmand, S	1
Keegan, KA	1
Todenhöfer, T	1
Mischinger, J	1
Schubert, T	1
Zaid, HB	1
Hrbacek, J	1
Ali-El-Dein, B	1
Clayman, RH	1
Galland, S	1
Olugbade, K	1
Rink, M	1
Fritsche, HM	1
Burger, M	1
Chang, SS	1
Babjuk, M	1
Thalmann, GN	1
Stenzl, A	1
Efstathiou, JA	1
Salihi, R	1
Leunen, K	1
Van Limbergen, E	1
Moerman, P	1
Neven, P	1
Vergote, I	1
Zwenger, AO	1
Grosman, G	1
Iturbe, J	1
Leone, J	1
Vallejo, CT	2
Leone, JP	1
Verdera, PP	1
Pérez, JE	2
Leone, BA	2
Minig, L	1
Cárdenas-Rebollo, JM	1
Colombo, N	5
Hancock, SB	1
Krempl, GA	1
Canfield, V	1
Bogardus, C	1
Kojouri, K	1
Kaneaster, SK	1
Medina, JE	1
Rivera, F	1
Eugenia Vega-Villegas, M	1
López, C	1
Francisca López-Brea, M	1
Rubio, A	1
Del Valle, A	1
García-Reija, F	1
García-Montesinos, B	1
Rodríguez-Iglesias, J	1
Hinojo, C	1
Márquez, R	1
Angel Alonso-Bermejo, M	1
Salcedo, M	1
Blanco, Y	1
Vega, N	1
López-Tarruella, S	1
Sanz-Ortiz, J	1
Maneo, A	1
Chiari, S	2
Bonazzi, C	1
Mangioni, C	4
Lissoni, AA	1
Pellegrino, A	2
Parma, G	2
Zola, P	2
Katsaros, D	2
Buda, A	2
Landoni, F	2
Peiretti, M	1
Dell'anna, T	1
Fruscio, R	1
Signorelli, M	1
Grassi, R	1
Floriani, I	2
Fossati, R	2
Torri, V	2
Rulli, E	1
Holsinger, FC	1
Kies, MS	2
Diaz, EM	1
Gillenwater, AM	2
Lewin, JS	1
Ginsberg, LE	1
Glisson, BS	7
Garden, AS	1
Ark, N	1
Lin, HY	1
Lee, JJ	3
El-Naggar, AK	2
Ki Hong, W	1
Shin, DM	9
Khuri, FR	8
Kumar, JV	1
Doval, DC	1
Rao, R	1
Rawal, S	1
Bhatt, L	1
Fernando, I	1
Saba, NF	1
Choi, M	1
Muller, S	1
Shin, HJ	1
Tighiouart, M	1
Papadimitrakopoulou, VA	1
Chen, ZG	1
Specenier, PM	1
Van Den Brande, J	1
Schrijvers, D	1
Huizing, MT	1
Altintas, S	1
Dyck, J	1
Van Den Weyngaert, D	1
Van Laer, C	1
Vermorken, JB	1
Pagliaro, LC	1
Williams, DL	1
Daliani, D	1
Williams, MB	1
Osai, W	1
Kincaid, M	1
Wen, S	1
Thall, PF	1
Pettaway, CA	1
Downs, LS	1
Chura, JC	1
Argenta, PA	1
Judson, PL	1
Ghebre, R	1
Geller, MA	1
Carson, LF	1
Huang, YC	1
Chang, PM	1
Chen, MH	1
Chu, PY	1
Tzeng, CH	1
Chang, SY	1
Yang, MH	1
Zheng, M	1
Huang, L	1
Liu, JH	1
Xiong, Y	1
Li, JD	1
Huang, X	1
He, L	1
Ren, YF	1
Wang, HY	1
Wang, Y	1
Wang, G	1
Wei, LH	1
Huang, LH	1
Wang, JL	1
Wang, SJ	1
Li, XP	1
Shen, DH	1
Bao, DM	1
Gao, J	1
Sasaki, Y	1
Kjellén, E	1
Ekblad, L	1
Wahlberg, P	1
Mineta, H	1
Wennerberg, J	1
Gong, L	1
Lou, JY	1
Wang, P	1
Zhang, JW	1
Liu, H	1
Peng, ZL	1
Wang, PL	1
Cheng, YB	1
Kuerban, G	1
Hasegawa, K	1
Okamoto, H	1
Kawamura, K	1
Kato, R	1
Kobayashi, Y	1
Sekiya, T	1
Udagawa, Y	1
Vercellino, GF	1
Piek, JM	1
Schneider, A	1
Köhler, C	1
Mangler, M	1
Speiser, D	1
Chiantera, V	1
Mouillet, G	1
Monnet, E	1
Milleron, B	1
Puyraveau, M	1
Quoix, E	1
David, P	1
Ducoloné, A	1
Molinier, O	1
Zalcman, G	1
Depierre, A	1
Westeel, V	1
Dede, DS	1
Aksoy, S	1
Cengiz, M	1
Gullu, I	1
Altundag, K	1
Pirovano, C	1
Ieda, N	1
Lippman, SM	8
Ginsberg, L	4
Diaz, E	1
Papadimitrakopoulou, V	2
Feng, L	1
Francisco, M	1
Garden, A	1
Myers, J	1
Clayman, G	2
Hong, WK	9
Gebbia, V	1
Galetta, D	1
Caruso, M	1
Verderame, F	1
Pezzella, G	1
Valdesi, M	1
Borsellino, N	1
Pandolfo, G	1
Durini, E	1
Rinaldi, M	1
Loizzi, M	1
Gebbia, N	1
Valenza, R	1
Tirrito, ML	1
Varvara, F	1
Colucci, G	1
Chen, YM	1
Shih, JF	1
Lee, CS	1
Chen, MC	1
Lin, WC	2
Tsai, CM	2
Perng, RP	2
Haddad, R	1
Posner, M	1
Fujita, A	3
Ohkubo, T	1
Hoshino, H	1
Takabatake, H	1
Tagaki, S	1
Sekine, K	2
Abe, S	1
Darnton, SJ	6
Archer, VR	1
Stocken, DD	1
Mulholland, PJ	1
Casson, AG	1
Ferry, DR	2
Airoldi, M	1
Cortesina, G	1
Giordano, C	1
Pedani, F	1
Bumma, C	1
Cavaletti, G	1
Bogliun, G	1
Marzorati, L	1
Zincone, A	1
Piatti, M	1
Lissoni, A	3
Fei, F	3
Cundari, S	1
Zanna, C	1
Sculier, JP	1
Lafitte, JJ	1
Berghmans, T	1
Van Houtte, P	1
Lecomte, J	1
Thiriaux, J	1
Efremidis, A	1
Koumakis, G	1
Giner, V	1
Richez, M	1
Corhay, JL	1
Wackenier, P	1
Lothaire, P	1
Paesmans, M	1
Mommen, P	1
Ninane, V	1
Omrcen, T	2
Gorchev, G	1
Kornovski, Ia	1
Aoki, M	1
Akahira, J	1
Niikura, H	1
Saito, S	1
Abe, Y	1
Aida, T	1
Sato, N	1
Kitamura, T	1
Otsuki, K	1
Katahira, A	1
Utsunomiya, H	1
Okamura, C	1
Takano, T	1
Ito, K	1
Okamura, K	1
Yaegashi, N	1
Watanabe, A	1
Taniguchi, M	1
Rapidis, AD	1
Gakiopoulou, H	1
Stavrianos, SD	1
Vilos, GA	1
Faratzis, G	1
Douzinas, EE	1
Givalos, N	1
Patsouris, E	1
Situm, K	1
Boraska, T	1
Frleta Ilić, N	1
Janković, S	1
Kato, D	1
Achiwa, H	1
Sato, S	1
Bessho, Y	1
Shimizu, S	1
Hattori, N	1
Maeda, H	1
Niimi, T	1
Oguri, T	1
Ueda, R	1
Gueli Alletti, D	1
Malzoni, C	1
Sartori, E	1
Duck, L	1
Devogelaer, JP	1
Persu, A	1
Berlière, M	1
Caussin, E	1
Baurain, JF	1
Machiels, JP	1
Mizuno, K	1
Kidokoro, K	1
Miyazaki, K	1
Yoshida, K	1
Nakagawa, A	1
Mizuno, M	1
Suzuki, S	1
Kuno, N	1
Furuhashi, M	1
Ishizuka, T	1
Ishikawa, K	1
Boutemy, M	1
Mispelaere, D	1
Krzisch, C	1
Jounieaux, V	1
Galsky, MD	1
Iasonos, A	1
Mironov, S	1
Scattergood, J	1
Donat, SM	1
Bochner, BH	1
Herr, HW	1
Russo, P	1
Boyle, MG	1
Bajorin, DF	1
Khoury-Collado, F	1
Bowes, RJ	1
Jhamb, N	1
Aghajanian, C	1
Abu-Rustum, NR	1
Ferrandina, G	1
Fanfani, F	1
Ludovisi, M	1
Fagotti, A	1
Carbone, A	1
Zannoni, G	1
Guerriero, M	1
Petrillo, M	1
Scambia, G	1
Han, JQ	1
Han, CY	1
Bi, YH	1
Park, BB	1
Im, YH	1
Hwang, IG	1
Lee, SC	1
Ahn, JS	1
Ahn, MJ	1
Lim, HY	1
Kang, WK	1
Park, K	1
Recchia, F	2
Candeloro, G	1
Di Staso, M	1
Necozione, S	1
Bisegna, R	1
Bratta, M	1
Tombolini, V	1
Rea, S	2
Drings, P	4
Stiefel, P	3
Dirks, HP	1
Grimm, V	1
Kleckow, M	2
Manke, HG	3
Queisser, W	2
Abel, U	2
Heinrich, S	1
Saiers, JH	2
Slavik, M	2
Harrison, EF	1
Hawke, JE	1
Hunter, HL	1
Costanzi, JJ	3
Morgan, LR	2
Plotkin, D	1
Tucker, WG	1
Worrall, PM	1
Hokanson, J	1
Holoye, PY	2
Anderson, T	2
Duelge, J	2
Hansen, RM	2
Ritch, PS	2
Bakowski, MT	1
Crouch, JC	1
Joss, RA	1
Cavalli, F	1
Goldhirsch, A	1
Mermillod, B	1
Brunner, KW	1
Araujo, CE	4
Tessler, J	1
Focan, C	1
Salamon, E	1
Le Hung, S	1
Frère, MH	1
Mbuyamba, P	1
Claessens, JJ	1
Gad-el-Mawla, N	1
Ziegler, JL	1
Hamza, R	1
Elserafi, M	1
Khaled, H	1
Matthiessen, W	1
Stempinski, E	1
Göbel, D	1
Thalmann, U	1
Kohno, I	1
Kazuta, M	1
Miyao, J	1
Kunimi, N	1
Kawamoto, M	1
Tanimura, T	1
Fujiwara, K	1
Sekiba, K	1
Issell, BF	3
MacFadyen, BV	1
Gum, ET	1
Valdivieso, M	3
Dudrick, SJ	2
Bodey, GP	3
Benner, SE	2
Huber, MH	2
Murad, AM	1
Triginelli, SA	1
Ribalta, JC	1
Singhal, RM	1
Jindel, R	1
Gupta, AK	1
Kumar, L	2
Kaushal, R	1
Nandy, M	1
Biswal, BM	1
Kumar, S	1
Kriplani, A	1
Singh, R	1
Rath, GK	1
Kochupillai, V	1
Forastiere, AA	1
Urba, SG	1
Wagner, W	2
von Eiff, M	1
Klinke, F	1
Micke, O	1
Rübe, C	1
Willich, N	1
Zulian, GB	1
Tullen, E	1
Maton, B	1
Cervellino, JC	3
Sánchez, O	2
Miles, H	1
Nishihama, A	1
Somma-Mauvais, H	1
Farisse, P	1
Viallat, JR	1
Antonakopoulos, GN	1
Newman, J	1
Duffy, JP	2
Matthews, HR	5
Fanning, J	1
Ladd, C	1
Hilgers, RD	1
Allen, SM	2
Walker, SJ	1
Cullen, MH	3
Filtenborg, TA	1
Hansen, HH	1
Aage Engelholm, S	1
Rørth, M	1
Martín, M	1
Diaz-Rubio, E	1
González Larriba, JL	1
Casado, A	1
Sastre, J	1
López-Vega, JM	1
Almenarez, J	1
Dominguez, S	1
Edwards, CW	1
Sutton, GP	4
Blessing, JA	6
McGuire, WP	1
Patton, T	1
Look, KY	1
Jenner, K	1
Steyn, RS	2
Souquet, PJ	1
Fournel, P	1
Bohas, CH	1
Fortune, IC	1
Chatte, G	1
Niehues, T	1
Harms, D	1
Jürgens, H	1
Göbel, U	1
Shirinian, M	2
Dimery, IW	1
Dunnington, JS	1
Vansteenkiste, J	1
Vandebroek, J	1
Mariën, S	1
Roex, L	1
Bertrand, P	1
Bockaert, J	1
De Beukelaar, T	1
Deman, R	1
De Muynck, P	1
Ulrichts, H	1
Lokich, J	1
Anderson, N	1
Moore, C	1
Bern, M	1
Coco, F	1
Dow, E	1
Scagliotti, GV	1
Ricardi, U	1
Crinó, L	1
Maranzano, E	1
De Marinis, F	1
Morandi, MG	1
Meacci, L	1
Marangolo, M	1
Emiliani, E	1
Rosti, G	1
Figoli, F	1
Bolzicco, G	1
Masiero, P	1
Gentile, A	1
Tonato, M	1
Omura, GA	1
Vaccarello, L	1
Berman, ML	3
Clarke-Pearson, DL	1
Mutch, DG	1
Anderson, B	1
Kyriakakis, Z	1
Kostakopoulos, A	1
Karayiannis, A	1
Sofras, F	1
Zervas, A	1
Giannopoulos, A	1
Dimopoulos, C	1
Noda, K	1
Hirabayashi, K	2
Terashima, Y	1
Ozaki, M	1
Yakushiji, M	2
Hatae, M	1
Kanazawa, K	1
Sur, M	1
Taylor, L	1
Cooper, K	1
Sur, RK	1
Lawhorn, K	2
Sandler, A	1
Saxman, S	1
Bandealy, M	1
Heilman, D	1
Monaco, F	1
McClean, J	1
Arquette, M	1
Ang, KK	2
Clayman, GL	1
Callender, DL	1
Latz, D	1
Schulze, T	1
Manegold, C	1
Schraube, P	1
Flentje, M	1
Weber, KJ	1
McManus, KG	1
McAleer, JA	1
Zanetta, G	2
Sessa, C	1
Gueli-Alletti, D	1
Kodama, J	1
Ikuhashi, H	1
Hongo, A	1
Mizutani, Y	1
Miyagi, Y	1
Yoshinouchi, M	1
Kobashi, Y	1
Okuda, H	1
Kudo, T	1
Sánchez Parra, M	1
Churruca, C	1
Paredes, A	1
Lacasta, A	1
López de Argumedo, G	1
Alvárez, I	1
Abad, T	1
Egana, L	1
Guimón, E	1
Piera, JM	1
Levitan, N	1
Dowlati, A	1
Craffey, M	1
Tahsildar, H	1
MacKay, W	1
McKenney, J	1
Remick, SC	1
Brücker, C	1
Sieg, P	2
Chen, Y	1
Yang, KY	1
Wu, HW	1
Whang-Peng, J	1
Domínguez, ME	1
Machiavelli, MR	1
Lacava, JA	1
Romero, AO	1
Ortiz, EH	1
Grasso, S	1
Amato, S	1
Rodríguez, R	1
Barbieri, M	1
Romero Acuña, J	1
Focaccia, G	1
Suttora, G	1
Scenna, M	1
Boughen, JM	1
Romero Acuña, LA	1
Langhi, MJ	1
Ressel, A	1
Weiss, C	1
Feyerabend, T	2
Papadimitrakopoulou, VM	1
Thurnher, D	1
Kornfehl, J	1
Burian, M	1
Gedlicka, C	1
Selzer, E	1
Quint, C	1
Neuchrist, C	1
Kornek, GV	1
Sommer, K	1
Peters, SO	1
Robins, IH	1
Raap, M	1
Wiedemann, GJ	1
Remmert, S	1
Bittner, C	1
Hermann, RM	1
Krech, R	1
Hartlapp, J	1
Esser, E	1
Christoph, B	1
Müller, MK	1
Lalli, A	1
Lombardo, M	1
De Filippis, S	1
Saggio, G	1
Fabbri, F	1
Rosselli, M	1
Capomolla, E	1
Bloss, JD	1
Behrens, BC	1
Mannel, RS	1
Rader, JS	1
Sood, AK	1
Markman, M	1
Benda, J	1
Zaren, HA	1
Freireich, EJ	1
Copeland, EW	1
Gagliano, R	1
Loukas, D	1
Panettiere, FJ	1
Hokanson, JA	1
Hersh, EM	1
Richman, S	1
Gutterman, JU	1
Tay, SK	1
Lai, FM	1
Soh, LT	1
Ho, TH	1
Ang, PT	1
Au, E	1
Lee, JS	1
Dhingra, HH	1
Greenberg, J	1
Okada, E	1
Nakazuma, Y	1
Akamatsu, Y	1
Sezaki, H	1
Ohta, M	1
Nakanishi, Y	1
Buxton, EJ	4
Kuehnle, H	1
Meerpohl, HG	1
Eiermann, W	2
Achterrath, W	1
Arai, N	1
Annoh, S	1
Kaneko, H	1
Umeda, M	1
Tsukahara, T	1
Shirai, T	1
Saunders, N	1
Blackledge, GR	1
Kelly, K	1
Redman, CW	1
Monaghan, J	2
Paterson, ME	1
Luesley, DM	1
Bhargava, VL	1
Hannigan, EV	1
Dinh, TV	1
Doherty, MG	1
Pirisi, C	2
Francia, A	1
Cerruti, R	1
Inoue, Y	2
Sasaki, H	1
Nakajima, S	1
Honda, R	2
Asakawa, M	2
Suzuki, A	2
Brosto, M	1
Rossi, R	1
Photopulos, G	2
Homesley, HD	2
Fujii, M	1
Segawa, Y	1
Matsutomo, S	1
Genba, K	1
Paccagnella, A	1
Favaretto, A	1
Brandes, A	1
Ghiotto, C	1
Fornasiero, A	1
Volpi, A	1
Pappagallo, G	1
Festi, G	1
Cipriani, A	1
Vinante, O	1
Coleman, RE	2
Clarke, JM	1
Slevin, ML	2
Sweetenham, J	1
Williams, CJ	1
Blake, P	1
Calman, F	1
Wiltshaw, E	1
Harper, PG	2
Lara, PC	1
Garcia-Puche, JL	1
Pedraza, V	1
Barton, C	1
Blackledge, G	3
Mould, JJ	3
Meanwell, CA	3
Paterson, M	1
Tobias, J	1
Alcock, C	1
Spooner, D	2
Nishida, T	1
Nagasue, N	1
Arimatsu, T	1
Nagano, H	1
Izumi, S	1
Okura, N	1
Matsumura, T	1
Ansell, SM	1
Alberts, AS	1
Falkson, G	1
Adcock, L	1
Webster, KD	1
DeEulis, T	1
Meier, W	1
Stieber, P	1
Fateh-Moghadam, A	1
Hepp, H	1
Ardizzoni, A	1
Fusco, V	1
Gulisano, M	1
Pronzato, P	1
Baracco, F	1
Capaccio, A	1
Pastorino, G	1
Nosenzo, M	1
Felletti, R	1
Fabiano, F	1
Ohnoshi, T	1
Hiraki, S	1
Ueoka, H	1
Tamura, T	1
Kawahara, S	1
Yonei, T	1
Yamashita, H	1
Ishii, J	1
Tamai, M	1
Egawa, T	1
Becker, H	1
Bülzebruck, H	2
Djawid, N	1
Ruchalla, E	1
Tessen, HW	1
Paschke, R	1
Worst, P	1
Brust, J	1
Banks, J	1
Anderson, EG	1
Smith, AP	1
Gatzemeier, U	1
Hossfeld, DK	1
Radenbach, D	1
Zschaber, R	1
Lawton, FG	1
Stuart, NS	1
Kavanagh, J	1
Latief, TN	1
Chetiyawardana, AD	1
Nanus, DM	1
Kelsen, DP	1
Lipperman, R	1
Eisenberger, M	1
Verweij, J	1
Alexieva-Figusch, J	1
de Boer, MF	1
Reichgelt, B	1
Stoter, G	1
Gallagher, C	1
Osborne, R	1
Rankin, EM	1
Silverstone, AC	1
Souhami, RL	1
Tobias, JS	1
Trask, CW	1

Clinical Trials (8)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers[NCT01587703]	Phase 1	196 participants (Actual)	Interventional	2012-03-28	Completed
Prospective Study for the Validation of the Genetic Signature 354849 to Predict the Response to Standard Treatment in Patients With Locally Advanced Cervical Cancer[NCT04067882]		189 participants (Anticipated)	Observational	2019-09-30	Recruiting
Multicenter Prospective Randomized Study on NeoAdjuvant Chemotherapy Followed by Radical Hysterectomy (OP) Versus Primary Chemo-RADiation in Patients With Cervical Cancer FIGO Stage IB2 and IIB[NCT02422563]	Phase 3	534 participants (Anticipated)	Interventional	2015-10-31	Not yet recruiting
A Randomized Phase II Study to Evaluate the Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma[NCT02014831]	Phase 2	0 participants (Actual)	Interventional	2016-02-29	Withdrawn (stopped due to Industry decline to supply study drug)
A Phase II Study of (Neoadjuvant Chemotherapy Trial Prior to Extirpative Surgery) for Clinical Stage TanyN2-3M0 Squamous Cell Carcinoma of the Penis[NCT00512096]	Phase 2	30 participants (Actual)	Interventional	1999-08-31	Completed
Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC): an Open-label, Single-center, Phase 2, Single-arm Trial (CaboPen)[NCT03943602]	Phase 2	37 participants (Anticipated)	Interventional	2019-08-01	Recruiting
Phase III Trial Comparing 2 Chemotherapy Schedules (Preoperative vs Pre and Postoperative) in Stage I and II NSCLC[NCT00198354]	Phase 3	530 participants (Actual)	Interventional	2001-05-31	Completed
"Phase III Clinical Trial: Evaluation of the Combination of TRANSKRIP ® Plus Carboplatin and Paclitaxel as First Line Chemotherapy on Survival of Patients With Recurrent - Persistent Cervical Cancer"[NCT02446652]	Phase 3	230 participants (Anticipated)	Interventional	2015-07-31	Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Apparent Terminal Phase Elimination Rate Constant (Lambda z) for GSK525762-Besylate Sub-study

Blood samples for pharmacokinetic analysis of GSK525762 were collected at the indicated time points. (NCT01587703)
Timeframe: Week1 Day1, Day3 and Week2 Day1 (pre-dose,0.25,0.5,1,1.5,2,3,4,6,8,24,48 hours post-dose)

Intervention	Per hour (Geometric Mean)
GSK525762 80 mg Amorphous+6 mg Stable Isotope	5.628
GSK525762 80 mg Besylate+6 mg Stable Isotope	5.176
GSK525762 30 mg Besylate+6 mg Stable Isotope	5.088
GSK525762 80 mg Besylate Fed	5.954

Maximum Observed Concentration (Cmax) of GSK525762-Besylate Sub-study

Intervention	Nanograms per milliliter (Geometric Mean)
GSK525762 80 mg Amorphous+6 mg Stable Isotope	1431.41
GSK525762 80 mg Besylate+6 mg Stable Isotope	1483.21
GSK525762 30 mg Besylate+6 mg Stable Isotope	655.33
GSK525762 80 mg Besylate Fed	1305.59

Number of Participants With Dose Reductions or Delays-Besylate Sub-study

The number of participants who had any dose reductions or delays is presented. (NCT01587703)
Timeframe: Median of 1.87 months of drug exposure

Intervention	Participants (Count of Participants)
80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes	3
80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes	1

Number of Participants With Dose Reductions or Delays-Part 1 BID

The number of participants who had any dose reductions or delays is presented. (NCT01587703)
Timeframe: Median of 1.41 months of drug exposure

Intervention	Participants (Count of Participants)
Part 1: GSK525762 20 mg BID	0
Part 1: GSK525762 30 mg BID	3
Part 1: GSK525762 40 mg BID	1

Number of Participants With Dose Reductions or Delays-Part 1 QD

The number of participants who had any dose reductions or delays is presented. (NCT01587703)
Timeframe: Median of 1.38 months of drug exposure

Intervention	Participants (Count of Participants)
Part 1: GSK525762 2 mg QD	0
Part 1: GSK525762 4 mg QD	0
Part 1: GSK525762 8 mg QD	0
Part 1: GSK525762 16 mg QD	0
Part 1: GSK525762 30 mg QD	0
Part 1: GSK525762 60 mg QD	2
Part 1: GSK525762 80 mg QD	8
Part 1: GSK525762 100 mg QD	7

Number of Participants With Dose Reductions or Delays-Part 2

The number of participants who had any dose reductions or delays is presented. (NCT01587703)
Timeframe: Median of 1.41 months of drug exposure

Intervention	Participants (Count of Participants)
Participants With NMC	7
Participants With SCLC	4
Participants With CRPC	11
Participants With TNBC	6
Participants With ER+BC	6
Participants With GIST	4

Number of Participants With Prostate Specific Antigen (PSA)50 Response-Part 1 QD

PSA 50 response rate is defined as the response rate that a PSA reduction from Baseline >=50% is observed at 12 weeks and beyond (must be confirmed by a second value). The number of participants with PSA >=50% reduction is presented along with 95% confidence intervals. (NCT01587703)
Timeframe: Median of 1.38 months of drug exposure

Intervention	Participants (Number)
Part 1: GSK525762 2 mg QD	0
Part 1: GSK525762 4 mg QD	0
Part 1: GSK525762 8 mg QD	0
Part 1: GSK525762 16 mg QD	0
Part 1: GSK525762 30 mg QD	0
Part 1: GSK525762 60 mg QD	0
Part 1: GSK525762 80 mg QD	2
Part 1: GSK525762 100 mg QD	1

Number of Participants With PSA50 Response Rate-Part 1 BID

PSA 50 Response rate is defined as the response rate that a PSA reduction from Baseline >=50% is observed at 12 weeks and beyond (must be confirmed by a second value). The number of participants with PSA >=50% reduction is presented along with 95% confidence intervals. (NCT01587703)
Timeframe: Median of 1.41 months of drug exposure

Intervention	Participants (Number)
Part 1: GSK525762 20 mg BID	0
Part 1: GSK525762 30 mg BID	0
Part 1: GSK525762 40 mg BID	0

Number of Participants With PSA50 Response-Besylate Sub-study

Intervention	Participants (Number)
80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes	0
80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes	0

Number of Participants With PSA50 Response-Part 2

Intervention	Participants (Number)
Participants With NMC	0
Participants With SCLC	0
Participants With CRPC	0
Participants With TNBC	0
Participants With ER+BC	0
Participants With GIST	0

Number of Participants Withdrawn Due to Toxicities-Besylate Sub-study

Number of participants withdrawn due to toxicities is presented. (NCT01587703)
Timeframe: Median of 1.87 months of drug exposure

Intervention	Participants (Count of Participants)
80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes	0
80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes	0

Number of Participants Withdrawn Due to Toxicities-Part 1 BID

Number of participants withdrawn due to toxicities is presented. (NCT01587703)
Timeframe: Median of 1.41 months of drug exposure

Intervention	Participants (Count of Participants)
Part 1: GSK525762 20 mg BID	0
Part 1: GSK525762 30 mg BID	2
Part 1: GSK525762 40 mg BID	2

Number of Participants Withdrawn Due to Toxicities-Part 1 QD

Number of participants withdrawn due to toxicities is presented. (NCT01587703)
Timeframe: Median of 1.38 months of drug exposure

Intervention	Participants (Count of Participants)
Part 1: GSK525762 2 mg QD	0
Part 1: GSK525762 4 mg QD	1
Part 1: GSK525762 8 mg QD	0
Part 1: GSK525762 16 mg QD	0
Part 1: GSK525762 30 mg QD	0
Part 1: GSK525762 60 mg QD	2
Part 1: GSK525762 80 mg QD	7
Part 1: GSK525762 100 mg QD	2

Number of Participants Withdrawn Due to Toxicities-Part 2

Number of participants withdrawn due to toxicities is presented. (NCT01587703)
Timeframe: Median of 1.41 months of drug exposure

Intervention	Participants (Count of Participants)
Participants With NMC	1
Participants With SCLC	3
Participants With CRPC	6
Participants With TNBC	4
Participants With ER+BC	6
Participants With GIST	2

Overall Response Rate-Besylate Sub-study

Overall response rate is defined as the percentage of participants who achieved a confirmed CR or PR from the start of treatment until disease progression or the start of new anticancer therapy, among participants who received at least 1 dose of treatment. Overall response rate was determined by the investigator according to RECIST v 1.1. CR=Disappearance of all target lesions. Any pathological lymph nodes must be <10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters. (NCT01587703)
Timeframe: Median of 1.87 months of drug exposure

Intervention	Percentage of participants (Number)
All Participants in Besylate Substudy	0

Overall Response Rate-Part 1 BID

Intervention	Percentage of participants (Number)
Part 1: GSK525762 20 mg BID	0
Part 1: GSK525762 30 mg BID	0
Part 1: GSK525762 40 mg BID	0

Overall Response Rate-Part 1 QD

Overall response rate is defined as the percentage of participants who achieved a confirmed complete response (CR) or partial response (PR) from the start of treatment until disease progression or the start of new anticancer therapy, among participants who received at least 1 dose of treatment. Overall response rate was determined by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST version (v) 1.1). CR=Disappearance of all target lesions. Any pathological lymph nodes must be <10 millimeters (mm) in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters. (NCT01587703)
Timeframe: Median of 1.38 months of drug exposure

Intervention	Percentage of participants (Number)
Part 1: GSK525762 2 mg QD	0
Part 1: GSK525762 4 mg QD	25
Part 1: GSK525762 8 mg QD	0
Part 1: GSK525762 16 mg QD	0
Part 1: GSK525762 30 mg QD	0
Part 1: GSK525762 60 mg QD	0
Part 1: GSK525762 80 mg QD	3
Part 1: GSK525762 100 mg QD	11

Overall Response Rate-Part 2

Intervention	Percentage of participants (Number)
Participants With NMC	8
Participants With SCLC	0
Participants With CRPC	4
Participants With TNBC	0
Participants With ER+BC	0
Participants With GIST	0

Overall Survival-Besylate Sub-study

Overall survival is defined as the interval of time (in months) between the date of first dose and the date of death due to any cause. The median overall survival is presented along with 95% confidence interval. Confidence intervals were estimated using Brookmeyer Crowley method. (NCT01587703)
Timeframe: Median of 1.87 months of drug exposure

Intervention	Months (Median)
All Participants in Besylate Substudy	6.3

Overall Survival-Part 1 BID

Intervention	Months (Median)
Part 1: GSK525762 20 mg BID	NA
Part 1: GSK525762 30 mg BID	6.0
Part 1: GSK525762 40 mg BID	13.3

Overall Survival-Part 1 QD

Intervention	Months (Median)
Part 1: GSK525762 2 mg QD	0.6
Part 1: GSK525762 4 mg QD	4.1
Part 1: GSK525762 8 mg QD	2.2
Part 1: GSK525762 16 mg QD	9.1
Part 1: GSK525762 30 mg QD	3.8
Part 1: GSK525762 60 mg QD	8.9
Part 1: GSK525762 80 mg QD	7.1
Part 1: GSK525762 100 mg QD	9.8

Overall Survival-Part 2

Intervention	Months (Median)
Participants With NMC	5.0
Participants With SCLC	2.6
Participants With CRPC	9.1
Participants With TNBC	5.0
Participants With ER+BC	8.8
Participants With GIST	7.3

Progression Free Survival-Besylate Sub-study

Progression free survival is defined as the interval of time (in months) between the date of first dose and the earlier of the date of disease progression and the date of death due to any cause. Confidence intervals were estimated using Brookmeyer Crowley method. (NCT01587703)
Timeframe: Median of 1.87 months of drug exposure

Intervention	Months (Median)
All Participants in Besylate Substudy	3.5

Progression Free Survival-Part 1 BID

Progression free survival is defined as the interval of time (in months) between the date of first dose and the earlier of the date of disease progression and date of death due to any cause. Confidence intervals were estimated using Brookmeyer Crowley method. (NCT01587703)
Timeframe: Median of 1.41 months of drug exposure

Intervention	Months (Median)
Part 1: GSK525762 20 mg BID	7.7
Part 1: GSK525762 30 mg BID	5.6
Part 1: GSK525762 40 mg BID	8.0

Progression Free Survival-Part 1 QD

Intervention	Months (Median)
Part 1: GSK525762 2 mg QD	0.3
Part 1: GSK525762 4 mg QD	4.1
Part 1: GSK525762 8 mg QD	2.2
Part 1: GSK525762 16 mg QD	9.1
Part 1: GSK525762 30 mg QD	3.8
Part 1: GSK525762 60 mg QD	3.6
Part 1: GSK525762 80 mg QD	6.5
Part 1: GSK525762 100 mg QD	7.5

Progression Free Survival-Part 2

Intervention	Months (Median)
Participants With NMC	4.8
Participants With SCLC	2.2
Participants With CRPC	8.0
Participants With TNBC	2.4
Participants With ER+BC	4.7
Participants With GIST	3.4

Time to Reach Cmax (Tmax) for GSK525762-Besylate Sub-study

Intervention	Hours (Median)
GSK525762 80 mg Amorphous+6 mg Stable Isotope	0.5833
GSK525762 80 mg Besylate+6 mg Stable Isotope	0.8083
GSK525762 30 mg Besylate+6 mg Stable Isotope	0.8333
GSK525762 80 mg Besylate Fed	2.0000

Apparent Clearance of GSK525762-Part 1 BID

Blood samples were collected at indicated time points post ante-meridiem (AM) and post-meridiem (PM) dose for pharmacokinetic analysis of GSK525762. (NCT01587703)
Timeframe: pre-dose,0.25,0.5,1,2,4,8,12 hours post-AM dose at Week1Day1 and Week3 Day 4; Week1 Day5(0.5, 3 hours post-AM dose); pre-dose, 0.25,0.5,1,2,4,8,12, 36 hours post-PM dose at Week1Day1 and Week3 Day4

Intervention	Liter per hour (Geometric Mean)
	Week1 AM dose;n=3,10,5	Week1 PM dose;n=4,7,5	Week3 AM dose;n=3,7,3	Week3 PM dose;n=3,5,3
Part 1: GSK525762 20 mg BID	23.246	21.745	16.731	18.867
Part 1: GSK525762 30 mg BID	9.621	11.057	11.949	20.133
Part 1: GSK525762 40 mg BID	14.155	16.382	34.623	37.097

Apparent Clearance of GSK525762-Part 1 QD

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK525762. (NCT01587703)
Timeframe: pre-dose,0.25,0.5,1,2,4,8,12,24 and 48 hours post-dose at Week1 Day1 and Week 3 Day 4

,,,,,,,

Intervention	Liter per hour (Geometric Mean)
	Week1;n=3,4,1,3,4,9,32,9	Week3;n=1,2,1,3,4,6,16,6
Part 1: GSK525762 100 mg QD	13.707	26.188
Part 1: GSK525762 16 mg QD	18.036	23.823
Part 1: GSK525762 2 mg QD	11.467	13.082
Part 1: GSK525762 30 mg QD	6.720	9.535
Part 1: GSK525762 4 mg QD	11.085	11.955
Part 1: GSK525762 60 mg QD	13.769	23.296
Part 1: GSK525762 8 mg QD	18.470	24.277
Part 1: GSK525762 80 mg QD	13.589	27.029

Area Under the Concentration-time Curve (AUC) From Time Zero to 24 Hours(AUC[0 to 24]); AUC From Time 0 to Last Quantifiable Concentration (AUC [0 to t]) and AUC Extrapolated to Infinity (AUC[0 to Inf]) of GSK525762-Besylate Sub-study

Blood samples for pharmacokinetic analysis of GSK525762 were collected at the indicated time points. Besylate sub-study pharmacokinetic (PK) Parameter Population consisted of all participants in the PK Parameter Population who participated in the besylate substudy. (NCT01587703)
Timeframe: Week1 Day1, Day3 and Week2 Day1 (pre-dose,0.25,0.5,1,1.5,2,3,4,6,8,24,48 hours post-dose)

,,,

Intervention	Hours*nanograms per milliliter (Geometric Mean)
	AUC(0 to 24)	AUC(0 to inf)	AUC(0 to t)
GSK525762 30 mg Besylate+6 mg Stable Isotope	2977.3	3096.9	3053.9
GSK525762 80 mg Amorphous+6 mg Stable Isotope	6954.3	7292.0	7227.1
GSK525762 80 mg Besylate Fed	9123.8	9727.7	9597.1
GSK525762 80 mg Besylate+6 mg Stable Isotope	7377.9	7703.4	7657.6

AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID

Intervention	Hours*nanogram per milliter (Geometric Mean)
	AUC (0 to 24); Week1 AM dose;n=3,10,5	AUC (0 to 24); Week1 PM dose;n=4,7,5	AUC (0 to 24); Week3 AM dose;n=3,7,3	AUC (0 to 24); Week3 PM dose;n=3,5,3	AUC (0 to inf); Week1 AM dose;n=3,10,5	AUC (0 to t); Week1 AM dose;n=4,10,5	AUC (0 to t); Week1 PM dose;n=4,9,5	AUC (0 to t); Week3 AM dose;n=3,7,3	AUC (0 to t); Week3 PM dose;n=3,6,3
Part 1: GSK525762 20 mg BID	856.1	981.4	1279.0	1155.8	860.4	932.2	927.5	1194.6	1053.6
Part 1: GSK525762 30 mg BID	3067.0	3261.1	2725.3	1662.1	3118.3	2727.2	2840.4	2472.4	1490.8
Part 1: GSK525762 40 mg BID	2794.4	2607.6	1184.6	1131.6	2825.8	2579.0	2446.7	1140.9	1073.6

AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK525762. PK parameter population comprised of all participants in the PK Concentration Population (all participants in the All Treated Population for whom a blood sample for pharmacokinetics is obtained and analyzed) for whom a PK parameter has been obtained. (NCT01587703)
Timeframe: pre-dose,0.25,0.5,1,2,4,8,12,24 and 48 hours post-dose at Week1 Day1 and Week 3 Day 4

,,,,,,,

Intervention	Hours*nanogram per milliliter (Geometric Mean)
	AUC (0 to 24); Week1;n=3,4,1,3,4,9,32,9	AUC (0 to 24); Week3;n=1,2,1,3,4,6,16,6	AUC (0 to inf); Week1;n=3,4,1,3,4,9,32,9	AUC (0 to t); Week1;n=3,4,1,3,4,9,32,9	AUC (0 to t); Week3;n=1,2,1,3,4,6,16,6
Part 1: GSK525762 100 mg QD	6958.3	3818.5	7295.6	7218.4	3819.9
Part 1: GSK525762 16 mg QD	867.9	671.6	887.1	877.7	672.3
Part 1: GSK525762 2 mg QD	169.2	152.9	174.4	168.6	152.8
Part 1: GSK525762 30 mg QD	3943.2	3146.2	4464.5	4147.8	3164.3
Part 1: GSK525762 4 mg QD	354.3	334.6	360.8	357.5	334.3
Part 1: GSK525762 60 mg QD	4225.0	2575.6	4357.5	4304.1	2576.9
Part 1: GSK525762 8 mg QD	431.5	329.5	433.1	431.1	330.6
Part 1: GSK525762 80 mg QD	5692.4	2959.8	5887.2	5667.3	2953.8

Lambda z for GSK525762-Part 1 BID

Intervention	Per hour (Geometric Mean)
	Week1 AM dose;n=3,10,5	Week1 PM dose;n=3,7,3	Week3 AM dose;n=3,7,3	Week3 PM dose;n=3,5,3
Part 1: GSK525762 20 mg BID	0.23463	0.21171	0.23565	0.20507
Part 1: GSK525762 30 mg BID	0.19989	0.14307	0.21751	0.19263
Part 1: GSK525762 40 mg BID	0.23721	0.18789	0.30868	0.29133

Lambda z for GSK525762-Part 1 QD

,,,,,,,

Intervention	Per hour (Geometric Mean)
	Week1;n=3,4,1,3,4,9,32,9	Week3;n=1,2,1,3,4,6,16,6
Part 1: GSK525762 100 mg QD	0.10992	0.17560
Part 1: GSK525762 16 mg QD	0.09903	0.15599
Part 1: GSK525762 2 mg QD	0.21411	0.15579
Part 1: GSK525762 30 mg QD	0.07863	0.12513
Part 1: GSK525762 4 mg QD	0.13554	0.15472
Part 1: GSK525762 60 mg QD	0.12468	0.17629
Part 1: GSK525762 8 mg QD	0.23126	0.14087
Part 1: GSK525762 80 mg QD	0.15613	0.16667

Maximum Observed Concentration for GSK525762-Part 1 QD

,,,,,,,

Intervention	Nanogram per milliliter (Geometric Mean)
	Week1;n=3,4,1,3,4,9,32,9	Week3;n=1,2,1,3,4,6,16,6
Part 1: GSK525762 100 mg QD	1080.49	918.56
Part 1: GSK525762 16 mg QD	179.45	137.57
Part 1: GSK525762 2 mg QD	50.95	52.04
Part 1: GSK525762 30 mg QD	603.92	602.70
Part 1: GSK525762 4 mg QD	70.46	53.37
Part 1: GSK525762 60 mg QD	889.52	633.71
Part 1: GSK525762 8 mg QD	120.35	103.18
Part 1: GSK525762 80 mg QD	1099.81	815.40

Maximum Observed Concentration of GSK525762-Part 1 BID

Intervention	Nanogram per milliter (Geometric Mean)
	Week1 AM dose;n=4,10,5	Week1 PM dose;n=4,9,5	Week3 AM dose;n=3,7,3	Week3 PM dose;n=3,6,3
Part 1: GSK525762 20 mg BID	231.68	166.62	284.71	256.08
Part 1: GSK525762 30 mg BID	628.01	445.17	604.38	263.72
Part 1: GSK525762 40 mg BID	703.31	425.76	419.15	229.91

Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QD

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the outcomes mentioned; events of possible study treatment-induced liver injury with hyperbilirubinemia; any new primary cancers; significant cardiac dysfunction; Grade 4 laboratory abnormalities; and drug related hepatobiliary event leading to permanent discontinuation of study treatment. All Treated Population comprised of all participants who received at least one dose of study treatment. (NCT01587703)
Timeframe: Median of 1.38 months of drug exposure

,,,,,,,

Intervention	Participants (Count of Participants)
	Any AE	Any SAE
Part 1: GSK525762 100 mg QD	9	3
Part 1: GSK525762 16 mg QD	3	0
Part 1: GSK525762 2 mg QD	3	0
Part 1: GSK525762 30 mg QD	3	1
Part 1: GSK525762 4 mg QD	4	2
Part 1: GSK525762 60 mg QD	9	2
Part 1: GSK525762 8 mg QD	1	0
Part 1: GSK525762 80 mg QD	31	21

Number of Participants With AEs and SAEs-Part 1 BID

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the outcomes mentioned; events of possible study treatment-induced liver injury with hyperbilirubinemia; any new primary cancers; significant cardiac dysfunction; Grade 4 laboratory abnormalities; and drug related hepatobiliary event leading to permanent discontinuation of study treatment (NCT01587703)
Timeframe: Median of 1.41 months of drug exposure

Intervention	Participants (Count of Participants)
	Any AE	Any SAE
Part 1: GSK525762 20 mg BID	4	0
Part 1: GSK525762 30 mg BID	10	4
Part 1: GSK525762 40 mg BID	5	2

Number of Participants With AEs and SAEs-Part 2

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the outcomes mentioned; events of possible study treatment-induced liver injury with hyperbilirubinemia; any new primary cancers; significant cardiac dysfunction; Grade 4 laboratory abnormalities; and drug related hepatobiliary event leading to permanent discontinuation of study treatment. (NCT01587703)
Timeframe: Median of 1.41 months of drug exposure

,,,,,

Intervention	Participants (Count of Participants)
	Any AE	Any SAE
Participants With CRPC	23	16
Participants With ER+BC	21	15
Participants With GIST	13	8
Participants With NMC	11	6
Participants With SCLC	14	9
Participants With TNBC	19	11

Number of Participants With Changes in Blood Pressure From Baseline-Part 2

SBP and DBP were measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. Grading of SBP and DBP were done using NCI-CTCAE version 4.0 where, SBP (millimeters of mercury): Grade 0 (<120), Grade 1 (120-139), Grade 2 (140-159), Grade 3/4 (>=160) and DBP: Grade 0 (<80), Grade 1 (80-89), Grade 2 (90-99), Grade 3/4 (>=100). An increase is defined as an increase in CTCAE grade relative to baseline grade. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure

,,,,,

Intervention	Participants (Count of Participants)
	DBP; Increase to Grade 1;n=11,14,22,19,19,12	DBP; Increase to Grade 2;n=11,14,22,19,19,12	DBP; Increase to Grade 3/4;n=11,14,22,19,19,12	SBP; Increase to Grade 1;n=11,14,21,19,19,12	SBP; Increase to Grade 2;n=11,14,21,19,19,12	SBP; Increase to Grade 3/4;n=11,14,21,19,19,12
Participants With CRPC	8	4	1	2	11	3
Participants With ER+BC	4	6	1	7	4	1
Participants With GIST	3	1	2	1	7	0
Participants With NMC	2	4	0	4	2	0
Participants With SCLC	3	1	0	4	4	1
Participants With TNBC	5	3	2	9	3	1

Number of Participants With Changes in Pulse Rate From Baseline-Besylate Sub-study

Pulse rate was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for pulse rate is <60 beats per minute and >100 beats per minute. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.87 months of drug exposure

Intervention	Participants (Count of Participants)
	Pulse rate; decrease to <60	Pulse rate; Change to normal/no change	Pulse rate; increase to >100
80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes	0	3	2
80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes	0	1	4

Number of Participants With Changes in Pulse Rate From Baseline-Part 1 BID

Pulse rate was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure

Intervention	Participants (Count of Participants)
	Pulse rate; decrease to <60	Pulse rate; Change to normal/no change	Pulse rate; increase to >100
Part 1: GSK525762 20 mg BID	0	3	1
Part 1: GSK525762 30 mg BID	0	4	6
Part 1: GSK525762 40 mg BID	0	2	3

Number of Participants With Changes in Pulse Rate From Baseline-Part 1 QD

"Pulse rate was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for pulse rate is <60 beats per minute and >100 beats per minute. Participants were counted twice if the participant Decreased to <60 and Increased to >100 post-baseline. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented" (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure

,,,,,,,

Intervention	Participants (Count of Participants)
	Pulse rate; decrease to <60	Pulse rate; Change to normal/no change	Pulse rate; increase to >100
Part 1: GSK525762 100 mg QD	1	4	5
Part 1: GSK525762 16 mg QD	1	1	1
Part 1: GSK525762 2 mg QD	0	2	1
Part 1: GSK525762 30 mg QD	0	1	3
Part 1: GSK525762 4 mg QD	1	1	2
Part 1: GSK525762 60 mg QD	1	5	2
Part 1: GSK525762 8 mg QD	0	0	1
Part 1: GSK525762 80 mg QD	1	12	18

Number of Participants With Changes in Pulse Rate From Baseline-Part 2

"Pulse rate was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for pulse rate is <60 beats per minute and >100 beats per minute. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. Participants were counted twice if the participant Decreased to <60 and Increased to >100 post-baseline." (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure

,,,,,

Intervention	Participants (Count of Participants)
	Pulse rate; decrease to <60	Pulse rate; Change to normal/no change	Pulse rate; increase to >100
Participants With CRPC	0	13	9
Participants With ER+BC	1	9	10
Participants With GIST	1	8	3
Participants With NMC	0	7	5
Participants With SCLC	1	10	4
Participants With TNBC	0	11	9

Number of Participants With Changes in Temperature From Baseline-Besylate Sub-study

Temperature was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for temperature is <=35 degree Celsius and >=38 degree Celsius. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.87 months of drug exposure

Intervention	Participants (Count of Participants)
	Decrease to <=35	Change to normal/No change	Increase to >=38
80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes	0	4	1
80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes	0	5	0

Number of Participants With Changes in Temperature From Baseline-Part 1 BID

Intervention	Participants (Count of Participants)
	Decrease to <=35	Change to normal/No change	Increase to >=38
Part 1: GSK525762 20 mg BID	0	4	0
Part 1: GSK525762 30 mg BID	0	9	1
Part 1: GSK525762 40 mg BID	0	5	0

Number of Participants With Changes in Temperature From Baseline-Part 1 QD

,,,,,,,

Intervention	Participants (Count of Participants)
	Decrease to <=35	Change to normal/No change	Increase to >=38
Part 1: GSK525762 100 mg QD	1	8	0
Part 1: GSK525762 16 mg QD	0	3	0
Part 1: GSK525762 2 mg QD	0	3	0
Part 1: GSK525762 30 mg QD	0	3	1
Part 1: GSK525762 4 mg QD	0	3	1
Part 1: GSK525762 60 mg QD	0	9	0
Part 1: GSK525762 8 mg QD	0	1	0
Part 1: GSK525762 80 mg QD	2	27	3

Number of Participants With Changes in Temperature From Baseline-Part 2

,,,,,

Intervention	Participants (Count of Participants)
	Decrease to <=35	Change to normal/No change	Increase to >=38
Participants With CRPC	0	20	2
Participants With ER+BC	1	18	1
Participants With GIST	0	12	0
Participants With NMC	1	10	0
Participants With SCLC	0	11	3
Participants With TNBC	0	18	1

Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study

Blood samples were collected for the analysis of clinical chemistry parameters: glucose, albumin, ALP, ALT, amylase, AST, Dir bil, bilirubin, NT-BNP, calcium, cholesterol, CK, chloride, CO2, creatinine, GGT, HDL and LDL cholesterol, insulin, potassium, LDH, lipase, magnesium, protein, sodium, thyroxine, testosterone, triglycerides, troponin I and T, urate and urea. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.87 months of drug exposure

Intervention	Participants (Count of Participants)
	Glucose; Any grade increase; n=5,5	Glucose; Increase to Grade 3; n=5,5	Glucose; Increase to Grade 4; n=5,5	Albumin; Any grade increase; n=5,5	Albumin; Increase to Grade 3; n=5,5	Albumin; Increase to Grade 4; n=5,5	ALP; Any grade increase; n=5,5	ALP; Increase to Grade 3; n=5,5	ALP; Increase to Grade 4; n=5,5	ALT; Any grade increase; n=5,5	ALT; Increase to Grade 3; n=5,5	ALT; Increase to Grade 4; n=5,5	Amylase; Any grade increase; n=5,5	Amylase; Increase to Grade 3; n=5,5	Amylase; Increase to Grade 4; n=5,5	AST; Any grade increase; n=5,5	AST; Increase to Grade 3; n=5,5	AST; Increase to Grade 4; n=5,5	Dir bil; Any grade increase; n=5,5	Dir bil; Increase to Grade 3; n=5,5	Dir bil; Increase to Grade 4; n=5,5	Bilirubin; Any grade increase; n=5,5	Bilirubin; Increase to Grade 3; n=5,5	Bilirubin; Increase to Grade 4; n=5,5	NT-BNP; Any grade increase; n=5,5	NT-BNP; Increase to Grade 3; n=5,5	NT-BNP; Increase to Grade 4; n=5,5	Calcium; Any grade increase; n=5,5	Calcium; Increase to Grade 3; n=5,5	Calcium; Increase to Grade 4; n=5,5	Cholesterol; Any grade increase; n=5,3	Cholesterol; Increase to Grade 3; n=5,3	Cholesterol; Increase to Grade 4; n=5,3	CK; Any grade increase; n=5,5	CK; Increase to Grade 3; n=5,5	CK; Increase to Grade 4; n=5,5	Chloride; Any grade increase; n=5,5	Chloride; Increase to Grade 3; n=5,5	Chloride; Increase to Grade 4; n=5,5	CO2; Any grade increase; n=5,5	CO2; Increase to Grade 3; n=5,5	CO2; Increase to Grade 4; n=5,5	Creatinine; Any grade increase; n=5,5	Creatinine; Increase to Grade 3; n=5,5	Creatinine; Increase to Grade 4; n=5,5	GGT; Any grade increase; n=5,5	GGT; Increase to Grade 3; n=5,5	GGT; Increase to Grade 4; n=5,5	HDL; Any grade increase; n=5,3	HDL; Increase to Grade 3; n=5,3	HDL; Increase to Grade 4; n=5,3	Insulin; Any grade increase; n=5,5	Insulin; Increase to Grade 3; n=5,5	Insulin; Increase to Grade 4; n=5,5	Potassium; Any grade increase; n=5,5	Potassium; Increase to Grade 3; n=5,5	Potassium; Increase to Grade 4; n=5,5	LDL; Any grade increase; n=5,3	LDL; Increase to Grade 3; n=5,3	LDL; Increase to Grade 4; n=5,3	Lipase; Any grade increase; n=5,4	Lipase; Increase to Grade 3; n=5,4	Lipase; Increase to Grade 4;n=5,4	Magnesium; Any grade increase; n=5,5	Magnesium; Increase to Grade 3; n=5,5	Magnesium; Increase to Grade 4; n=5,5	Protein; Any grade increase; n=5,5	Protein; Increase to Grade 3; n=5,5	Protein; Increase to Grade 4; n=5,5	Sodium; Any grade increase; n=5,5	Sodium; Increase to Grade 3; n=5,5	Sodium; Increase to Grade 4; n=5,5	Thyroxine; Any grade increase; n=5,3	Thyroxine; Increase to Grade 3; n=5,3	Thyroxine; Increase to Grade 4; n=5,3	Testosterone; Any grade increase; n=2,1	Testosterone; Increase to Grade 3; n=2,1	Testosterone; Increase to Grade 4; n=2,1	Triglycerides; Any grade increase; n=5,3	Triglycerides; Increase to Grade 3; n=5,3	Triglycerides; Increase to Grade 4; n=5,3	Troponin T; Any grade increase; n=5,5	Troponin T; Increase to Grade 3; n=5,5	Troponin T; Increase to Grade 4; n=5,5	Urate; Any grade increase; n=5,5	Urate; Increase to Grade 3; n=5,5	Urate; Increase to Grade 4; n=5,5	Urea; Any grade increase; n=5,5	Urea; Increase to Grade 3; n=5,5	Urea; Increase to Grade 4; n=5,5
80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes	5	0	0	3	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	4	2	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	3	0	0	0	0	0	0	0	0	1	1	0	0	0	0	3	1	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0

Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study

Intervention	Participants (Count of Participants)
	Glucose; Any grade increase; n=5,5	Glucose; Increase to Grade 3; n=5,5	Glucose; Increase to Grade 4; n=5,5	Albumin; Any grade increase; n=5,5	Albumin; Increase to Grade 3; n=5,5	Albumin; Increase to Grade 4; n=5,5	ALP; Any grade increase; n=5,5	ALP; Increase to Grade 3; n=5,5	ALP; Increase to Grade 4; n=5,5	ALT; Any grade increase; n=5,5	ALT; Increase to Grade 3; n=5,5	ALT; Increase to Grade 4; n=5,5	Amylase; Any grade increase; n=5,5	Amylase; Increase to Grade 3; n=5,5	Amylase; Increase to Grade 4; n=5,5	AST; Any grade increase; n=5,5	AST; Increase to Grade 3; n=5,5	AST; Increase to Grade 4; n=5,5	Dir bil; Any grade increase; n=5,5	Dir bil; Increase to Grade 3; n=5,5	Dir bil; Increase to Grade 4; n=5,5	Bilirubin; Any grade increase; n=5,5	Bilirubin; Increase to Grade 3; n=5,5	Bilirubin; Increase to Grade 4; n=5,5	NT-BNP; Any grade increase; n=5,5	NT-BNP; Increase to Grade 3; n=5,5	NT-BNP; Increase to Grade 4; n=5,5	Calcium; Any grade increase; n=5,5	Calcium; Increase to Grade 3; n=5,5	Calcium; Increase to Grade 4; n=5,5	Cholesterol; Any grade increase; n=5,3	Cholesterol; Increase to Grade 3; n=5,3	Cholesterol; Increase to Grade 4; n=5,3	CK; Any grade increase; n=5,5	CK; Increase to Grade 3; n=5,5	CK; Increase to Grade 4; n=5,5	Chloride; Any grade increase; n=5,5	Chloride; Increase to Grade 3; n=5,5	Chloride; Increase to Grade 4; n=5,5	CO2; Any grade increase; n=5,5	CO2; Increase to Grade 3; n=5,5	CO2; Increase to Grade 4; n=5,5	Creatinine; Any grade increase; n=5,5	Creatinine; Increase to Grade 3; n=5,5	Creatinine; Increase to Grade 4; n=5,5	GGT; Any grade increase; n=5,5	GGT; Increase to Grade 3; n=5,5	GGT; Increase to Grade 4; n=5,5	HDL; Any grade increase; n=5,3	HDL; Increase to Grade 3; n=5,3	HDL; Increase to Grade 4; n=5,3	Insulin; Any grade increase; n=5,5	Insulin; Increase to Grade 3; n=5,5	Insulin; Increase to Grade 4; n=5,5	Potassium; Any grade increase; n=5,5	Potassium; Increase to Grade 3; n=5,5	Potassium; Increase to Grade 4; n=5,5	LDL; Any grade increase; n=5,3	LDL; Increase to Grade 3; n=5,3	LDL; Increase to Grade 4; n=5,3	Lipase; Any grade increase; n=5,4	Lipase; Increase to Grade 3; n=5,4	Lipase; Increase to Grade 4;n=5,4	Magnesium; Any grade increase; n=5,5	Magnesium; Increase to Grade 3; n=5,5	Magnesium; Increase to Grade 4; n=5,5	Protein; Any grade increase; n=5,5	Protein; Increase to Grade 3; n=5,5	Protein; Increase to Grade 4; n=5,5	Sodium; Any grade increase; n=5,5	Sodium; Increase to Grade 3; n=5,5	Sodium; Increase to Grade 4; n=5,5	Thyroxine; Any grade increase; n=5,3	Thyroxine; Increase to Grade 3; n=5,3	Thyroxine; Increase to Grade 4; n=5,3	Testosterone; Any grade increase; n=2,1	Testosterone; Increase to Grade 3; n=2,1	Testosterone; Increase to Grade 4; n=2,1	Triglycerides; Any grade increase; n=5,3	Triglycerides; Increase to Grade 3; n=5,3	Triglycerides; Increase to Grade 4; n=5,3	Troponin I; Any grade increase; n=1,0	Troponin I; Increase to Grade 3; n=1,0	Troponin I; Increase to Grade 4; n=1,0	Troponin T; Any grade increase; n=5,5	Troponin T; Increase to Grade 3; n=5,5	Troponin T; Increase to Grade 4; n=5,5	Urate; Any grade increase; n=5,5	Urate; Increase to Grade 3; n=5,5	Urate; Increase to Grade 4; n=5,5	Urea; Any grade increase; n=5,5	Urea; Increase to Grade 3; n=5,5	Urea; Increase to Grade 4; n=5,5
80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes	4	0	0	3	1	0	1	0	0	1	0	0	0	0	0	2	0	0	0	0	0	3	1	0	0	0	0	1	0	0	1	0	0	2	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	3	0	0	0	0	0	0	0	0	2	0	0	0	0	0	2	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID

Blood samples were collected for the analysis of clinical chemistry parameters: glucose, albumin, ALP, ALT, amylase, AST, Dir bil, bilirubin, NT-BNP, calcium, cholesterol, CK, chloride, CO2, creatinine, GGT, HDL and LDL cholesterol, insulin, potassium, LDH, lipase, magnesium, protein, sodium, thyroxine, testosterone, triglycerides, troponin I and T, urate and urea. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post-Baseline is presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure

Intervention	Participants (Count of Participants)
	Glucose; Any grade increase; n=4, 10, 5	Glucose; Increase to Grade 3; n=4, 10, 5	Glucose; Increase to Grade 4; n=4, 10, 5	Albumin; Any grade increase; n=4, 10, 5	Albumin; Increase to Grade 3; n=4, 10, 5	Albumin; Increase to Grade 4; n=4, 10, 5	ALP; Any grade increase; n=4, 10, 5	ALP; Increase to Grade 3; n=4, 10, 5	ALP; Increase to Grade 4; n=4, 10, 5	ALT; Any grade increase; n=4, 10, 5	ALT; Increase to Grade 3; n=4, 10, 5	ALT; Increase to Grade 4; n=4, 10, 5	Amylase; Any grade increase; n=4, 10, 5	Amylase; Increase to Grade 3; n=4, 10, 5	Amylase; Increase to Grade 4; n=4, 10, 5	AST; Any grade increase; n=4, 10, 5	AST; Increase to Grade 3; n=4, 10, 5	AST; Increase to Grade 4; n=4, 10, 5	Dir bil; Any grade increase; n=4, 9, 4	Dir bil; Increase to Grade 3; n=4, 9, 4	Dir bil; Increase to Grade 4; n=4, 9, 4	Bilirubin; Any grade increase; n=4, 10, 5	Bilirubin; Increase to Grade 3; n=4, 10, 5	Bilirubin; Increase to Grade 4; n=4, 10, 5	NT-BNP; Any grade increase; n=4, 10, 5	NT-BNP; Increase to Grade 3; n=4, 10, 5	NT-BNP; Increase to Grade 4; n=4, 10, 5	Calcium; Any grade increase; n=4, 10, 5	Calcium; Increase to Grade 3; n=4, 10, 5	Calcium; Increase to Grade 4; n=4, 10, 5	Cholesterol; Any grade increase; n=2, 9, 5	Cholesterol; Increase to Grade 3; n=2, 9, 5	Cholesterol; Increase to Grade 4; n=2, 9, 5	CK; Any grade increase; n=4, 10, 5	CK; Increase to Grade 3; n=n=4, 10, 5	CK; Increase to Grade 4; n=n=4, 10, 5	Chloride; Any grade increase; n=4, 10, 5	Chloride; Increase to Grade 3; n=4, 10, 5	Chloride; Increase to Grade 4; n=4, 10, 5	CO2; Any grade increase; n=4, 10, 5	CO2; Increase to Grade 3; n=4, 10, 5	CO2; Increase to Grade 4; n=4, 10, 5	Creatinine; Any grade increase; n=4, 10, 5	Creatinine; Increase to Grade 3; n=4, 10, 5	Creatinine; Increase to Grade 4; n=4, 10, 5	GGT; Any grade increase; n=4, 10, 5	GGT; Increase to Grade 3; n=4, 10, 5	GGT; Increase to Grade 4; n=4, 10, 5	HDL; Any grade increase; n=2, 9, 5	HDL; Increase to Grade 3; n=2, 9, 5	HDL; Increase to Grade 4; n=2, 9, 5	Insulin; Any grade increase; n=4, 10, 5	Insulin; Increase to Grade 3; n=4, 10, 5	Insulin; Increase to Grade 4; n=4, 10, 5	Potassium; Any grade increase; n=4, 10, 5	Potassium; Increase to Grade 3; n=4, 10, 5	Potassium; Increase to Grade 4; n=4, 10, 5	LDL; Any grade increase; n=2, 9, 5	LDL; Increase to Grade 3; n=2, 9, 5	LDL; Increase to Grade 4; n=2, 9, 5	Lipase; Any grade increase; n=4, 10, 5	Lipase; Increase to Grade 3; n=4, 10, 5	Lipase; Increase to Grade 4; n=4, 10, 5	Magnesium; Any grade increase; n=4, 10, 5	Magnesium; Increase to Grade 3; n=4, 10, 5	Magnesium; Increase to Grade 4; n=4, 10, 5	Protein; Any grade increase; n=4, 10, 5	Protein; Increase to Grade 3; n=4, 10, 5	Protein; Increase to Grade 4; n=4, 10, 5	Sodium; Any grade increase; n=4, 10, 5	Sodium; Increase to Grade 3; n=4, 10, 5	Sodium; Increase to Grade 4; n=4, 10, 5	Thyroxine; Any grade increase; n=3, 9, 5	Thyroxine; Increase to Grade 3; n=3, 9, 5	Thyroxine; Increase to Grade 4; n=3, 9, 5	Testosterone; Any grade increase; n=1, 4, 4	Testosterone; Increase to Grade 3; n=1, 4, 4	Testosterone; Increase to Grade 4; n=1, 4, 4	Triglycerides; Any grade increase; n=2, 9, 5	Triglycerides; Increase to Grade 3; n=2, 9, 5	Triglycerides; Increase to Grade 4; n=2, 9, 5	Troponin I; Any grade increase; n=3, 10, 5	Troponin I; Increase to Grade 3; n=3, 10, 5	Troponin I; Increase to Grade 4; n=3, 10, 5	Troponin T; Any grade increase; n=4, 10, 5	Troponin T; Increase to Grade 3; n=4, 10, 5	Troponin T; Increase to Grade 4; n=4, 10, 5	Urate; Any grade increase; n=4, 10, 5	Urate; Increase to Grade 3; n=4, 10, 5	Urate; Increase to Grade 4; n=4, 10, 5	Urea; Any grade increase; n=4, 10, 5	Urea; Increase to Grade 3; n=4, 10, 5	Urea; Increase to Grade 4; n=4, 10, 5
Part 1: GSK525762 20 mg BID	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 1: GSK525762 30 mg BID	9	3	0	4	0	0	4	2	0	5	1	0	2	0	0	6	2	0	0	0	0	7	1	1	0	0	0	2	0	0	2	0	0	3	0	0	0	0	0	0	0	0	2	0	0	4	1	1	0	0	0	0	0	0	5	0	0	0	0	0	2	1	0	2	0	1	0	0	0	7	2	0	0	0	0	0	0	0	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 1: GSK525762 40 mg BID	5	1	0	1	0	0	2	0	0	1	0	0	2	0	0	1	0	0	0	0	0	2	1	0	0	0	0	1	0	0	0	0	0	2	0	0	0	0	0	0	0	0	2	0	0	1	0	0	0	0	0	0	0	0	2	0	0	0	0	0	3	0	0	2	0	0	0	0	0	2	0	0	0	0	0	0	0	0	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD

Blood samples were collected for the analysis of: glucose, albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), amylase, aspartate aminotransferase (AST), direct bilirubin (Dir bil), bilirubin, N-Terminal proB-type natriuretic peptide (NT-BNP), calcium, cholesterol, creatine kinase (CK), chloride, carbon dioxide (CO2), creatinine, gamma glutamyl transferase (GGT), high and low density lipoprotein (HDL and LDL), insulin, potassium, lactate dehydrogenase (LDH), lipase, magnesium, protein, sodium, thyroxine, testosterone, triglycerides, troponin I and T, urate and urea. Grading was done according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on first study treatment dose date. Data for worst case post-Baseline is presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure

Intervention	Participants (Count of Participants)
	Glucose; Any grade increase; n=2,4,1,3,4,9,32,9	Glucose; Increase to Grade 3; n=2,4,1,3,4,9,32,9	Glucose; Increase to Grade 4; n=2,4,1,3,4,9,32,9	Albumin; Any grade increase; n=2,4,1,3,4,9,32,9	Albumin; Increase to Grade 3; n=2,4,1,3,4,9,32,9	Albumin; Increase to Grade 4; n=2,4,1,3,4,9,32,9	ALP; Any grade increase; n=2,4,1,3,4,9,31,9	ALP; Increase to Grade 3; n=2,4,1,3,4,9,31,9	ALP; Increase to Grade 4; n=2,4,1,3,4,9,31,9	ALT; Any grade increase; n=2,4,1,3,4,9,32,9	ALT; Increase to Grade 3; n=2,4,1,3,4,9,32,9	ALT; Increase to Grade 4; n=2,4,1,3,4,9,32,9	Amylase; Any grade increase; n=2,4,1,3,4,9,32,9	Amylase; Increase to Grade 3; n=2,4,1,3,4,9,32,9	Amylase; Increase to Grade 4; n=2,4,1,3,4,9,32,9	AST; Any grade increase; n=2,4,1,3,4,9,32,9	AST; Increase to Grade 3; n=2,4,1,3,4,9,32,9	AST; Increase to Grade 4; n=2,4,1,3,4,9,32,9	Dir bil; Any grade increase; n=2,4,1,3,4,9,30,9	Dir bil; Increase to Grade 3; n=2,4,1,3,4,9,30,9	Dir bil; Increase to Grade 4; n=2,4,1,3,4,9,30,9	Bilirubin; Any grade increase; n=2,4,1,3,4,9,32,9	Bilirubin; Increase to Grade 3; n=2,4,1,3,4,9,32,9	Bilirubin; Increase to Grade 4; n=2,4,1,3,4,9,32,9	NT-BNP; Any grade increase; n=2,4,1,3,4,9,30,9	NT-BNP; Increase to Grade 3; n=2,4,1,3,4,9,30,9	NT-BNP; Increase to Grade 4; n=2,4,1,3,4,9,30,9	Calcium; Any grade increase; n=2,4,1,3,4,9,32,9	Calcium; Increase to Grade 3; n=2,4,1,3,4,9,32,9	Calcium; Increase to Grade 4; n=2,4,1,3,4,9,32,9	Cholesterol;Any grade increase;n=2,4,1,3,4,7,29,9	Cholesterol;Increase to Grade 3;n=2,4,1,3,4,7,29,9	Cholesterol;Increase to Grade 4;n=2,4,1,3,4,7,29,9	CK;Any grade increase;n=3,4,1,3,4,9,31,9	CK; Increase to Grade 3; n=3, 4, 1, 3, 4, 9, 31, 9	CK; Increase to Grade 4; n=3, 4, 1, 3, 4, 9, 31, 9	Chloride; Any grade increase; n=2,4,1,3,4,9,32,9	Chloride; Increase to Grade 3;n=2,4,1,3,4,9,32,9	Chloride;Increase to Grade 4;n=2,4,1,3,4,9,32,9	CO2; Any grade increase; n=2, 4, 1, 3, 4, 9, 32, 9	CO2; Increase to Grade 3; n=2,4,1,3,4,9,32,9	CO2; Increase to Grade 4; n=2,4,1,3,4,9,32,9	Creatinine;Any grade increase;n=2,4,1,3,4,9,32,9	Creatinine;Increase to Grade 3;n=2,4,1,3,4,9,32,9	Creatinine;Increase to Grade 4;n=2,4,1,3,4,9,32,9	GGT; Any grade increase; n=2, 4, 1, 3, 4, 9, 31, 7	GGT;Increase to Grade 3; n=2,4,1,3,4,9,31,7	GGT; Increase to Grade 4; n=2,4,1,3,4,9,31,7	HDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 9	HDL; Increase to Grade 3; n=2,4,1,3,4,7,28,9	HDL; Increase to Grade 4; n=2,4,1,3,4,7,28,9	Insulin; Any grade increase; n=2,4,1,3,4,9,31,9	Insulin; Increase to Grade 3; n=2,4,1,3,4,9,31,9	Insulin; Increase to Grade 4; n=2,4,1,3,4,9,31,9	Potassium;Any grade increase;n=3,4,1,3,4,9,32,9	Potassium;Increase to Grade 3;n=3,4,1,3,4,9,32,9	Potassium;Increase to Grade 4;n=3,4,1,3,4,9,32,9	LDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 8	LDL;Increase to Grade 3; n=2,4,1,3,4,7,28,8	LDL;Increase to Grade 4; n=2,4,1,3,4,7,28,8	Lipase;Any grade increase; n=2,4,1,3,4,9,31,9	Lipase;Increase to Grade 3; n=2,4,1,3,4,9,31,9	Lipase;Increase to Grade 4; n=2,4,1,3,4,9,31,9	Magnesium;Any grade increase;n=3,4,1,3,4,9,32,9	Magnesium;Increase to Grade 3;n=3,4,1,3,4,9,32,9	Magnesium;Increase to Grade 4;n=3,4,1,3,4,9,32,9	Protein;Any grade increase; n=2,4,1,3,4,9,32,9	Protein;Increase to Grade 3; n=2,4,1,3,4,9,32,9	Protein;Increase to Grade 4; n=2,4,1,3,4,9,32,9	Sodium;Any grade increase; n=3,4,1,3,4,9,32,9	Sodium;Increase to Grade 3; n=3,4,1,3,4,9,32,9	Sodium;Increase to Grade 4; n=3,4,1,3,4,9,32,9	Thyroxine;Any grade increase;n=2,4,1,3,4,7,29,9	Thyroxine;Increase to Grade 3; n=2,4,1,3,4,7,29,9	Thyroxine;Increase to Grade 4; n=2,4,1,3,4,7,29,9	Triglyc;Any grade increase;n=2,4,1,3,4,7,29,9	Triglyc;Increase to Grade 3;n=2,4,1,3,4,7,29,9	Triglyc;Increase to Grade 4;n=2,4,1,3,4,7,29,9	Troponin T;Any grade increase;n=3,4,1,3,4,9,31,9	Troponin T;Increase to Grade 3; n=3,4,1,3,4,9,31,9	Troponin T;Increase to Grade 4; n=3,4,1,3,4,9,31,9	Urate;Any grade increase; n=2,4,1,3,4,9,32,9	Urate; Increase to Grade 3; n=2,4,1,3,4,9,32,9	Urate; Increase to Grade 4; n=2,4,1,3,4,9,32,9	Urea; Any grade increase; n=2,4,1,3,4,9,31,9	Urea; Increase to Grade 3; n=2,4,1,3,4,9,31,9	Urea; Increase to Grade 4; n=2,4,1,3,4,9,31,9
Part 1: GSK525762 16 mg QD	3	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 1: GSK525762 4 mg QD	2	0	0	2	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	2	0	0	0	0	0	3	0	1	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0
Part 1: GSK525762 8 mg QD	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD

Intervention	Participants (Count of Participants)
	Glucose; Any grade increase; n=2,4,1,3,4,9,32,9	Glucose; Increase to Grade 3; n=2,4,1,3,4,9,32,9	Glucose; Increase to Grade 4; n=2,4,1,3,4,9,32,9	Albumin; Any grade increase; n=2,4,1,3,4,9,32,9	Albumin; Increase to Grade 3; n=2,4,1,3,4,9,32,9	Albumin; Increase to Grade 4; n=2,4,1,3,4,9,32,9	ALP; Any grade increase; n=2,4,1,3,4,9,31,9	ALP; Increase to Grade 3; n=2,4,1,3,4,9,31,9	ALP; Increase to Grade 4; n=2,4,1,3,4,9,31,9	ALT; Any grade increase; n=2,4,1,3,4,9,32,9	ALT; Increase to Grade 3; n=2,4,1,3,4,9,32,9	ALT; Increase to Grade 4; n=2,4,1,3,4,9,32,9	Amylase; Any grade increase; n=2,4,1,3,4,9,32,9	Amylase; Increase to Grade 3; n=2,4,1,3,4,9,32,9	Amylase; Increase to Grade 4; n=2,4,1,3,4,9,32,9	AST; Any grade increase; n=2,4,1,3,4,9,32,9	AST; Increase to Grade 3; n=2,4,1,3,4,9,32,9	AST; Increase to Grade 4; n=2,4,1,3,4,9,32,9	Dir bil; Any grade increase; n=2,4,1,3,4,9,30,9	Dir bil; Increase to Grade 3; n=2,4,1,3,4,9,30,9	Dir bil; Increase to Grade 4; n=2,4,1,3,4,9,30,9	Bilirubin; Any grade increase; n=2,4,1,3,4,9,32,9	Bilirubin; Increase to Grade 3; n=2,4,1,3,4,9,32,9	Bilirubin; Increase to Grade 4; n=2,4,1,3,4,9,32,9	NT-BNP; Any grade increase; n=2,4,1,3,4,9,30,9	NT-BNP; Increase to Grade 3; n=2,4,1,3,4,9,30,9	NT-BNP; Increase to Grade 4; n=2,4,1,3,4,9,30,9	Calcium; Any grade increase; n=2,4,1,3,4,9,32,9	Calcium; Increase to Grade 3; n=2,4,1,3,4,9,32,9	Calcium; Increase to Grade 4; n=2,4,1,3,4,9,32,9	Cholesterol;Any grade increase;n=2,4,1,3,4,7,29,9	Cholesterol;Increase to Grade 3;n=2,4,1,3,4,7,29,9	Cholesterol;Increase to Grade 4;n=2,4,1,3,4,7,29,9	CK;Any grade increase;n=3,4,1,3,4,9,31,9	CK; Increase to Grade 3; n=3, 4, 1, 3, 4, 9, 31, 9	CK; Increase to Grade 4; n=3, 4, 1, 3, 4, 9, 31, 9	Chloride; Any grade increase; n=2,4,1,3,4,9,32,9	Chloride; Increase to Grade 3;n=2,4,1,3,4,9,32,9	Chloride;Increase to Grade 4;n=2,4,1,3,4,9,32,9	CO2; Any grade increase; n=2, 4, 1, 3, 4, 9, 32, 9	CO2; Increase to Grade 3; n=2,4,1,3,4,9,32,9	CO2; Increase to Grade 4; n=2,4,1,3,4,9,32,9	Creatinine;Any grade increase;n=2,4,1,3,4,9,32,9	Creatinine;Increase to Grade 3;n=2,4,1,3,4,9,32,9	Creatinine;Increase to Grade 4;n=2,4,1,3,4,9,32,9	GGT; Any grade increase; n=2, 4, 1, 3, 4, 9, 31, 7	GGT;Increase to Grade 3; n=2,4,1,3,4,9,31,7	GGT; Increase to Grade 4; n=2,4,1,3,4,9,31,7	HDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 9	HDL; Increase to Grade 3; n=2,4,1,3,4,7,28,9	HDL; Increase to Grade 4; n=2,4,1,3,4,7,28,9	Insulin; Any grade increase; n=2,4,1,3,4,9,31,9	Insulin; Increase to Grade 3; n=2,4,1,3,4,9,31,9	Insulin; Increase to Grade 4; n=2,4,1,3,4,9,31,9	Potassium;Any grade increase;n=3,4,1,3,4,9,32,9	Potassium;Increase to Grade 3;n=3,4,1,3,4,9,32,9	Potassium;Increase to Grade 4;n=3,4,1,3,4,9,32,9	LDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 8	LDL;Increase to Grade 3; n=2,4,1,3,4,7,28,8	LDL;Increase to Grade 4; n=2,4,1,3,4,7,28,8	Lipase;Any grade increase; n=2,4,1,3,4,9,31,9	Lipase;Increase to Grade 3; n=2,4,1,3,4,9,31,9	Lipase;Increase to Grade 4; n=2,4,1,3,4,9,31,9	Magnesium;Any grade increase;n=3,4,1,3,4,9,32,9	Magnesium;Increase to Grade 3;n=3,4,1,3,4,9,32,9	Magnesium;Increase to Grade 4;n=3,4,1,3,4,9,32,9	Protein;Any grade increase; n=2,4,1,3,4,9,32,9	Protein;Increase to Grade 3; n=2,4,1,3,4,9,32,9	Protein;Increase to Grade 4; n=2,4,1,3,4,9,32,9	Sodium;Any grade increase; n=3,4,1,3,4,9,32,9	Sodium;Increase to Grade 3; n=3,4,1,3,4,9,32,9	Sodium;Increase to Grade 4; n=3,4,1,3,4,9,32,9	Thyroxine;Any grade increase;n=2,4,1,3,4,7,29,9	Thyroxine;Increase to Grade 3; n=2,4,1,3,4,7,29,9	Thyroxine;Increase to Grade 4; n=2,4,1,3,4,7,29,9	Testosterone;Any grade increase;n=1,0,0,0,3,3,14,7	Testosterone;Increase to Grade3;n=1,0,0,0,3,3,14,7	Testosterone;Increase to Grade4;n=1,0,0,0,3,3,14,7	Triglyc;Any grade increase;n=2,4,1,3,4,7,29,9	Triglyc;Increase to Grade 3;n=2,4,1,3,4,7,29,9	Triglyc;Increase to Grade 4;n=2,4,1,3,4,7,29,9	Troponin T;Any grade increase;n=3,4,1,3,4,9,31,9	Troponin T;Increase to Grade 3; n=3,4,1,3,4,9,31,9	Troponin T;Increase to Grade 4; n=3,4,1,3,4,9,31,9	Urate;Any grade increase; n=2,4,1,3,4,9,32,9	Urate; Increase to Grade 3; n=2,4,1,3,4,9,32,9	Urate; Increase to Grade 4; n=2,4,1,3,4,9,32,9	Urea; Any grade increase; n=2,4,1,3,4,9,31,9	Urea; Increase to Grade 3; n=2,4,1,3,4,9,31,9	Urea; Increase to Grade 4; n=2,4,1,3,4,9,31,9
Part 1: GSK525762 2 mg QD	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	1	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0

Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD

Intervention	Participants (Count of Participants)
	Glucose; Any grade increase; n=2,4,1,3,4,9,32,9	Glucose; Increase to Grade 3; n=2,4,1,3,4,9,32,9	Glucose; Increase to Grade 4; n=2,4,1,3,4,9,32,9	Albumin; Any grade increase; n=2,4,1,3,4,9,32,9	Albumin; Increase to Grade 3; n=2,4,1,3,4,9,32,9	Albumin; Increase to Grade 4; n=2,4,1,3,4,9,32,9	ALP; Any grade increase; n=2,4,1,3,4,9,31,9	ALP; Increase to Grade 3; n=2,4,1,3,4,9,31,9	ALP; Increase to Grade 4; n=2,4,1,3,4,9,31,9	ALT; Any grade increase; n=2,4,1,3,4,9,32,9	ALT; Increase to Grade 3; n=2,4,1,3,4,9,32,9	ALT; Increase to Grade 4; n=2,4,1,3,4,9,32,9	Amylase; Any grade increase; n=2,4,1,3,4,9,32,9	Amylase; Increase to Grade 3; n=2,4,1,3,4,9,32,9	Amylase; Increase to Grade 4; n=2,4,1,3,4,9,32,9	AST; Any grade increase; n=2,4,1,3,4,9,32,9	AST; Increase to Grade 3; n=2,4,1,3,4,9,32,9	AST; Increase to Grade 4; n=2,4,1,3,4,9,32,9	Dir bil; Any grade increase; n=2,4,1,3,4,9,30,9	Dir bil; Increase to Grade 3; n=2,4,1,3,4,9,30,9	Dir bil; Increase to Grade 4; n=2,4,1,3,4,9,30,9	Bilirubin; Any grade increase; n=2,4,1,3,4,9,32,9	Bilirubin; Increase to Grade 3; n=2,4,1,3,4,9,32,9	Bilirubin; Increase to Grade 4; n=2,4,1,3,4,9,32,9	NT-BNP; Any grade increase; n=2,4,1,3,4,9,30,9	NT-BNP; Increase to Grade 3; n=2,4,1,3,4,9,30,9	NT-BNP; Increase to Grade 4; n=2,4,1,3,4,9,30,9	Calcium; Any grade increase; n=2,4,1,3,4,9,32,9	Calcium; Increase to Grade 3; n=2,4,1,3,4,9,32,9	Calcium; Increase to Grade 4; n=2,4,1,3,4,9,32,9	Cholesterol;Any grade increase;n=2,4,1,3,4,7,29,9	Cholesterol;Increase to Grade 3;n=2,4,1,3,4,7,29,9	Cholesterol;Increase to Grade 4;n=2,4,1,3,4,7,29,9	CK;Any grade increase;n=3,4,1,3,4,9,31,9	CK; Increase to Grade 3; n=3, 4, 1, 3, 4, 9, 31, 9	CK; Increase to Grade 4; n=3, 4, 1, 3, 4, 9, 31, 9	Chloride; Any grade increase; n=2,4,1,3,4,9,32,9	Chloride; Increase to Grade 3;n=2,4,1,3,4,9,32,9	Chloride;Increase to Grade 4;n=2,4,1,3,4,9,32,9	CO2; Any grade increase; n=2, 4, 1, 3, 4, 9, 32, 9	CO2; Increase to Grade 3; n=2,4,1,3,4,9,32,9	CO2; Increase to Grade 4; n=2,4,1,3,4,9,32,9	Creatinine;Any grade increase;n=2,4,1,3,4,9,32,9	Creatinine;Increase to Grade 3;n=2,4,1,3,4,9,32,9	Creatinine;Increase to Grade 4;n=2,4,1,3,4,9,32,9	GGT; Any grade increase; n=2, 4, 1, 3, 4, 9, 31, 7	GGT;Increase to Grade 3; n=2,4,1,3,4,9,31,7	GGT; Increase to Grade 4; n=2,4,1,3,4,9,31,7	HDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 9	HDL; Increase to Grade 3; n=2,4,1,3,4,7,28,9	HDL; Increase to Grade 4; n=2,4,1,3,4,7,28,9	Insulin; Any grade increase; n=2,4,1,3,4,9,31,9	Insulin; Increase to Grade 3; n=2,4,1,3,4,9,31,9	Insulin; Increase to Grade 4; n=2,4,1,3,4,9,31,9	Potassium;Any grade increase;n=3,4,1,3,4,9,32,9	Potassium;Increase to Grade 3;n=3,4,1,3,4,9,32,9	Potassium;Increase to Grade 4;n=3,4,1,3,4,9,32,9	LDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 8	LDL;Increase to Grade 3; n=2,4,1,3,4,7,28,8	LDL;Increase to Grade 4; n=2,4,1,3,4,7,28,8	Lipase;Any grade increase; n=2,4,1,3,4,9,31,9	Lipase;Increase to Grade 3; n=2,4,1,3,4,9,31,9	Lipase;Increase to Grade 4; n=2,4,1,3,4,9,31,9	Magnesium;Any grade increase;n=3,4,1,3,4,9,32,9	Magnesium;Increase to Grade 3;n=3,4,1,3,4,9,32,9	Magnesium;Increase to Grade 4;n=3,4,1,3,4,9,32,9	Protein;Any grade increase; n=2,4,1,3,4,9,32,9	Protein;Increase to Grade 3; n=2,4,1,3,4,9,32,9	Protein;Increase to Grade 4; n=2,4,1,3,4,9,32,9	Sodium;Any grade increase; n=3,4,1,3,4,9,32,9	Sodium;Increase to Grade 3; n=3,4,1,3,4,9,32,9	Sodium;Increase to Grade 4; n=3,4,1,3,4,9,32,9	Thyroxine;Any grade increase;n=2,4,1,3,4,7,29,9	Thyroxine;Increase to Grade 3; n=2,4,1,3,4,7,29,9	Thyroxine;Increase to Grade 4; n=2,4,1,3,4,7,29,9	Testosterone;Any grade increase;n=1,0,0,0,3,3,14,7	Testosterone;Increase to Grade3;n=1,0,0,0,3,3,14,7	Testosterone;Increase to Grade4;n=1,0,0,0,3,3,14,7	Triglyc;Any grade increase;n=2,4,1,3,4,7,29,9	Triglyc;Increase to Grade 3;n=2,4,1,3,4,7,29,9	Triglyc;Increase to Grade 4;n=2,4,1,3,4,7,29,9	Troponin I;Any grade increase;n=0,0,0,0, 2,5,24,5	Troponin I;Increase to Grade 3;n=0,0,0,0,2,5,24,5	Troponin I;Increase to Grade 4; n=0,0,0,0,2,5,24,5	Troponin T;Any grade increase;n=3,4,1,3,4,9,31,9	Troponin T;Increase to Grade 3; n=3,4,1,3,4,9,31,9	Troponin T;Increase to Grade 4; n=3,4,1,3,4,9,31,9	Urate;Any grade increase; n=2,4,1,3,4,9,32,9	Urate; Increase to Grade 3; n=2,4,1,3,4,9,32,9	Urate; Increase to Grade 4; n=2,4,1,3,4,9,32,9	Urea; Any grade increase; n=2,4,1,3,4,9,31,9	Urea; Increase to Grade 3; n=2,4,1,3,4,9,31,9	Urea; Increase to Grade 4; n=2,4,1,3,4,9,31,9
Part 1: GSK525762 100 mg QD	8	3	0	1	0	0	0	0	0	2	0	0	1	1	0	3	1	0	0	0	0	8	1	0	0	0	0	3	0	0	1	0	0	5	0	0	0	0	0	0	0	0	3	0	0	1	0	0	0	0	0	0	0	0	3	1	0	0	0	0	2	0	0	2	0	0	0	0	0	4	0	0	0	0	0	0	0	0	6	0	1	0	0	0	0	0	0	0	0	0	0	0	0
Part 1: GSK525762 30 mg QD	2	0	0	1	0	0	1	0	0	1	0	0	2	0	0	2	0	0	0	0	0	1	1	0	0	0	0	2	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	2	1	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	1	0	1	0	0	0
Part 1: GSK525762 80 mg QD	24	2	0	12	0	0	7	1	0	9	0	0	10	1	1	14	0	0	0	0	0	15	5	0	0	0	0	17	0	0	11	0	0	11	2	0	0	0	0	0	0	0	7	1	0	11	2	1	0	0	0	0	0	0	13	1	1	0	0	0	8	3	0	9	0	0	0	0	0	16	4	0	0	0	0	0	0	0	17	0	0	0	0	0	0	0	0	1	0	1	0	0	0

Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD

Intervention	Participants (Count of Participants)
	Glucose; Any grade increase; n=2,4,1,3,4,9,32,9	Glucose; Increase to Grade 3; n=2,4,1,3,4,9,32,9	Glucose; Increase to Grade 4; n=2,4,1,3,4,9,32,9	Albumin; Any grade increase; n=2,4,1,3,4,9,32,9	Albumin; Increase to Grade 3; n=2,4,1,3,4,9,32,9	Albumin; Increase to Grade 4; n=2,4,1,3,4,9,32,9	ALP; Any grade increase; n=2,4,1,3,4,9,31,9	ALP; Increase to Grade 3; n=2,4,1,3,4,9,31,9	ALP; Increase to Grade 4; n=2,4,1,3,4,9,31,9	ALT; Any grade increase; n=2,4,1,3,4,9,32,9	ALT; Increase to Grade 3; n=2,4,1,3,4,9,32,9	ALT; Increase to Grade 4; n=2,4,1,3,4,9,32,9	Amylase; Any grade increase; n=2,4,1,3,4,9,32,9	Amylase; Increase to Grade 3; n=2,4,1,3,4,9,32,9	Amylase; Increase to Grade 4; n=2,4,1,3,4,9,32,9	AST; Any grade increase; n=2,4,1,3,4,9,32,9	AST; Increase to Grade 3; n=2,4,1,3,4,9,32,9	AST; Increase to Grade 4; n=2,4,1,3,4,9,32,9	Dir bil; Any grade increase; n=2,4,1,3,4,9,30,9	Dir bil; Increase to Grade 3; n=2,4,1,3,4,9,30,9	Dir bil; Increase to Grade 4; n=2,4,1,3,4,9,30,9	Bilirubin; Any grade increase; n=2,4,1,3,4,9,32,9	Bilirubin; Increase to Grade 3; n=2,4,1,3,4,9,32,9	Bilirubin; Increase to Grade 4; n=2,4,1,3,4,9,32,9	NT-BNP; Any grade increase; n=2,4,1,3,4,9,30,9	NT-BNP; Increase to Grade 3; n=2,4,1,3,4,9,30,9	NT-BNP; Increase to Grade 4; n=2,4,1,3,4,9,30,9	Calcium; Any grade increase; n=2,4,1,3,4,9,32,9	Calcium; Increase to Grade 3; n=2,4,1,3,4,9,32,9	Calcium; Increase to Grade 4; n=2,4,1,3,4,9,32,9	Cholesterol;Any grade increase;n=2,4,1,3,4,7,29,9	Cholesterol;Increase to Grade 3;n=2,4,1,3,4,7,29,9	Cholesterol;Increase to Grade 4;n=2,4,1,3,4,7,29,9	CK;Any grade increase;n=3,4,1,3,4,9,31,9	CK; Increase to Grade 3; n=3, 4, 1, 3, 4, 9, 31, 9	CK; Increase to Grade 4; n=3, 4, 1, 3, 4, 9, 31, 9	Chloride; Any grade increase; n=2,4,1,3,4,9,32,9	Chloride; Increase to Grade 3;n=2,4,1,3,4,9,32,9	Chloride;Increase to Grade 4;n=2,4,1,3,4,9,32,9	CO2; Any grade increase; n=2, 4, 1, 3, 4, 9, 32, 9	CO2; Increase to Grade 3; n=2,4,1,3,4,9,32,9	CO2; Increase to Grade 4; n=2,4,1,3,4,9,32,9	Creatinine;Any grade increase;n=2,4,1,3,4,9,32,9	Creatinine;Increase to Grade 3;n=2,4,1,3,4,9,32,9	Creatinine;Increase to Grade 4;n=2,4,1,3,4,9,32,9	GGT; Any grade increase; n=2, 4, 1, 3, 4, 9, 31, 7	GGT;Increase to Grade 3; n=2,4,1,3,4,9,31,7	GGT; Increase to Grade 4; n=2,4,1,3,4,9,31,7	HDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 9	HDL; Increase to Grade 3; n=2,4,1,3,4,7,28,9	HDL; Increase to Grade 4; n=2,4,1,3,4,7,28,9	Insulin; Any grade increase; n=2,4,1,3,4,9,31,9	Insulin; Increase to Grade 3; n=2,4,1,3,4,9,31,9	Insulin; Increase to Grade 4; n=2,4,1,3,4,9,31,9	Potassium;Any grade increase;n=3,4,1,3,4,9,32,9	Potassium;Increase to Grade 3;n=3,4,1,3,4,9,32,9	Potassium;Increase to Grade 4;n=3,4,1,3,4,9,32,9	LDH; Any grade increase; n=0, 0, 0, 0, 0, 1, 0, 0	LDH; Increase to Grade 3; n=0, 0, 0, 0, 0, 1, 0, 0	LDH; Increase to Grade 4; n=0, 0, 0, 0, 0, 1, 0, 0	LDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 8	LDL;Increase to Grade 3; n=2,4,1,3,4,7,28,8	LDL;Increase to Grade 4; n=2,4,1,3,4,7,28,8	Lipase;Any grade increase; n=2,4,1,3,4,9,31,9	Lipase;Increase to Grade 3; n=2,4,1,3,4,9,31,9	Lipase;Increase to Grade 4; n=2,4,1,3,4,9,31,9	Magnesium;Any grade increase;n=3,4,1,3,4,9,32,9	Magnesium;Increase to Grade 3;n=3,4,1,3,4,9,32,9	Magnesium;Increase to Grade 4;n=3,4,1,3,4,9,32,9	Protein;Any grade increase; n=2,4,1,3,4,9,32,9	Protein;Increase to Grade 3; n=2,4,1,3,4,9,32,9	Protein;Increase to Grade 4; n=2,4,1,3,4,9,32,9	Sodium;Any grade increase; n=3,4,1,3,4,9,32,9	Sodium;Increase to Grade 3; n=3,4,1,3,4,9,32,9	Sodium;Increase to Grade 4; n=3,4,1,3,4,9,32,9	Thyroxine;Any grade increase;n=2,4,1,3,4,7,29,9	Thyroxine;Increase to Grade 3; n=2,4,1,3,4,7,29,9	Thyroxine;Increase to Grade 4; n=2,4,1,3,4,7,29,9	Testosterone;Any grade increase;n=1,0,0,0,3,3,14,7	Testosterone;Increase to Grade3;n=1,0,0,0,3,3,14,7	Testosterone;Increase to Grade4;n=1,0,0,0,3,3,14,7	Triglyc;Any grade increase;n=2,4,1,3,4,7,29,9	Triglyc;Increase to Grade 3;n=2,4,1,3,4,7,29,9	Triglyc;Increase to Grade 4;n=2,4,1,3,4,7,29,9	Troponin I;Any grade increase;n=0,0,0,0, 2,5,24,5	Troponin I;Increase to Grade 3;n=0,0,0,0,2,5,24,5	Troponin I;Increase to Grade 4; n=0,0,0,0,2,5,24,5	Troponin T;Any grade increase;n=3,4,1,3,4,9,31,9	Troponin T;Increase to Grade 3; n=3,4,1,3,4,9,31,9	Troponin T;Increase to Grade 4; n=3,4,1,3,4,9,31,9	Urate;Any grade increase; n=2,4,1,3,4,9,32,9	Urate; Increase to Grade 3; n=2,4,1,3,4,9,32,9	Urate; Increase to Grade 4; n=2,4,1,3,4,9,32,9	Urea; Any grade increase; n=2,4,1,3,4,9,31,9	Urea; Increase to Grade 3; n=2,4,1,3,4,9,31,9	Urea; Increase to Grade 4; n=2,4,1,3,4,9,31,9
Part 1: GSK525762 60 mg QD	7	0	0	3	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2

Blood samples were collected for the analysis of clinical chemistry parameters: glucose, albumin, ALP, ALT, amylase, AST, Dir bil, bilirubin, NT-BNP, calcium, cholesterol, CK, chloride, CO2, creatinine, GGT, HDL and LDL cholesterol, insulin, potassium, LDH, lipase, magnesium, protein, sodium, thyroxine, testosterone, triglycerides (triglyc), troponin I and T, urate and urea. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post-Baseline is presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure

,,,,,

Intervention	Participants (Count of Participants)
	Glucose; Any grade increase; n=11,13,23,19,21,12	Glucose; Increase to Grade 3; n=11,13,23,19,21,12	Glucose; Increase to Grade 4; n=11,13,23,19,21,12	Albumin; Any grade increase; n=11,13,23,19,21,12	Albumin; Increase to Grade 3; n=11,13,23,19,21,12	Albumin; Increase to Grade 4; n=11,13,23,19,21,12	ALP; Any grade increase; n=11,13,23,19,21,12	ALP; Increase to Grade 3; n=11,13,23,19,21,12	ALP; Increase to Grade 4; n=11,13,23,19,21,12	ALT; Any grade increase; n=11,14,23,19,21,12	ALT; Increase to Grade 3; n=11,14,23,19,21,12	ALT; Increase to Grade 4; n=11,14,23,19,21,12	Amylase; Any grade increase; n=11,12,22,19,20,12	Amylase; Increase to Grade 3; n=11,12,22,19,20,12	Amylase; Increase to Grade 4; n=11,12,22,19,20,12	AST; Any grade increase; n=11,13,23,19,21,12	AST; Increase to Grade 3; n=11,13,23,19,21,12	AST; Increase to Grade 4; n=11,13,23,19,21,12	Dir bil; Any grade increase; n=11,13,23,19,20,12	Dir bil; Increase to Grade 3; n=11,13,23,19,20,12	Dir bil; Increase to Grade 4; n=11,13,23,19,20,12	Bilirubin;Any grade increase;n=11,14,23,19,21,12	Bilirubin;Increase to Grade 3; n=11,14,23,19,21,12	Bilirubin;Increase to Grade 4; n=11,14,23,19,21,12	NT-BNP; Any grade increase; n=11,12,22,17,15,12	NT-BNP; Increase to Grade 3; n=11,12,22,17,15,12	NT-BNP; Increase to Grade 4; n=11,12,22,17,15,12	Calcium; Any grade increase; n=11,13,23,19,21,12	Calcium; Increase to Grade 3; n=11,13,23,19,21,12	Calcium; Increase to Grade 4; n=11,13,23,19,21,12	Cholesterol;Any grade increase;n=10,12,22,19,20,12	Cholesterol;Increase to Grade3;n=10,12,22,19,20,12	Cholesterol;Increase to Grade4;n=10,12,22,19,20,12	CK; Any grade increase; n=9,9,21,17,18,11	CK; Increase to Grade 3; n=9,9,21,17,18,11	CK; Increase to Grade 4; n=9,9,21,17,18,11	Chloride; Any grade increase; n=11,13,23,19,21,12	Chloride; Increase to Grade 3; n=11,13,23,19,21,12	Chloride; Increase to Grade 4; n=11,13,23,19,21,12	CO2; Any grade increase; n=11,12,23,19,21,12	CO2; Increase to Grade 3; n=11,12,23,19,21,12	CO2; Increase to Grade 4; n=11,12,23,19,21,12	Creatinine;Any grade increase;n=11,14,23,19,21,12	Creatinine;Increase to Grade3;n=11,14,23,19,21,12	Creatinine;Increase to Grade4;n=11,14,23,19,21,12	GGT; Any grade increase; n=11,13,22,19,20,12	GGT; Increase to Grade 3; n=11,13,22,19,20,12	GGT; Increase to Grade 4; n=11,13,22,19,20,12	HDL; Any grade increase; n=10,10,22,19,19,12	HDL; Increase to Grade 3; n=10,10,22,19,19,12	HDL; Increase to Grade 4;n=10,10,22,19,19,12	Insulin; Any grade increase; n=11,12,22,19,20,12	Insulin; Increase to Grade 3; n=11,12,22,19,20,12	Insulin; Increase to Grade 4; n=11,12,22,19,20,12	Potassium; Any grade increase; n=11,14,23,19,21,12	Potassium;Increase to Grade3;n=11,14,23,19,21,12	Potassium;Increase to Grade4;n=11,14,23,19,21,12	LDL; Any grade increase; n=10,10,22,19,19,12	LDL; Increase to Grade 3; n=10,10,22,19,19,12	LDL; Increase to Grade 4;n=10,10,22,19,19,12	Lipase; Any grade increase; n=11,12,22,19,20,12	Lipase; Increase to Grade 3;n=11,12,22,19,20,12	Lipase; Increase to Grade 4;n=11,12,22,19,20,12	Magnesium; Any grade increase; n=11,12,22,19,21,12	Magnesium; Increase to Grade 3;n=11,12,22,19,21,12	Magnesium; Increase to Grade4;n=11,12,22,19,21,12	Protein; Any grade increase; n=11,13,23,19,21,12	Protein; Increase to Grade 3;n=11,13,23,19,21,12	Protein; Increase to Grade 4;n=11,13,23,19,21,12	Sodium; Any grade increase; n=11, 14,23,19,21,12	Sodium; Increase to Grade 3; n=11, 14,23,19,21,12	Sodium; Increase to Grade 4; n=11, 14,23,19,21,12	Thyroxine; Any grade increase;n=7,7,20,15,18,8	Thyroxine; Increase to Grade3;n=7,7,20,15,18,8	Thyroxine; Increase to Grade4;n=7,7,20,15,18,8	Testosterone; Any grade increase; n=4,3,18,0,1,5	Testosterone; Increase to Grade3; n=4,3,18,0,1,5	Testosterone; Increase to Grade4; n=4,3,18,0,1,5	Triglyc;Any grade increase;n=10,12,22,19,20,12	Triglyc;Increase to Grade3;n=10,12,22,19,20,12	Triglyc;Increase to Grade4;n=10,12,22,19,20,12	Troponin I; Any grade increase; n=7,6,15,15,14,7	Troponin I; Increase to Grade 3; n=7,6,15,15,14,7	Troponin I; Increase to Grade 4; n=7,6,15,15,14,7	Troponin T;Any grade increase;n=11,12,22,19,20,12	Troponin T;Increase to Grade3;n=11,12,22,19,20,12	Troponin T;Increase to Grade4;n=11,12,22,19,20,12	Urate; Any grade increase; n=11,12,22,19,20,12	Urate; Increase to Grade 3; n=11,12,22,19,20,12	Urate; Increase to Grade 4; n=11,12,22,19,20,12	Urea; Any grade increase; n=11,14,23,17,17,11	Urea; Increase to Grade 3; n=11,14,23,17,17,11	Urea; Increase to Grade 4;n=11,14,23,17,17,11
Part 2: Participants With CRPC	20	0	0	9	0	0	6	2	0	6	0	0	9	2	0	10	1	0	0	0	0	13	2	0	0	0	0	8	2	0	2	0	0	4	0	0	0	0	0	0	0	0	9	2	1	7	2	0	0	0	0	0	0	0	10	1	0	0	0	0	7	0	0	5	0	0	0	0	0	8	1	0	0	0	0	0	0	0	15	4	0	0	0	0	0	0	0	2	0	2	0	0	0
Part 2: Participants With ER+BC	18	1	0	7	1	0	4	0	0	12	0	0	6	2	0	14	3	0	0	0	0	13	3	0	0	0	0	3	1	0	9	0	0	7	0	0	0	0	0	0	0	0	6	0	0	6	3	1	0	0	0	0	0	0	7	0	0	0	0	0	4	0	1	4	0	0	0	0	0	4	0	0	0	0	0	0	0	0	11	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 2: Participants With GIST	9	2	0	5	0	0	4	0	0	3	0	0	1	0	0	6	0	0	0	0	0	4	0	0	0	0	0	3	0	0	5	0	0	5	0	0	0	0	0	0	0	0	3	0	0	1	0	0	0	0	0	0	0	0	7	1	0	0	0	0	2	0	0	1	0	0	0	0	0	5	2	0	0	0	0	0	0	0	8	0	0	0	0	0	0	0	0	2	0	2	0	0	0
Part 2: Participants With NMC	10	0	0	5	0	0	3	0	0	3	0	0	5	1	0	3	0	0	0	0	0	8	1	0	0	0	0	6	1	0	5	0	0	3	0	0	0	0	0	0	0	0	3	0	0	0	0	0	0	0	0	0	0	0	6	0	0	0	0	0	3	2	0	2	0	0	0	0	0	5	0	1	0	0	0	0	0	0	7	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 2: Participants With SCLC	10	0	0	6	0	0	1	0	0	6	1	0	5	2	0	5	0	0	0	0	0	10	1	0	0	0	0	3	0	0	2	0	0	2	0	0	0	0	0	0	0	0	4	0	0	3	0	0	0	0	0	0	0	0	4	0	0	0	0	0	5	3	0	2	0	0	0	0	0	5	1	0	0	0	0	0	0	0	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 2: Participants With TNBC	16	0	0	8	0	0	3	0	0	5	0	0	5	2	0	8	1	0	0	0	0	6	0	0	0	0	0	4	0	0	2	0	0	0	0	0	0	0	0	0	0	0	2	0	0	5	2	0	0	0	0	0	0	0	5	0	0	0	0	0	5	1	1	1	0	0	0	0	0	5	2	0	0	0	0	0	0	0	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study

Blood samples were collected for the analysis of hematology parameters: aPTT, platelet count, RBC, WBC, INR, PT, Fib, hemoglobin, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.87 months of drug exposure

Intervention	Participants (Count of Participants)
	Basophils; Any grade increase	Basophils; Increase to Grade 3	Basophils; Increase to Grade 4	Eosinophils; Any grade increase	Eosinophils; Increase to Grade 3	Eosinophils; Increase to Grade 4	Hemoglobin; Any grade increase	Hemoglobin; Increase to Grade 3	Hemoglobin; Increase to Grade 4	INR; Any grade increase	INR; Increase to Grade 3	INR; Increase to Grade 4	Lymphocytes; Any grade increase	Lymphocytes; Increase to Grade 3	Lymphocytes; Increase to Grade 4	Monocytes; Any grade increase	Monocytes; Increase to Grade 3	Monocytes; Increase to Grade 4	Neutrophils; Any grade increase	Neutrophils; Increase to Grade 3	Neutrophils; Increase to Grade 4	Platelets; Any grade increase	Platelets; Increase to Grade 3	Platelets; Increase to Grade 4	PT; Any grade increase	PT; Increase to Grade 3	PT; Increase to Grade 4	RBC; Any grade increase	RBC; Increase to Grade 3	RBC; Increase to Grade 4	WBC; Any grade increase	WBC; Increase to Grade 3	WBC; Increase to Grade 4	Fib; Any grade increase	Fib; Increase to Grade 3	Fib; Increase to Grade 4	aPTT; Any grade increase	aPTT; Increase to Grade 3	aPTT; Increase to Grade 4
80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes	0	0	0	0	0	0	4	2	0	1	0	0	3	1	2	0	0	0	1	0	0	5	0	3	0	0	0	0	0	0	3	0	0	0	0	0	4	0	0
80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes	0	0	0	0	0	0	3	2	0	1	0	0	4	0	0	0	0	0	1	0	0	5	2	1	0	0	0	0	0	0	1	0	0	0	0	0	2	0	0

Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID

Intervention	Participants (Count of Participants)
	Basophils; Any grade increase; n=4,10,5	Basophils; Increase to Grade 3; n=4,10,5	Basophils; Increase to Grade 4; n=4,10,5	Eosinophils; Any grade increase; n=4,10,5	Eosinophils; Increase to Grade3; n=4,10,5	Eosinophils; Increase to Grade4; n=4,10,5	Hemoglobin; Any grade increase; n=4,10,5	Hemoglobin; Increase to Grade 3; n=4,10,5	Hemoglobin; Increase to Grade 4; n=4,10,5	INR; Any grade increase; n=4,10,5	INR; Increase to Grade 3; n=4,10,5	INR; Increase to Grade 4; n=4,10,5	Lymphocytes; Any grade increase; n=4,10,5	Lymphocytes; Increase to Grade3; n=4,10,5	Lymphocytes; Increase to Grade4; n=4,10,5	Monocytes; Any grade increase; n=4,10,5	Monocytes;Increase to Grade3; n=4,10,5	Monocytes; Increase to Grade 4; n=4,10,5	Neutrophils; Any grade increase; n=4,10,5	Neutrophils; Increase to Grade 3; n=4,10,5	Neutrophils; Increase to Grade 4; n=4,10,5	Platelets; Any grade increase; n=4,10,5	Platelets; Increase to Grade 3; n=4,10,5	Platelets; Increase to Grade 4; n=4,10,5	PT; Any grade increase;n=4,10,5	PT; Increase to Grade 3; n=4,10,5	PT; Increase to Grade 4; n=4,10,5	RBC; Any grade increase; n=4,10,5	RBC; Increase to Grade 3; n=4,10,5	RBC; Increase to Grade 4; n=4,10,5	WBC; Any grade increase; n=4,10,5	WBC; Increase to Grade 3; n=4,10,5	WBC; Increase to Grade 4; n=4,10,5	Fib; Any grade increase; n=4,10,5	Fib; Increase to Grade 3; n=4,10,5	Fib; Increase to Grade 4; n=4,10,5	aPTT; Any grade increase; n=4,10,5	aPTT; Increase to Grade 3; n=4,10,5	aPTT; Increase to Grade 4; n=4,10,5
Part 1: GSK525762 20 mg BID	0	0	0	0	0	0	4	0	0	0	0	0	2	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
Part 1: GSK525762 30 mg BID	0	0	0	0	0	0	8	3	0	6	0	0	8	4	0	0	0	0	0	0	0	10	2	0	0	0	0	0	0	0	0	0	0	0	0	0	5	0	0
Part 1: GSK525762 40 mg BID	0	0	0	0	0	0	4	2	0	3	0	0	2	0	0	0	0	0	1	0	0	5	2	1	0	0	0	0	0	0	1	0	0	0	0	0	2	0	0

Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD

Blood samples were collected for the analysis of hematology parameters: activated partial thromboplastin time (aPTT), platelet count, red blood cell count (RBC), white blood cell count (WBC), prothrombin international normalized ratio (INR), prothrombin time (PT), fibrinogen (Fib), hemoglobin, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure

,,,,,,,

Intervention	Participants (Count of Participants)
	Basophils;Any grade increase	Basophils;Increase to Grade 3	Basophils;Increase to Grade 4	Eosinophils;Any grade increase	Eosinophils;Increase to Grade3	Eosinophils;Increase to Grade 4	Hemoglobin;Any grade increase	Hemoglobin;Increase to Grade 3; n=2,4,1,3,4,9,32,9	Hemoglobin;Increase to Grade 4	INR; Any grade increase	INR;Increase to Grade 3	INR; Increase to Grade 4	Lymphocytes;Any grade increase	Lymphocytes;Increase to Grade3	Lymphocytes;Increase to Grade4	Monocytes;Any grade increase	Monocytes;Increase to Grade3	Monocytes;Increase to Grade 4	Neutrophils;Any grade increase	Neutrophils;Increase to Grade 3	Neutrophils;Increase to Grade 4	Platelets;Any grade increase	Platelets;Increase to Grade 3	Platelets;Increase to Grade 4	PT; Any grade increase	PT; Increase to Grade 3	PT; Increase to Grade 4	RBC; Any grade increase	RBC;Increase to Grade 3	RBC;Increase to Grade 4	WBC; Any grade increase	WBC; Increase to Grade 3	WBC; Increase to Grade 4	Fib; Any grade increase	Fib;Increase to Grade 3	Fib;Increase to Grade 4	aPTT; Any grade increase	aPTT; Increase to Grade 3	aPTT; Increase to Grade 4
Part 1: GSK525762 100 mg QD	0	0	0	0	0	0	7	1	0	2	0	0	4	1	1	0	0	0	3	1	0	8	5	2	0	0	0	0	0	0	5	1	0	0	0	0	2	0	0
Part 1: GSK525762 16 mg QD	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 1: GSK525762 2 mg QD	0	0	0	0	0	0	1	0	0	2	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 1: GSK525762 30 mg QD	0	0	0	0	0	0	2	1	0	0	0	0	2	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 1: GSK525762 4 mg QD	0	0	0	0	0	0	1	0	0	2	0	0	2	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
Part 1: GSK525762 60 mg QD	0	0	0	0	0	0	2	1	0	1	0	0	5	2	0	0	00	0	0	0	0	5	0	1	0	0	0	0	0	0	3	0	0	0	0	0	0	0	0
Part 1: GSK525762 8 mg QD	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Part 1: GSK525762 80 mg QD	0	0	0	0	0	0	21	9	0	21	0	0	19	8	1	0	0	0	7	0	1	26	11	5	0	0	0	0	0	0	11	0	1	4	0	0	14	1	0

Number of Participants With Grade Change From Baseline in Hematology Data-Part 2

,,,,,

Intervention	Participants (Count of Participants)
	Basophils; Any grade increase; n=11,13,23,19,21,13	Basophils; Increase to Grade3; n=11,13,23,19,21,13	Basophils; Increase to Grade4; n=11,13,23,19,21,13	Eosinophils;Any grade increase;n=11,13,23,19,21,13	Eosinophils;Increase to Grade3;n=11,13,23,19,21,13	Eosinophils;Increase to Grade4;n=11,13,23,19,21,13	Hemoglobin;Any grade increase;n=11,14,23,19,21,13	Hemoglobin;Increase to Grade3;n=11,14,23,19,21,13	Hemoglobin;Increase to Grade4;n=11,14, 23,19,21,13	INR; Any grade increase; n=11,12,21,17,18,12	INR; Increase to Grade3; n=11,12,21,17,18,12	INR; Increase to Grade4; n=11,12,21,17,18,12	Lymphocytes;Any grade increase;n=11,13,23,19,21,13	Lymphocytes;Increase to Grade3;n=11,13,23,19,21,13	Lymphocytes;Increase to Grade4;n=11,13,23,19,21,13	Monocytes; Any grade increase; n=11,13,23,19,21,13	Monocytes;Increase to Grade3; n=11,13,23,19,21,13	Monocytes; Increase to Grade4; n=11,13,23,19,21,13	Neutrophils;Any grade increase;n=11,14,23,19,21,13	Neutrophils;Increase to Grade3;n=11,14,23,19,21,13	Neutrophils;Increase to Grade4;n=11,14,23,19,21,13	Platelets; Any grade increase; n=11,14,23,19,21,13	Platelets; Increase to Grade3; n=11,14,23,19,21,13	Platelets; Increase to Grade4; n=11,14,23,19,21,13	PT; Any grade increase;n=10,10, 18, 17, 18, 12	PT; Increase to Grade 3; n=10,10, 18, 17, 18, 12	PT; Increase to Grade 4; n=10,10, 18, 17, 18, 12	RBC; Any grade increase; n=11, 13, 23, 19, 21, 13	RBC; Increase to Grade 3; n=11, 13, 23, 19, 21, 13	RBC; Increase to Grade 4; n=11, 13, 23, 19, 21, 13	WBC; Any grade increase; n=11, 14, 23, 19, 21, 13	WBC; Increase to Grade 3; n=11, 14, 23, 19, 21, 13	WBC; Increase to Grade 4; n=11, 14, 23, 19, 21, 13	Fib; Any grade increase; n=11, 11, 21, 17, 18, 12	Fib; Increase to Grade 3; n=11, 11, 21, 17, 18, 12	Fib; Increase to Grade 4; n=11, 11, 21, 17, 18, 12	aPTT; Any grade increase; n=11,12,21,17,18,12	aPTT; Increase to Grade3; n=11,12,21, 17, 18, 12	aPTT; Increase to Grade4; n=11,12,21,17,18,12
Participants With CRPC	0	0	0	0	0	0	18	9	0	13	0	0	14	6	0	0	00	0	8	0	0	20	5	8	0	0	0	0	0	0	9	1	0	1	0	0	1	0	0
Participants With ER+BC	0	0	0	0	0	0	18	5	0	11	0	0	13	1	0	0	0	0	6	1	0	18	6	2	0	0	0	0	0	0	6	0	0	0	0	0	5	0	0
Participants With GIST	0	0	0	0	0	0	6	3	0	7	0	0	6	0	0	0	0	0	1	0	0	7	0	0	0	0	0	0	0	0	3	0	0	1	0	0	4	0	0
Participants With NMC	0	0	0	0	0	0	6	3	0	8	0	0	8	2	0	0	0	0	4	1	0	7	4	2	0	0	0	0	0	0	7	1	0	2	1	0	4	0	0
Participants With SCLC	0	0	0	0	0	0	10	2	0	6	0	0	7	2	1	0	0	0	4	1	0	12	4	3	0	0	0	0	0	0	5	0	0	0	0	0	4	0	0
Participants With TNBC	0	0	0	0	0	0	10	4	0	8	0	0	9	2	0	0	0	0	3	2	0	17	6	4	0	0	0	0	0	0	5	1	0	0	0	0	3	1	0

Number of Participants With Increase in Blood Pressure From Baseline-Besylate Sub-study

Intervention	Participants (Count of Participants)
	DBP; Increase to Grade 1	DBP; Increase to Grade 2	DBP; Increase to Grade 3/4	SBP; Increase to Grade 1	SBP; Increase to Grade 2	SBP; Increase to Grade 3/4
80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes	1	2	0	1	0	0
80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes	1	1	0	1	1	0

Number of Participants With Increase in Blood Pressure From Baseline-Part 1 BID

SBP and DBP were measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. Grading of SBP and DBP were done using NCI-CTCAE version 4.0 where, SBP (millimeters of mercury): Grade 0 (<120), Grade 1 (120-139), Grade 2 (140-159), Grade 3/4 (>=160) and DBP: Grade 0 (<80), Grade 1 (80-89), Grade 2 (90-99), Grade 3/4 (>=100). An increase is defined as an increase in CTCAE grade relative to baseline grade. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure

Intervention	Participants (Count of Participants)
	DBP; Increase to Grade 1;n=4,10,4	DBP; Increase to Grade 2;n=4,10,4	DBP; Increase to Grade 3/4;n=4,10,4	SBP; Increase to Grade 1;n=4,9,5	SBP; Increase to Grade 2;n=4,9,5	SBP; Increase to Grade 3/4;n=4,9,5
Part 1: GSK525762 20 mg BID	2	0	0	1	1	0
Part 1: GSK525762 30 mg BID	4	4	0	2	6	0
Part 1: GSK525762 40 mg BID	1	1	1	2	1	1

Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD

Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. Grading of SBP and DBP were done using NCI-CTCAE version 4.0 where, SBP (millimeters of mercury): Grade 0 (<120), Grade 1 (120-139), Grade 2 (140-159), Grade 3/4 (>=160) and DBP: Grade 0 (<80), Grade 1 (80-89), Grade 2 (90-99), Grade 3/4 (>=100). An increase is defined as an increase in CTCAE grade relative to baseline grade. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure

,,,,,,,

Intervention	Participants (Count of Participants)
	DBP; Increase to Grade 1	DBP; Increase to Grade 2	DBP; Increase to Grade 3/4	SBP; Increase to Grade 1	SBP; Increase to Grade 2	SBP; Increase to Grade 3/4
Part 1: GSK525762 100 mg QD	0	1	2	1	3	2
Part 1: GSK525762 16 mg QD	0	1	0	1	1	0
Part 1: GSK525762 2 mg QD	2	0	0	1	1	0
Part 1: GSK525762 30 mg QD	0	1	0	1	3	0
Part 1: GSK525762 4 mg QD	1	0	0	1	0	1
Part 1: GSK525762 60 mg QD	3	0	1	2	1	2
Part 1: GSK525762 8 mg QD	0	1	0	1	0	0
Part 1: GSK525762 80 mg QD	9	10	2	11	9	5

Number of Participants With Increase in QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)-Part 1 QD

Electrocardiogram (ECG) measurements were done using an automated 12-lead ECG machine. QTc parameters were graded according to NCI-CTCAE version 4.0. Grade 0 (<450 milliseconds [msec]), Grade 1 (450-480 msec), Grade 2 (481-500 msec), Grade 3 (>=501 msec). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Number of participants with increase in QTcF at worst-case post Baseline is reported. (NCT01587703)
Timeframe: Median of 1.38 months of drug exposure

,,,,,,,

Intervention	Participants (Count of Participants)
	Any Grade increase	Increase to Grade 2	Increase to Grade 3
Part 1: GSK525762 100 mg QD	4	1	0
Part 1: GSK525762 16 mg QD	1	0	0
Part 1: GSK525762 2 mg QD	1	0	1
Part 1: GSK525762 30 mg QD	4	0	0
Part 1: GSK525762 4 mg QD	0	0	0
Part 1: GSK525762 60 mg QD	4	1	0
Part 1: GSK525762 8 mg QD	0	0	0
Part 1: GSK525762 80 mg QD	13	0	0

Number of Participants With Increase in QTcF-Besylate Sub-study

ECG measurements were done using 12-lead ECG machine that automatically calculated the heart rate and measured PR, QRS, QT and QTcF intervals. QTc parameters were graded according to NCI-CTCAE version 4.0. Grade 0 (<450 milliseconds [msec]), Grade 1 (450-480 msec), Grade 2 (481-500 msec), Grade 3 (>=501 msec). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Number of participants with increase in QTcF at worst-case post Baseline is reported. (NCT01587703)
Timeframe: Median of 1.87 months of drug exposure

Intervention	Participants (Count of Participants)
	Any Grade increase	Increase to Grade 2	Increase to Grade 3
80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes	2	0	0
80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes	0	0	0

Number of Participants With Increase in QTcF-Part 1 BID

ECG measurements were done using an automated 12-lead ECG machine. QTc parameters were graded according to NCI-CTCAE version 4.0. Grade 0 (<450 milliseconds [msec]), Grade 1 (450-480 msec), Grade 2 (481-500 msec), Grade 3 (>=501 msec). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Number of participants with increase in QTcF at worst-case post Baseline is reported. (NCT01587703)
Timeframe: Median of 1.41 months of drug exposure

Intervention	Participants (Count of Participants)
	Any Grade increase	Increase to Grade 2	Increase to Grade 3
Part 1: GSK525762 20 mg BID	3	3	0
Part 1: GSK525762 30 mg BID	4	0	0
Part 1: GSK525762 40 mg BID	2	0	0

Number of Participants With Increase in QTcF-Part 2

,,,,,

Intervention	Participants (Count of Participants)
	Any Grade increase	Increase to Grade 2	Increase to Grade 3
Participants With CRPC	6	0	0
Participants With ER+BC	2	2	0
Participants With GIST	0	0	0
Participants With NMC	1	0	1
Participants With SCLC	2	0	0
Participants With TNBC	1	0	0

Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID

Urine samples were collected for the analysis of following urine parameters: pH, glucose, protein, occult blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and Weeks 5,9,17 and discharge/progression

Intervention	Participants (Count of Participants)
	Glucose; Week 5;n=2,7,3	Glucose; Week 9;n=0,4,2	Glucose; disc/prog;n=0,6,1	Ketones; Week 5;n=2,7,3	Occult blood; Week 5;n=2,7,3	Occult blood; Week 9;n=0,4,2	Occult blood; disc/prog;n=0,6,1	pH; Week 5;n=2,7,3	pH; Week 9;n=0,4,2	pH; disc/prog;n=0,7,1	Protein; Week 5;n=2,7,3	Protein; Week 9;n=0,4,2	Protein; disc/prog;n=0,7,1	Erythrocytes; Week 5;n=1,5,1	Erythrocytes; Week 9;n=0,1,1	Specific gravity; Week 5;n=2,7,3	Specific gravity; Week 9;n=0,4,2	Specific gravity; disc/prog;n=0,7,1	Leukocytes; Week 5;n=1,5,1	Leukocytes; Week 9;n=0,1,1
Part 1: GSK525762 40 mg BID	1	0	0	0	0	0	0	2	1	1	1	0	1	1	1	2	1	0	1	1

Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID

Intervention	Participants (Count of Participants)
	Glucose; Week 5;n=2,7,3	Glucose; Week 9;n=0,4,2	Glucose; Week 17;n=0,2,0	Glucose; disc/prog;n=0,6,1	Ketones; Week 5;n=2,7,3	Ketones; Week 17;n=0,2,0	Occult blood; Week 5;n=2,7,3	Occult blood; Week 9;n=0,4,2	Occult blood; disc/prog;n=0,6,1	pH; Week 5;n=2,7,3	pH; Week 9;n=0,4,2	pH; Week 17;n=0,2,0	pH; disc/prog;n=0,7,1	Protein; Week 5;n=2,7,3	Protein; Week 9;n=0,4,2	Protein; Week 17;n=0,2,0	Protein; disc/prog;n=0,7,1	Erythrocytes; Week 5;n=1,5,1	Erythrocytes; Week 9;n=0,1,1	Erythrocytes; Week 17;n=0,1,0	Specific gravity; Week 5;n=2,7,3	Specific gravity; Week 9;n=0,4,2	Specific gravity; Week 17;n=0,2,0	Specific gravity; disc/prog;n=0,7,1	Leukocytes; Week 5;n=1,5,1	Leukocytes; Week 9;n=0,1,1	Leukocytes; Week 17;n=0,1,0
Part 1: GSK525762 30 mg BID	0	1	1	1	1	1	2	1	2	4	4	1	4	3	2	2	1	4	0	1	1	1	1	2	4	0	1

Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID

Intervention	Participants (Count of Participants)
	Glucose; Week 5;n=2,7,3	Ketones; Week 5;n=2,7,3	Occult blood; Week 5;n=2,7,3	pH; Week 5;n=2,7,3	Protein; Week 5;n=2,7,3	Erythrocytes; Week 5;n=1,5,1	Specific gravity; Week 5;n=2,7,3	Leukocytes; Week 5;n=1,5,1
Part 1: GSK525762 20 mg BID	0	0	0	2	0	1	2	0

Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study

Intervention	Participants (Count of Participants)
	Hyaline casts; Week5;n=1,1	Hyaline casts; Week9;n=2,1	Glucose; Week5;n=3,2	Glucose; Week9;n=4,1	Ketones; Week9;n=4,1	pH;Week5;n=3,2	pH;Week9;n=4,1	pH;disc/prog;n=2,2	Protein; Week5; n=3,2	Protein; Week9; n=4,1	Erythrocytes; Week9; n=4,1	Specific gravity; Week5; n=3,2	Specific gravity; Week9; n=4,1	Specific gravity; disc/prog; n=2,2	Leukocytes; Week5; n=3,1	Leukocytes; Week9; n=4,1
80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes	1	0	1	0	0	1	0	1	1	1	1	1	0	1	1	1

Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study

Intervention	Participants (Count of Participants)
	Hyaline casts; Week5;n=1,1	Hyaline casts; Week9;n=2,1	Hyaline casts; Week17;n=1,0	Hyaline casts; Week25;n=1,0	Glucose; Week5;n=3,2	Glucose; Week9;n=4,1	Glucose; Week17;n=2,0	Ketones; Week9;n=4,1	pH;Week5;n=3,2	pH;Week9;n=4,1	pH;Week17;n=2,0	pH;Week25;n=1,0	pH;disc/prog;n=2,2	Protein; Week5; n=3,2	Protein; Week9; n=4,1	Protein; Week17; n=2,0	Protein; Week25; n=1,0	Erythrocytes; Week9; n=4,1	Erythrocytes; Week17; n=2,0	Erythrocytes; Week25; n=1,0	Erythrocytes; disc/prog; n=1,0	Specific gravity; Week5; n=3,2	Specific gravity; Week9; n=4,1	Specific gravity; Week17; n=2,0	Specific gravity; Week25; n=1,0	Specific gravity; disc/prog; n=2,2	Leukocytes; Week5; n=3,1	Leukocytes; Week9; n=4,1	Leukocytes; Week17; n=2,0	Leukocytes; Week25; n=1,0	Leukocytes; disc/prog; n=1,0
80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes	1	1	1	1	1	1	1	1	3	3	2	1	2	3	3	2	1	2	1	1	1	1	2	1	1	0	3	4	1	1	1

Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD

Urine samples were collected for the analysis of following urine parameters: potential of hydrogen (pH), glucose, protein, occult blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and Weeks 5, 9, 17, 25, 33, 41, 49 and discharge/progression (disc/prog)

Intervention	Participants (Count of Participants)
	Glucose;Week 5; n=1,2,1,3,2,7,20,7	Glucose;Disc/Prog; n=0, 1, 0,1,0,3,17,2	Ketones;Week 5; n=1,2,1,3,2,7,20,7	Occult blood;Week 5; n=1,2,1,3,2,7,17,7	pH;Week 5; n=1, 2, 1, 3,2,7,20,7	pH;Week 9; n=1,1,0,1,1,3,12,5	pH;Week 25; n=0,1,0,0,0,0,3,1	Protein;Week 5; n=1, 2,1,3,2,7,20,7	Specific gravity;Week 5; n=1,2,1,3,2,7,20,7	Leukocytes;Week 5; n=1,2,1,2,2,6,11,6
Part 1: GSK525762 8 mg QD	0	0	0	0	0	0	0	0	0	0

Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD

Intervention	Participants (Count of Participants)
	Hyaline casts;Week 5; n=0,1,0,0,1,2,5,3	Glucose;Week 5; n=1,2,1,3,2,7,20,7	Glucose;Week 9; n=1, 1, 0, 1,1,3,12,5	Ketones;Week 5; n=1,2,1,3,2,7,20,7	Ketones;Week 9; n=1,1,0,1,1,3,12,5	Occult blood;Week 5; n=1,2,1,3,2,7,17,7	Occult blood;Week 9; n=1,1,0,1,1,3,11,5	pH;Week 5; n=1, 2, 1, 3,2,7,20,7	pH;Week 9; n=1,1,0,1,1,3,12,5	Protein;Week 5; n=1, 2,1,3,2,7,20,7	Protein;Week 9; n=1,1,0,1,1,3,12,5	Specific gravity;Week 5; n=1,2,1,3,2,7,20,7	Specific gravity;Week 9; n=1,1,0,1,1,3,12,5	Leukocytes;Week 5; n=1,2,1,2,2,6,11,6	Leukocytes;Week 9; n=1,1,0,1,1,1,6,4
Part 1: GSK525762 30 mg QD	0	0	0	0	0	2	0	0	0	0	0	2	0	1	1

Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD

Intervention	Participants (Count of Participants)
	Glucose;Week 5; n=1,2,1,3,2,7,20,7	Glucose;Week 9; n=1, 1, 0, 1,1,3,12,5	Glucose;Disc/Prog; n=0, 1, 0,1,0,3,17,2	Ketones;Week 5; n=1,2,1,3,2,7,20,7	Ketones;Week 9; n=1,1,0,1,1,3,12,5	Occult blood;Week 5; n=1,2,1,3,2,7,17,7	Occult blood;Week 9; n=1,1,0,1,1,3,11,5	pH;Week 5; n=1, 2, 1, 3,2,7,20,7	pH;Week 9; n=1,1,0,1,1,3,12,5	pH;Week 25; n=0,1,0,0,0,0,3,1	Protein;Week 5; n=1, 2,1,3,2,7,20,7	Protein;Week 9; n=1,1,0,1,1,3,12,5	Specific gravity;Week 5; n=1,2,1,3,2,7,20,7	Specific gravity;Week 9; n=1,1,0,1,1,3,12,5	Leukocytes;Week 5; n=1,2,1,2,2,6,11,6	Leukocytes;Week 9; n=1,1,0,1,1,1,6,4
Part 1: GSK525762 2 mg QD	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0

Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD

Intervention	Participants (Count of Participants)
	Glucose;Week 5; n=1,2,1,3,2,7,20,7	Glucose;Week 9; n=1, 1, 0, 1,1,3,12,5	Glucose;Disc/Prog; n=0, 1, 0,1,0,3,17,2	Ketones;Week 5; n=1,2,1,3,2,7,20,7	Ketones;Week 9; n=1,1,0,1,1,3,12,5	Occult blood;Week 5; n=1,2,1,3,2,7,17,7	Occult blood;Week 9; n=1,1,0,1,1,3,11,5	Occult blood;Disc/Prog; n=0,1,0,1,0,3,17,2	pH;Week 5; n=1, 2, 1, 3,2,7,20,7	pH;Week 9; n=1,1,0,1,1,3,12,5	pH;Week 25; n=0,1,0,0,0,0,3,1	pH;Disc/Prog; n=0,1,0,1,0,3,17,2	Protein;Week 5; n=1, 2,1,3,2,7,20,7	Protein;Week 9; n=1,1,0,1,1,3,12,5	Protein;Disc/Prog; n=0,1,0,1,0,3,17,2	Specific gravity;Week 5; n=1,2,1,3,2,7,20,7	Specific gravity;Week 9; n=1,1,0,1,1,3,12,5	Specific gravity;Disc/Prog; n=0,1,0,1,0,3,16,2	Leukocytes;Week 5; n=1,2,1,2,2,6,11,6	Leukocytes;Week 9; n=1,1,0,1,1,1,6,4	Leukocytes;Disc/Prog; n=0,1,0,1,0,2,6,1
Part 1: GSK525762 16 mg QD	0	0	1	0	0	1	0	0	1	1	0	0	0	0	0	2	0	1	0	0	0

Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD

Intervention	Participants (Count of Participants)
	Cellular casts; Week 9; n=0,0, 0, 0, 0,1,4,1	Cellular casts; Disc/Prog; n=0,0,0,0,0,1,5,1	Hyaline casts;Week 5; n=0,1,0,0,1,2,5,3	Hyaline casts;Week 9; n=0,1,0, 0,0,1,5,3	Glucose;Week 5; n=1,2,1,3,2,7,20,7	Glucose;Week 9; n=1, 1, 0, 1,1,3,12,5	Glucose;Disc/Prog; n=0, 1, 0,1,0,3,17,2	Ketones;Week 5; n=1,2,1,3,2,7,20,7	Ketones;Week 9; n=1,1,0,1,1,3,12,5	Occult blood;Week 5; n=1,2,1,3,2,7,17,7	Occult blood;Week 9; n=1,1,0,1,1,3,11,5	Occult blood;Disc/Prog; n=0,1,0,1,0,3,17,2	pH;Week 5; n=1, 2, 1, 3,2,7,20,7	pH;Week 9; n=1,1,0,1,1,3,12,5	pH;Disc/Prog; n=0,1,0,1,0,3,17,2	Protein;Week 5; n=1, 2,1,3,2,7,20,7	Protein;Week 9; n=1,1,0,1,1,3,12,5	Protein;Disc/Prog; n=0,1,0,1,0,3,17,2	Specific gravity;Week 5; n=1,2,1,3,2,7,20,7	Specific gravity;Week 9; n=1,1,0,1,1,3,12,5	Specific gravity;Disc/Prog; n=0,1,0,1,0,3,16,2	Leukocytes;Week 5; n=1,2,1,2,2,6,11,6	Leukocytes;Week 9; n=1,1,0,1,1,1,6,4	Leukocytes;Disc/Prog; n=0,1,0,1,0,2,6,1
Part 1: GSK525762 60 mg QD	0	0	0	0	0	0	0	0	0	0	0	0	5	2	1	3	1	0	5	2	1	2	0	0

Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD

Intervention	Participants (Count of Participants)
	Cellular casts; Week 9; n=0,0, 0, 0, 0,1,4,1	Cellular casts; Disc/Prog; n=0,0,0,0,0,1,5,1	Hyaline casts;Week 5; n=0,1,0,0,1,2,5,3	Hyaline casts;Week 9; n=0,1,0, 0,0,1,5,3	Glucose;Week 5; n=1,2,1,3,2,7,20,7	Glucose;Week 9; n=1, 1, 0, 1,1,3,12,5	Glucose;Week 25; n=0,1,0,0,0,0,3,1	Glucose;Disc/Prog; n=0, 1, 0,1,0,3,17,2	Ketones;Week 5; n=1,2,1,3,2,7,20,7	Ketones;Week 9; n=1,1,0,1,1,3,12,5	Occult blood;Week 5; n=1,2,1,3,2,7,17,7	Occult blood;Week 9; n=1,1,0,1,1,3,11,5	Occult blood;Week 17; n=0, 1,0,0,0,0,5,3	Occult blood;Week 25; n=0,1,0,0,0,0,3,1	Occult blood;Disc/Prog; n=0,1,0,1,0,3,17,2	pH;Week 5; n=1, 2, 1, 3,2,7,20,7	pH;Week 9; n=1,1,0,1,1,3,12,5	pH;Week 25; n=0,1,0,0,0,0,3,1	pH;Disc/Prog; n=0,1,0,1,0,3,17,2	Protein;Week 5; n=1, 2,1,3,2,7,20,7	Protein;Week 9; n=1,1,0,1,1,3,12,5	Protein;Week 17; n=0,1,0,0,0,0,5,3	Protein;Week 25; n=0,1,0,0,0,0,3,1	Protein;Disc/Prog; n=0,1,0,1,0,3,17,2	Specific gravity;Week 5; n=1,2,1,3,2,7,20,7	Specific gravity;Week 9; n=1,1,0,1,1,3,12,5	Specific gravity;Week 17; n=0,1,0,0,0,0,5,3	Specific gravity;Week 25; n=0,1,0,0,0,0,3,1	Specific gravity;Disc/Prog; n=0,1,0,1,0,3,16,2	Leukocytes;Week 5; n=1,2,1,2,2,6,11,6	Leukocytes;Week 9; n=1,1,0,1,1,1,6,4	Leukocytes;Week 17; n=0,1,0,0,0,0,1,2	Leukocytes;Disc/Prog; n=0,1,0,1,0,2,6,1
Part 1: GSK525762 100 mg QD	1	0	1	1	2	1	1	0	1	0	0	0	0	0	0	3	2	1	1	4	3	0	0	1	5	4	2	0	1	2	1	0	1

Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD

Intervention	Participants (Count of Participants)
	Hyaline casts;Week 5; n=0,1,0,0,1,2,5,3	Hyaline casts;Week 9; n=0,1,0, 0,0,1,5,3	Glucose;Week 5; n=1,2,1,3,2,7,20,7	Glucose;Week 9; n=1, 1, 0, 1,1,3,12,5	Glucose;Week 25; n=0,1,0,0,0,0,3,1	Glucose;Disc/Prog; n=0, 1, 0,1,0,3,17,2	Ketones;Week 5; n=1,2,1,3,2,7,20,7	Ketones;Week 9; n=1,1,0,1,1,3,12,5	Occult blood;Week 5; n=1,2,1,3,2,7,17,7	Occult blood;Week 9; n=1,1,0,1,1,3,11,5	Occult blood;Week 17; n=0, 1,0,0,0,0,5,3	Occult blood;Week 25; n=0,1,0,0,0,0,3,1	Occult blood;Week 33; n=0,1,0,0,0,0,2,0	Occult blood;Disc/Prog; n=0,1,0,1,0,3,17,2	pH;Week 5; n=1, 2, 1, 3,2,7,20,7	pH;Week 9; n=1,1,0,1,1,3,12,5	pH;Week 25; n=0,1,0,0,0,0,3,1	pH;Week 33; n=0,1,0,0,0,0,2,0	pH;Disc/Prog; n=0,1,0,1,0,3,17,2	Protein;Week 5; n=1, 2,1,3,2,7,20,7	Protein;Week 9; n=1,1,0,1,1,3,12,5	Protein;Week 17; n=0,1,0,0,0,0,5,3	Protein;Week 25; n=0,1,0,0,0,0,3,1	Protein;Disc/Prog; n=0,1,0,1,0,3,17,2	Specific gravity;Week 5; n=1,2,1,3,2,7,20,7	Specific gravity;Week 9; n=1,1,0,1,1,3,12,5	Specific gravity;Week 17; n=0,1,0,0,0,0,5,3	Specific gravity;Week 25; n=0,1,0,0,0,0,3,1	Specific gravity;Week 33; n=0,1,0,0,0,0,2,0	Specific gravity;Disc/Prog; n=0,1,0,1,0,3,16,2	Leukocytes;Week 5; n=1,2,1,2,2,6,11,6	Leukocytes;Week 9; n=1,1,0,1,1,1,6,4	Leukocytes;Week 17; n=0,1,0,0,0,0,1,2	Leukocytes;Disc/Prog; n=0,1,0,1,0,2,6,1
Part 1: GSK525762 4 mg QD	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	0	1	0	0	0	1	0	1	1	1	1	0	0	0	0

Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD

Intervention	Participants (Count of Participants)
	Cellular casts; Week 9; n=0,0, 0, 0, 0,1,4,1	Cellular casts; Week 17; n=0,0, 0, 0, 0,0,1,0	Cellular casts; Disc/Prog; n=0,0,0,0,0,1,5,1	Hyaline casts;Week 5; n=0,1,0,0,1,2,5,3	Hyaline casts;Week 9; n=0,1,0, 0,0,1,5,3	Glucose;Week 5; n=1,2,1,3,2,7,20,7	Glucose;Week 9; n=1, 1, 0, 1,1,3,12,5	Glucose;Week 25; n=0,1,0,0,0,0,3,1	Glucose;Disc/Prog; n=0, 1, 0,1,0,3,17,2	Ketones;Week 5; n=1,2,1,3,2,7,20,7	Ketones;Week 9; n=1,1,0,1,1,3,12,5	Occult blood;Week 5; n=1,2,1,3,2,7,17,7	Occult blood;Week 9; n=1,1,0,1,1,3,11,5	Occult blood;Week 17; n=0, 1,0,0,0,0,5,3	Occult blood;Week 25; n=0,1,0,0,0,0,3,1	Occult blood;Week 33; n=0,1,0,0,0,0,2,0	Occult blood;Disc/Prog; n=0,1,0,1,0,3,17,2	pH;Week 5; n=1, 2, 1, 3,2,7,20,7	pH;Week 9; n=1,1,0,1,1,3,12,5	pH;Week 25; n=0,1,0,0,0,0,3,1	pH;Week 33; n=0,1,0,0,0,0,2,0	pH;Disc/Prog; n=0,1,0,1,0,3,17,2	Protein;Week 5; n=1, 2,1,3,2,7,20,7	Protein;Week 9; n=1,1,0,1,1,3,12,5	Protein;Week 17; n=0,1,0,0,0,0,5,3	Protein;Week 25; n=0,1,0,0,0,0,3,1	Protein;Disc/Prog; n=0,1,0,1,0,3,17,2	Specific gravity;Week 5; n=1,2,1,3,2,7,20,7	Specific gravity;Week 9; n=1,1,0,1,1,3,12,5	Specific gravity;Week 17; n=0,1,0,0,0,0,5,3	Specific gravity;Week 25; n=0,1,0,0,0,0,3,1	Specific gravity;Week 33; n=0,1,0,0,0,0,2,0	Specific gravity;Disc/Prog; n=0,1,0,1,0,3,16,2	Specific gravity;Week 41; n=0,0,0,0,0,0,1,0	Specific gravity;Week 49; n=0,0,0,0,0,0,1,0	Leukocytes;Week 5; n=1,2,1,2,2,6,11,6	Leukocytes;Week 9; n=1,1,0,1,1,1,6,4	Leukocytes;Week 17; n=0,1,0,0,0,0,1,2	Leukocytes;Disc/Prog; n=0,1,0,1,0,2,6,1
Part 1: GSK525762 80 mg QD	1	1	1	2	0	4	1	0	1	2	2	2	3	1	1	1	2	6	8	1	0	9	9	7	1	1	5	7	6	4	1	1	6	1	1	4	3	1	4

Number of Participants With Maximum Urinalysis Change From Baseline-Part 2

Urine samples were collected for the analysis of following urine parameters: pH, glucose, protein, blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1), Weeks 5,9,13,25,37, 49, 73, 85 and discharge/progression

Intervention	Participants (Count of Participants)
	Granular cast;disc/prog;n=1,2,6,3,4,0	Hyaline cast;Week9;n=0,0,1,2,1,1	Glucose;Week 5;n=8,7,18,12,14,8	Glucose;Week9;n=8,3,12,3,6,5	Glucose;Week13;n=7,2,6,1,2,2	Glucose;disc/prog;n=3,6,16,12,12,5	Ketones;Week5;n=8,7,18,12,14,8	Ketones;Week9;n=8,3,12,3,6,5	Ketones;disc/prog;n=3,6,16,12,12,5	Occult blood;Week5;n=8,7,18,12,14,8	Occult blood;Week9;n=8,3,12,3,6,5	Occult blood;Week13;n=7,2,6,1,2,2	Occult blood;disc/prog;n=3,6,16,12,12,5	pH;Week5;n=8,7,18,12,14,8	pH;Week9;n=8,3,12,3,6,5	pH;Week13;n=7,2,6,1,2,2	pH;disc/prog;n=3,6,16,12,12,5	Protein;Week5;n=8,7,18,12,14,8	Protein;Week9;n=8,3,12,3,6,5	Protein;Week13;n=7,2,6,1,2,2	Protein;disc/prog;n=3,6,16,12,12,5	Erythrocytes;Week5;n=3,3,8,4,4,4	Erythrocytes;Week9;n=4,0,2,2,1,2	Erythrocytes;Week13;n=3,1,0,0,0,1	Erythrocytes;disc/prog;n=1,2,6,3,4,2	Specific gravity;Week5;n=8,7,18,12,14,8	Specific gravity;Week9;n=8,3,12,3,6,5	Specific gravity;Week13;n=7,2,6,1,2,2	Specific gravity;disc/prog;n=3,6,16,12,12,5	Leukocytes;Week5;n=3,3,8,4,4,4	Leukocytes;Week9;n=4,0,2,2,1,3	Leukocytes;Week13;n=3,1,0,0,0,1	Leukocytes;disc/prog;n=1,2,7,3,4,1
Part 2: Participants With GIST	0	1	1	0	0	0	0	0	0	0	0	0	0	3	2	1	2	6	3	0	2	2	1	0	0	2	3	1	1	4	3	0	1

Number of Participants With Maximum Urinalysis Change From Baseline-Part 2

Intervention	Participants (Count of Participants)
	Granular cast;Week5;n=0,2,2,1,3,0	Granular cast;disc/prog;n=1,2,6,3,4,0	Hyaline cast;Week5;n=1,2,2,2,4,0	Hyaline cast;Week13;n=1,1,0,0,0,0	Hyaline cast;disc/prog;n=1,2,6,3,4,0	Glucose;Week 5;n=8,7,18,12,14,8	Glucose;Week9;n=8,3,12,3,6,5	Glucose;Week13;n=7,2,6,1,2,2	Glucose;disc/prog;n=3,6,16,12,12,5	Ketones;Week5;n=8,7,18,12,14,8	Ketones;Week9;n=8,3,12,3,6,5	Ketones;disc/prog;n=3,6,16,12,12,5	Occult blood;Week5;n=8,7,18,12,14,8	Occult blood;Week9;n=8,3,12,3,6,5	Occult blood;Week13;n=7,2,6,1,2,2	Occult blood;disc/prog;n=3,6,16,12,12,5	pH;Week5;n=8,7,18,12,14,8	pH;Week9;n=8,3,12,3,6,5	pH;Week13;n=7,2,6,1,2,2	pH;disc/prog;n=3,6,16,12,12,5	Protein;Week5;n=8,7,18,12,14,8	Protein;Week9;n=8,3,12,3,6,5	Protein;Week13;n=7,2,6,1,2,2	Protein;disc/prog;n=3,6,16,12,12,5	Erythrocytes;Week5;n=3,3,8,4,4,4	Erythrocytes;Week13;n=3,1,0,0,0,1	Erythrocytes;disc/prog;n=1,2,6,3,4,2	Specific gravity;Week5;n=8,7,18,12,14,8	Specific gravity;Week9;n=8,3,12,3,6,5	Specific gravity;Week13;n=7,2,6,1,2,2	Specific gravity;disc/prog;n=3,6,16,12,12,5	Leukocytes;Week5;n=3,3,8,4,4,4	Leukocytes;Week13;n=3,1,0,0,0,1	Leukocytes;disc/prog;n=1,2,7,3,4,1
Part 2: Participants With SCLC	0	0	0	1	0	2	1	1	0	1	1	1	0	1	0	0	3	1	1	2	1	2	1	1	0	1	0	4	1	1	2	1	0	1

Number of Participants With Maximum Urinalysis Change From Baseline-Part 2

Intervention	Participants (Count of Participants)
	Granular cast;Week5;n=0,2,2,1,3,0	Granular cast;disc/prog;n=1,2,6,3,4,0	Hyaline cast;Week5;n=1,2,2,2,4,0	Hyaline cast;Week9;n=0,0,1,2,1,1	Hyaline cast;disc/prog;n=1,2,6,3,4,0	Glucose;Week 5;n=8,7,18,12,14,8	Glucose;Week9;n=8,3,12,3,6,5	Glucose;Week13;n=7,2,6,1,2,2	Glucose;disc/prog;n=3,6,16,12,12,5	Ketones;Week5;n=8,7,18,12,14,8	Ketones;Week9;n=8,3,12,3,6,5	Ketones;disc/prog;n=3,6,16,12,12,5	Occult blood;Week5;n=8,7,18,12,14,8	Occult blood;Week9;n=8,3,12,3,6,5	Occult blood;Week13;n=7,2,6,1,2,2	Occult blood;disc/prog;n=3,6,16,12,12,5	pH;Week5;n=8,7,18,12,14,8	pH;Week9;n=8,3,12,3,6,5	pH;Week13;n=7,2,6,1,2,2	pH;disc/prog;n=3,6,16,12,12,5	Protein;Week5;n=8,7,18,12,14,8	Protein;Week9;n=8,3,12,3,6,5	Protein;Week13;n=7,2,6,1,2,2	Protein;disc/prog;n=3,6,16,12,12,5	Erythrocytes;Week5;n=3,3,8,4,4,4	Erythrocytes;Week9;n=4,0,2,2,1,2	Erythrocytes;disc/prog;n=1,2,6,3,4,2	Specific gravity;Week5;n=8,7,18,12,14,8	Specific gravity;Week9;n=8,3,12,3,6,5	Specific gravity;Week13;n=7,2,6,1,2,2	Specific gravity;disc/prog;n=3,6,16,12,12,5	Leukocytes;Week5;n=3,3,8,4,4,4	Leukocytes;Week9;n=4,0,2,2,1,3	Leukocytes;disc/prog;n=1,2,7,3,4,1
Part 2: Participants With ER+BC	1	0	1	0	0	0	0	0	1	1	0	1	0	0	0	0	6	4	0	5	5	0	0	3	3	1	2	7	5	0	5	4	0	3
Part 2: Participants With TNBC	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	3	2	1	6	3	0	0	2	2	1	1	5	2	0	3	3	1	3

Number of Participants With Maximum Urinalysis Change From Baseline-Part 2

Intervention	Participants (Count of Participants)
	Granular cast;Week5;n=0,2,2,1,3,0	Granular cast;disc/prog;n=1,2,6,3,4,0	Hyaline cast;Week5;n=1,2,2,2,4,0	Hyaline cast;Week9;n=0,0,1,2,1,1	Hyaline cast;disc/prog;n=1,2,6,3,4,0	Glucose;Week 5;n=8,7,18,12,14,8	Glucose;Week9;n=8,3,12,3,6,5	Glucose;Week13;n=7,2,6,1,2,2	Glucose;Week37;n=3,0,1,0,0,0	Glucose;Week49;n=1,0,1,0,0,0	Glucose;disc/prog;n=3,6,16,12,12,5	Ketones;Week5;n=8,7,18,12,14,8	Ketones;Week9;n=8,3,12,3,6,5	Ketones;disc/prog;n=3,6,16,12,12,5	Occult blood;Week5;n=8,7,18,12,14,8	Occult blood;Week9;n=8,3,12,3,6,5	Occult blood;Week13;n=7,2,6,1,2,2	Occult blood;Week25;n=2,0,3,0,0,0	Occult blood;Week37;n=3,0,1,0,0,0	Occult blood;disc/prog;n=3,6,16,12,12,5	pH;Week5;n=8,7,18,12,14,8	pH;Week9;n=8,3,12,3,6,5	pH;Week13;n=7,2,6,1,2,2	pH;Week25;n=2,0,3,0,0,0	pH;Week37;n=3,0,1,0,0,0	pH;Week49;n=1,0,1,0,0,0	pH;disc/prog;n=3,6,16,12,12,5	Protein;Week5;n=8,7,18,12,14,8	Protein;Week9;n=8,3,12,3,6,5	Protein;Week13;n=7,2,6,1,2,2	Protein;Week37;n=1,0,1,0,0,0	Protein;disc/prog;n=3,6,16,12,12,5	Erythrocytes;Week5;n=3,3,8,4,4,4	Erythrocytes;Week9;n=4,0,2,2,1,2	Erythrocytes;disc/prog;n=1,2,6,3,4,2	Specific gravity;Week5;n=8,7,18,12,14,8	Specific gravity;Week9;n=8,3,12,3,6,5	Specific gravity;Week13;n=7,2,6,1,2,2	Specific gravity;disc/prog;n=3,6,16,12,12,5	Leukocytes;Week5;n=3,3,8,4,4,4	Leukocytes;Week9;n=4,0,2,2,1,3	Leukocytes;Week25;n=2,0,1,0,0,0	Leukocytes;disc/prog;n=1,2,7,3,4,1
Part 2: Participants With CRPC	0	2	0	0	2	2	0	1	0	0	0	0	0	2	5	5	0	1	0	8	8	7	3	1	0	0	6	9	4	2	0	6	5	1	5	2	2	1	3	5	2	1	2

Number of Participants With Maximum Urinalysis Change From Baseline-Part 2

Intervention	Participants (Count of Participants)
	Granular cast;disc/prog;n=1,2,6,3,4,0	Hyaline cast;Week5;n=1,2,2,2,4,0	Hyaline cast;Week13;n=1,1,0,0,0,0	Hyaline cast;disc/prog;n=1,2,6,3,4,0	Glucose;Week 5;n=8,7,18,12,14,8	Glucose;Week9;n=8,3,12,3,6,5	Glucose;Week13;n=7,2,6,1,2,2	Glucose;Week37;n=3,0,1,0,0,0	Glucose;Week49;n=1,0,1,0,0,0	Glucose;Week73;n=1,0,0,0,0,0	Glucose;Week85;n=1,0,0,0,0,0	Glucose;disc/prog;n=3,6,16,12,12,5	Ketones;Week5;n=8,7,18,12,14,8	Ketones;Week9;n=8,3,12,3,6,5	Ketones;disc/prog;n=3,6,16,12,12,5	Occult blood;Week5;n=8,7,18,12,14,8	Occult blood;Week9;n=8,3,12,3,6,5	Occult blood;Week13;n=7,2,6,1,2,2	Occult blood;Week25;n=2,0,3,0,0,0	Occult blood;Week37;n=3,0,1,0,0,0	Occult blood;disc/prog;n=3,6,16,12,12,5	pH;Week5;n=8,7,18,12,14,8	pH;Week9;n=8,3,12,3,6,5	pH;Week13;n=7,2,6,1,2,2	pH;Week25;n=2,0,3,0,0,0	pH;Week37;n=3,0,1,0,0,0	pH;Week49;n=1,0,1,0,0,0	pH;Week73;n=1,0,0,0,0,0	pH;Week85;n=1,0,0,0,0,0	pH;disc/prog;n=3,6,16,12,12,5	Protein;Week5;n=8,7,18,12,14,8	Protein;Week9;n=8,3,12,3,6,5	Protein;Week13;n=7,2,6,1,2,2	Protein;Week37;n=1,0,1,0,0,0	Protein;disc/prog;n=3,6,16,12,12,5	Erythrocytes;Week5;n=3,3,8,4,4,4	Erythrocytes;Week9;n=4,0,2,2,1,2	Erythrocytes;Week13;n=3,1,0,0,0,1	Erythrocytes;disc/prog;n=1,2,6,3,4,2	Specific gravity;Week5;n=8,7,18,12,14,8	Specific gravity;Week9;n=8,3,12,3,6,5	Specific gravity;Week13;n=7,2,6,1,2,2	Specific gravity;disc/prog;n=3,6,16,12,12,5	Leukocytes;Week5;n=3,3,8,4,4,4	Leukocytes;Week9;n=4,0,2,2,1,3	Leukocytes;Week13;n=3,1,0,0,0,1	Leukocytes;Week25;n=2,0,1,0,0,0	Leukocytes;disc/prog;n=1,2,7,3,4,1
Part 2: Participants With NMC	0	1	0	0	1	2	2	1	1	1	1	0	0	0	0	1	0	1	0	1	0	6	5	2	1	3	1	1	1	1	1	3	3	1	1	2	2	3	0	4	2	2	0	1	0	1	0	0

Number of Participants With Non-serious AEs and SAEs-Besylate Sub-study

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the outcomes mentioned; events of possible study treatment-induced liver injury with hyperbilirubinemia; any new primary cancers; significant cardiac dysfunction; Grade 4 laboratory abnormalities; and drug related hepatobiliary event leading to permanent discontinuation of study treatment (NCT01587703)
Timeframe: Median of 1.87 months of drug exposure

Intervention	Participants (Count of Participants)
	Any non-serious AE	Any SAE
80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes	5	3
80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes	5	3

Tmax for GSK525762-Part 1 BID

Intervention	Hour (Median)
	Week1 AM dose;n=4,10,5	Week1 PM dose;n=4,9,5	Week3 AM dose;n=3,7,3	Week3 PM dose;n=3,6,3
Part 1: GSK525762 20 mg BID	1.5500	1.9583	1.1833	1.0000
Part 1: GSK525762 30 mg BID	0.9667	1.9667	1.0667	1.4500
Part 1: GSK525762 40 mg BID	0.5500	1.9833	0.5833	2.0667

Tmax for GSK525762-Part 1 QD

,,,,,,,

Intervention	Hours (Median)
	Week1;n=3,4,1,3,4,9,32,9	Week3;n=1,2,1,3,4,6,16,6
Part 1: GSK525762 100 mg QD	1.0000	1.5000
Part 1: GSK525762 16 mg QD	2.0167	1.0500
Part 1: GSK525762 2 mg QD	0.5833	1.0000
Part 1: GSK525762 30 mg QD	2.0083	0.9000
Part 1: GSK525762 4 mg QD	1.2250	2.5083
Part 1: GSK525762 60 mg QD	1.0000	1.0583
Part 1: GSK525762 8 mg QD	1.1000	0.5000
Part 1: GSK525762 80 mg QD	1.0000	0.5667

Volume of Distribution of GSK525762-Part 1 BID

Intervention	Liters (Geometric Mean)
	Week1 AM dose;n=3,10,5	Week1 PM dose;n=3,7,3	Week3 AM dose;n=3,7,3	Week3 PM dose;n=3,5,3
Part 1: GSK525762 20 mg BID	99.07	116.52	71.00	92.00
Part 1: GSK525762 30 mg BID	48.13	77.28	54.94	104.52
Part 1: GSK525762 40 mg BID	59.67	81.11	112.17	127.34

Volume of Distribution of GSK525762-Part 1 QD

,,,,,,,

Intervention	Liters (Geometric Mean)
	Week1;n=3,4,1,3,4,9,32,9	Week3;n=1,2,1,3,4,6,16,6
Part 1: GSK525762 100 mg QD	124.70	149.14
Part 1: GSK525762 16 mg QD	182.13	152.72
Part 1: GSK525762 2 mg QD	53.56	83.97
Part 1: GSK525762 30 mg QD	85.46	76.20
Part 1: GSK525762 4 mg QD	81.79	77.27
Part 1: GSK525762 60 mg QD	110.44	132.14
Part 1: GSK525762 8 mg QD	79.87	172.33
Part 1: GSK525762 80 mg QD	87.03	162.17

Number of Participants With Pathologic Complete Remission (pCR)

Histopathologic assessment of surgical resection to confirm Pathologoic Complete Remission. Complete remission defined as disappearance of all target lesions. (NCT00512096)
Timeframe: restaging with second and fourth 21-day cycles followed by surgery

Intervention	participants (Number)
Cisplatin + Ifosfamide + Paclitaxel	3

Reviews

11 reviews available for ifosfamide and Carcinoma, Epidermoid

Article	Year
Ifosfamide in the treatment of head and neck cancer. Oncology, 2003, Volume: 65 Suppl 2 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo	2003
[Clinical features of patients with metastasis in phalanges as first symptom of primary lung cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:7 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcino	2007
Chemotherapy of non-small cell lung cancer: a reappraisal and a look to the future. Cancer treatment reviews, 1983, Volume: 10, Issue:3 Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Sm	1983
New agents in non-small cell lung cancer. Cancer treatment reviews, 1984, Volume: 11, Issue:3 Topics: Adenocarcinoma; Adult; Alkylating Agents; Animals; Anthraquinones; Antibiotics, Antineoplastic; Anti	1984
Chemotherapy followed by radiotherapy versus radiotherapy alone in locally advanced cervical cancer: a randomized study. Gynecologic oncology, 1994, Volume: 54, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brachytherapy; Carcinoma, Sq	1994
Single-agent paclitaxel and paclitaxel plus ifosfamide in the treatment of head and neck cancer. Seminars in oncology, 1995, Volume: 22, Issue:3 Suppl 6 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials	1995
Treatment of pediatric malignant thymoma: long-term remission in a 14-year-old boy with EBV-associated thymic carcinoma by aggressive, combined modality treatment. Medical and pediatric oncology, 1996, Volume: 26, Issue:6 Topics: Adolescent; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytoge	1996
Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza. Seminars in oncology, 2000, Volume: 27, Issue:1 Suppl 1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,	2000
Paclitaxel (Taxol)/ifosfamide-based chemotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Seminars in oncology, 2000, Volume: 27, Issue:1 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Cl	2000
Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions. Seminars in oncology, 2000, Volume: 27, Issue:4 Suppl 8 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Gemcitabine; Head and Nec	2000
Neoadjuvant therapy for cervical cancer. Seminars in oncology, 1992, Volume: 19, Issue:1 Suppl 2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell;	1992

Trials

68 trials available for ifosfamide and Carcinoma, Epidermoid

Article	Year
Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy. BMC cancer, 2017, Jun-28, Volume: 17, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carc	2017
Treatment of base of tongue cancer with paclitaxel, ifosfamide, and cisplatinum induction chemotherapy followed by chemoradiotherapy. The Laryngoscope, 2008, Volume: 118, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di	2008
A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell ce Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuv	2009
Docetaxel, ifosfamide and cisplatin (DIP) in squamous cell carcinoma of the head and neck. Anticancer research, 2009, Volume: 29, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Case-Control	2009
Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-20, Volume: 28, Issue:24 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,	2010
Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-20, Volume: 28, Issue:24 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,	2010
Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-20, Volume: 28, Issue:24 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,	2010
Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-20, Volume: 28, Issue:24 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,	2010
Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-20, Volume: 28, Issue:24 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,	2010
Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-20, Volume: 28, Issue:24 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,	2010
Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-20, Volume: 28, Issue:24 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,	2010
Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-20, Volume: 28, Issue:24 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,	2010
Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-20, Volume: 28, Issue:24 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,	2010
Ifosfamide, paclitaxel, and carboplatin, a novel triplet regimen for advanced, recurrent, or persistent carcinoma of the cervix: a phase II trial. Gynecologic oncology, 2011, Volume: 120, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell;	2011
A study using ifosfamide and etoposide in patients with cisplatin-refractory recurrent or metastatic head and neck squamous cell carcinoma. Japanese journal of clinical oncology, 2011, Volume: 41, Issue:5 Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo	2011
Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcino	2012
Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer, 2002, Jul-15, Volume: 95, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino	2002
Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospe Lung cancer (Amsterdam, Netherlands), 2003, Volume: 39, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell;	2003
Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel. Lung cancer (Amsterdam, Netherlands), 2003, Volume: 39, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy	2003
Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer. British journal of cancer, 2003, Sep-15, Volume: 89, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma	2003
Preoperative mitomycin, ifosfamide, and cisplatin followed by esophagectomy in squamous cell carcinoma of the esophagus: pathologic complete response induced by chemotherapy leads to long-term survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Nov-01, Volume: 21, Issue:21 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co	2003
A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcino	2004
[Effect of neoadjuvant chemotherapy in the treatment of patients with stage IIIB cervical cancer]. Akusherstvo i ginekologiia, 2003, Volume: 42, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Chemothe	2003
Retrospective analysis of concurrent chemoradiation with the combination of bleomycin, ifosfamide and cisplatin (BIP) for uterine cervical cancer. The Tohoku journal of experimental medicine, 2004, Volume: 204, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carci	2004
Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: results of a phase II study. International journal of radiation oncology, biology, physics, 2005, Mar-01, Volume: 61, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell	2005
Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Por Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-20, Volume: 23, Issue:18 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Di	2005
[Neoadjuvant chemotherapy with intra-arterial infusion in the treatment of advanced cervical cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ch	2005
Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology, 2007, Volume: 69, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biop	2007
Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma. Investigational new drugs, 2008, Volume: 26, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di	2008
Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck. Journal of immunotherapy (Hagerstown, Md. : 1997), 2008, Volume: 31, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; CD4-CD8 Ratio	2008
Single-dose ifosfamide: efficacy studies in non-small cell lung cancer. Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1 Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cl	1982
Use and safety of high-dose ifosfamide. Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1 Topics: Adenocarcinoma; Aged; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cyc	1982
Chemotherapy of non-small cell lung cancer: a reappraisal and a look to the future. Cancer treatment reviews, 1983, Volume: 10, Issue:3 Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Sm	1983
New agents in non-small cell lung cancer. Cancer treatment reviews, 1984, Volume: 11, Issue:3 Topics: Adenocarcinoma; Adult; Alkylating Agents; Animals; Anthraquinones; Antibiotics, Antineoplastic; Anti	1984
Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer. European journal of cancer & clinical oncology, 1983, Volume: 19, Issue:2 Topics: Administration, Oral; Adult; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Therapy, Combina	1983
Phase I study of paclitaxel, cisplatin, and ifosfamide in patients with recurrent or metastatic squamous cell cancer of the head and neck. Seminars in oncology, 1995, Volume: 22, Issue:5 Suppl 12 Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcin	1995
Phase II trial of bleomycin, ifosfamide, and carboplatin in metastatic cervical cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carcinoma, Squa	1994
Chemotherapy followed by radiotherapy versus radiotherapy alone in locally advanced cervical cancer: a randomized study. Gynecologic oncology, 1994, Volume: 54, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brachytherapy; Carcinoma, Sq	1994
[Neoadjuvant radiochemotherapy in locally advanced non-small cell bronchial carcinoma. Initial results of a prospective multicenter study]. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1995, Volume: 171, Issue:7 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain; Carboplatin; Carcinoma, Bronc	1995
Cisplatin and ifosfamide in patients with advanced squamous cell carcinoma of the uterine cervix. A phase II trial. Acta oncologica (Stockholm, Sweden), 1995, Volume: 34, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe	1995
Cisplatin, 5-fluorouracil, and ifosfamide in the treatment of recurrent or advanced cervical cancer. Gynecologic oncology, 1995, Volume: 56, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel	1995
A phase II study of mitomycin, ifosfamide and cisplatin in operable and inoperable squamous cell carcinoma of the oesophagus. Clinical oncology (Royal College of Radiologists (Great Britain)), 1994, Volume: 6, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophagea	1994
A phase II study of ifosfamide, carboplatin and cisplatin in advanced and recurrent squamous cell carcinoma of the uterine cervix. Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell;	1993
Mitomycin, ifosfamide, and cisplatin in non-small cell lung cancer. Oncology, 1993, Volume: 50 Suppl 1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Non-Small-Cell	1993
Ifosfamide in advanced epidermoid head and neck cancer. Cancer chemotherapy and pharmacology, 1993, Volume: 31, Issue:4 Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Hea	1993
Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study. American journal of obstetrics and gynecology, 1993, Volume: 168, Issue:3 Pt 1 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Female; Humans; Ifosfamide; Mesna; Middle	1993
Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small lung cancer. Seminars in oncology, 1996, Volume: 23, Issue:2 Suppl 5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplasti	1996
A phase II study of ifosfamide in recurrent squamous cell carcinoma of the head and neck. American journal of clinical oncology, 1996, Volume: 19, Issue:4 Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Alkylating; Carcinoma, Squamous Cell; Female; H	1996
Combination chemotherapy with vindesine-ifosfamide-cisplatin (VIP) in locally advanced unresectable stage III and in stage IV non-small cell lung cancer: a phase II trial. Lung cancer (Amsterdam, Netherlands), 1995, Volume: 13, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell;	1995
Pilot study of ambulatory infusional delivery of a multidrug regimen: ifosfamide, carboplatin and etoposide (ICE). The Journal of infusional chemotherapy, 1996,Winter, Volume: 6, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anemia; Antineoplastic Combined Che	1996
Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer. Cancer chemotherapy and pharmacology, 1996, Volume: 38, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma,	1996
Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:1 Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ca	1997
Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer. The Journal of urology, 1997, Volume: 158, Issue:2 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic A	1997
[Combination chemotherapy with nedaplatin, bleomycin and ifosfamide for advanced cervical cancer of the uterus--a preliminary study for phase III clinical study]. Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:10 Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Carci	1997
Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 19 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr	1997
Ifosfamide in the treatment of advanced or recurrent squamous cell carcinoma of the head and neck: a phase II Hoosier Oncology Group trial. American journal of clinical oncology, 1998, Volume: 21, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Carcinoma, Squamous Cell; Female;	1998
Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:4 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carc	1998
Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Seminars in oncology, 1998, Volume: 25, Issue:2 Suppl 4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di	1998
A phase II trial of four courses of preoperative chemotherapy in squamous or anaplastic carcinoma of the oesophagus. Clinical oncology (Royal College of Radiologists (Great Britain)), 1998, Volume: 10, Issue:3 Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Al	1998
Neoadjuvant chemotherapy with cisplatin, ifosfamide and paclitaxel for locally advanced squamous-cell cervical cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,	1998
Phase II clinical trial of cisplatin, 5-fluorouracil, and ifosfamide as treatment for advanced locoregional head and neck carcinoma. American journal of clinical oncology, 1999, Volume: 22, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fl	1999
A brief intensive cisplatin-based outpatient chemotherapy regimen with filgrastim and megestrol acetate support for advanced non-small cell lung cancer: results of a phase II trial. Lung cancer (Amsterdam, Netherlands), 1998, Volume: 22, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite Stimulants; Ca	1998
Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy. Lung cancer (Amsterdam, Netherlands), 2000, Volume: 29, Issue:2 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro	2000
Neoadjuvant chemotherapy with ifosfamide, cisplatin, and vinorelbine in advanced squamous cell carcinoma of the cervix. American journal of clinical oncology, 2000, Volume: 23, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe	2000
Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer, 2001, Apr-01, Volume: 91, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell;	2001
Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Anti-cancer drugs, 2001, Volume: 12, Issue:3 Topics: Adult; Aged; Anemia; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,	2001
Ifosfamide, cisplatin, and 13-Cis retinoic acid for patients with advanced or recurrent squamous cell carcinoma of the head and neck: a phase I-II study. Cancer, 2001, Aug-15, Volume: 92, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe	2001
Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Apr-01, Volume: 20, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antine	2002
Protection against chemotherapy toxicity by IV hyperalimentation. Cancer treatment reports, 1978, Volume: 62, Issue:8 Topics: Bacterial Vaccines; Carcinoma, Squamous Cell; Doxorubicin; Evaluation Studies as Topic; Humans; Ifos	1978
Combination chemoimmunotherapy for extensive non-oat cell lung cancer. Cancer treatment reports, 1978, Volume: 62, Issue:7 Topics: Adenocarcinoma; Adult; Aged; Bacterial Vaccines; Body Weight; Carcinoma, Squamous Cell; Clinical Tri	1978
Experience with bleomycin, ifosfamide, and cisplatin in primary and recurrent cervical cancer. Seminars in oncology, 1992, Volume: 19, Issue:2 Suppl 5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carcinoma, Squamo	1992
Neoadjuvant therapy for cervical cancer. Seminars in oncology, 1992, Volume: 19, Issue:1 Suppl 2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell;	1992
Ifosfamide and mesna for the treatment of advanced squamous cell head and neck cancer. A GETLAC study. Oncology, 1991, Volume: 48, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Head	1991
Gynecologic Oncology Group experience with ifosfamide. Seminars in oncology, 1990, Volume: 17, Issue:2 Suppl 4 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy;	1990
Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma. A phase II randomized study with cisplatin and etoposide as the control arm. Cancer, 1990, Jun-15, Volume: 65, Issue:12 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce	1990
The role of ifosfamide in cervical cancer. Seminars in oncology, 1989, Volume: 16, Issue:1 Suppl 3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci	1989

Other Studies

98 other studies available for ifosfamide and Carcinoma, Epidermoid

Article	Year
Metastatic penile squamous cell carcinoma with dramatic response to combined checkpoint blockade with ipilimumab and nivolumab. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Squamous Cell; Cisplatin;	2021
Response to Combination Chemotherapy With Paclitaxel/Ifosfamide/Platinum Versus Paclitaxel/Platinum for Patients With Metastatic, Recurrent, or Persistent Carcinoma of the Uterine Cervix: A Retrospective Analysis. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2018, Volume: 28, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell;	2018
Neoadjuvant docetaxel, cisplatin and ifosfamide (ITP) combination chemotherapy for treating penile squamous cell carcinoma patients with terminal lymph node metastasis. BMC cancer, 2019, Jun-25, Volume: 19, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di	2019
Transrectal ultrasound and magnetic resonance imaging in the evaluation of tumor size following neoadjuvant chemotherapy for locally advanced cervical cancer. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology, 2013, Volume: 42, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel	2013
Robotic radical hysterectomy following neoadjuvant chemotherapy in FIGO stage IIIB cervical cancer: a case report. The international journal of medical robotics + computer assisted surgery : MRCAS, 2014, Volume: 10, Issue:1 Topics: Adult; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Hysterectomy; If	2014
ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy. Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carb	2013
[Efficacy of postoperative simple chemotherapy and concurrent chemoradiotherapy in FIGO stage IB2-IIB cervical cancer]. Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2013, Dec-18, Volume: 45, Issue:6 Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamou	2013
NUT midline carcinoma: an aggressive intrathoracic neoplasm. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013, Volume: 8, Issue:10 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Etoposid	2013
Neoadjuvant chemotherapy followed by robotic radical hysterectomy in locally advanced cervical cancer: a multi-institution study. Gynecologic oncology, 2014, Volume: 133, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel	2014
Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2015, Volume: 21, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cetuximab;	2015
Oncological and pregnancy outcomes after high-dose density neoadjuvant chemotherapy and fertility-sparing surgery in cervical cancer. Gynecologic oncology, 2014, Volume: 135, Issue:2 Topics: Abortion, Spontaneous; Adenocarcinoma; Adolescent; Adult; Antineoplastic Combined Chemotherapy Proto	2014
Long follow-up of patients with locally advanced cervical cancer treated with concomitant chemobrachyradiotherapy with cisplatin and ifosfamide followed by consolidation chemotherapy. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2015, Volume: 25, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell	2015
[Dramatic response of penile cancer with inguinal lymph node metastases to neoadjuvant chemotherapy with paclitaxel, ifosfamide and cisplatin : a case report]. Hinyokika kiyo. Acta urologica Japonica, 2015, Volume: 61, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci	2015
Efficacy and tolerability of paclitaxel, ifosfamide, and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical carcinoma. Journal of gynecologic oncology, 2015, Volume: 26, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di	2015
Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:8 Topics: Adenocarcinoma; Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Carb	2015
Neoadjuvant chemotherapy followed by large cone resection as fertility-sparing therapy in stage IB cervical cancer. Gynecologic oncology, 2015, Volume: 139, Issue:3 Topics: Abortion, Missed; Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin	2015
Expression of ERCC1 and TUBB3 in locally advanced cervical squamous cell cancer and its correlation with different therapeutic regimens. The International journal of biological markers, 2015, Jul-22, Volume: 30, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brac	2015
Feasibility of robotic radical hysterectomy after neoadjuvant chemotherapy in women with locally advanced cervical cancer. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2016, Volume: 42, Issue:9 Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis	2016
Retrospective analysis of surgical resection after induction chemotherapy for patients with T4b squamous cell head and neck cancer. Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell;	2008
Neoadjuvant chemotherapy and conservative surgery for stage IB1 cervical cancer. Gynecologic oncology, 2008, Volume: 111, Issue:3 Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che	2008
Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Apr-20, Volume: 27, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,	2009
A retrospective study of patients with locally advanced cancer of the cervix treated with neoadjuvant chemotherapy followed by radical surgery. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2009, Volume: 19, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou	2009
Primary squamous cell carcinoma of the breast: achieving long-term control with cisplatin-based chemotherapy. Clinical breast cancer, 2009, Volume: 9, Issue:3 Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Combined Modalit	2009
Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma. Cancer prevention research (Philadelphia, Pa.), 2009, Volume: 2, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Case-Control	2009
Type II radical hysterectomy and adjuvant therapy for pelvic lymph node metastasis with stage IB-IIB cervical carcinoma: a retrospective study of 288 patients. Journal of surgical oncology, 2011, Volume: 104, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brachytherapy; Carcinoma, Sq	2011
Neoadjuvant chemotherapy for locally advanced cervical cancer reduces surgical risks and lymph-vascular space involvement. Chinese journal of cancer, 2011, Volume: 30, Issue:9 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplati	2011
The anti-tumour effect of cisplatin and ifosfamide on xenografted squamous cell carcinoma of the head and neck is schedule-dependent. Oral oncology, 2012, Volume: 48, Issue:1 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carcinoma, Squamous Cell; Cisplat	2012
Clinical evaluation of neoadjuvant chemotherapy followed by radical surgery in the management of stage IB2-IIB cervical cancer. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2012, Volume: 117, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, S	2012
The clinical characteristic differences between thrombosis-related edema and lymphedema following radiotherapy or chemoradiotherapy for patients with cervical cancer. Journal of radiation research, 2012, Volume: 53, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy	2012
The effect of chemotherapy or radiotherapy on thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in cancer of the uterine cervix. European journal of obstetrics, gynecology, and reproductive biology, 2012, Volume: 163, Issue:1 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Chemoradiother	2012
Laparoscopic lymph node dissection should be performed before fertility preserving treatment of patients with cervical cancer. Gynecologic oncology, 2012, Volume: 126, Issue:3 Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squ	2012
Ifosfamide and doxorubicin combination chemotherapy for recurrent nasopharyngeal carcinoma patients. Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:5 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamo	2012
Surgical outcomes of robotic radical hysterectomy after neoadjuvant chemotherapy for locally advanced cervical cancer: comparison with early stage disease. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2013, Volume: 39, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom	2013
Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer, 2003, Mar-15, Volume: 97, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Clinical Tria	2003
Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology, 2003, Nov-11, Volume: 61, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug-Related Si	2003
Long-lasting complete remission of a patient with cervical cancer FIGO IVB treated by concomitant chemobrachyradiotherapy with ifosfamide and cisplatin and consolidation chemotherapy--a case report. European journal of gynaecological oncology, 2004, Volume: 25, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin;	2004
[A case of oropharyngeal cancer with multiple bone metastases from prostate cancer that responded to docetaxel, ifosfamide and cisplatin combination therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisp	2005
Sarcomas of the head and neck. Results from the treatment of 25 patients. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2005, Volume: 31, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc	2005
[A case of thymic carcinoma responding to combination chemotherapy with nedaplatin, etoposide, and ifosfamide]. Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration	2005
Osteomalacia due to chemotherapy-induced Fanconi syndrome in an adult patient. Gynecologic oncology, 2005, Volume: 98, Issue:2 Topics: Carcinoma, Squamous Cell; Fanconi Syndrome; Female; Humans; Ifosfamide; Middle Aged; Osteomalacia; U	2005
[Evaluation of combined chemotherapy with vinorelbine, ifosfamide and cisplatin in the treatment of metastatic non-small cell bronchial carcinoma]. Revue des maladies respiratoires, 2005, Volume: 22, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcin	2005
Unexpected long-term survival without evidence of disease after salvage chemotherapy for recurrent metastatic cervical cancer: a case series. Gynecologic oncology, 2007, Volume: 105, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-	2007
Is frozen section analysis of pelvic lymph nodes accurate in locally advanced cervical cancer patients administered preoperative chemoradiation? Gynecologic oncology, 2008, Volume: 108, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous	2008
[Chemotherapy of the non-small cell carcinoma of the lung with ifosfamide and cisplatin]. Deutsche medizinische Wochenschrift (1946), 1984, Jul-06, Volume: 109, Issue:27 Topics: Adenocarcinoma; Adult; Aged; Alopecia; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; C	1984
Pilot study of intravenous ifosfamide plus oral acetylcysteine in the treatment of non-small cell lung cancer. Veterinary and human toxicology, 1981, Volume: 23, Issue:Suppl 1 Topics: Acetylcysteine; Adenocarcinoma; Administration, Oral; Carcinoma; Carcinoma, Small Cell; Carcinoma, S	1981
Ifosfamide in the treatment of extensive non-oat cell carcinoma of the lung. Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1 Topics: Adenocarcinoma; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Administrati	1982
[Efficacy of sequential chemotherapy including vincristine, cisplatin and ifosfamide in the treatment of stage IV head and neck carcinomas and melanomas with visceral involvement. Preliminary results]. Bulletin du cancer, 1984, Volume: 71, Issue:2 Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamou	1984
Phase II chemotherapy trials of 5-FU, cyclophosphamide, ifosfamide, and vincristine in carcinoma of the bilharzial bladder. Cancer treatment reports, 1984, Volume: 68, Issue:2 Topics: Carcinoma, Squamous Cell; Cyclophosphamide; Drug Administration Schedule; Drug Evaluation; Fluoroura	1984
Phase I clinical study of acetylcysteine's preventing ifosfamide-induced hematuria. Seminars in oncology, 1983, Volume: 10, Issue:1 Suppl 1 Topics: Acetylcysteine; Acrolein; Adenocarcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Cystitis; Dose	1983
Prophylaxis of ifosfamide toxicity with oral acetylcysteine. Seminars in oncology, 1983, Volume: 10, Issue:1 Suppl 1 Topics: Acetylcysteine; Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Dose-Response Rela	1983
[Combined cytostatic chemotherapy of advanced non-small-cell bronchial carcinoma with doxorubicin and ifosfamide]. Deutsche medizinische Wochenschrift (1946), 1983, May-27, Volume: 108, Issue:21 Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cyclophos	1983
[Clinical studies of ifosfamide for gynecological malignancies]. Gan to kagaku ryoho. Cancer & chemotherapy, 1983, Volume: 10, Issue:5 Topics: Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Evaluation; Female; Humans; I	1983
Serum zinc levels in lung cancer patients. Cancer, 1981, Apr-01, Volume: 47, Issue:7 Topics: Adult; Aged; Bacterial Vaccines; Carcinoma, Squamous Cell; Copper; Doxorubicin; Humans; Ifosfamide;	1981
Bleomycin, cisplatinum and ifosfamide infusion chemotherapy in advanced/recurrent cancer of cervix. Indian journal of cancer, 1993, Volume: 30, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci	1993
Methylene blue for ifosfamide-associated encephalopathy. The New England journal of medicine, 1995, May-04, Volume: 332, Issue:18 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Carcinoma, Squamous Cell; Cisp	1995
[Epileptic seizures and treatment with ifosfamide-mesna]. Revue neurologique, 1994, Volume: 150, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Epilepsy; Fatal Outcome; H	1994
Effects of chemotherapy on ultrastructure of oesophageal squamous cell carcinoma. Histopathology, 1994, Volume: 25, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous	1994
Histopathological findings in oesophageal carcinoma with and without preoperative chemotherapy. Journal of clinical pathology, 1993, Volume: 46, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc	1993
Lack of correlation of P-glycoprotein expression with response to MIC chemotherapy in oesophageal cancer. Journal of clinical pathology, 1995, Volume: 48, Issue:11 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Tr	1995
Lack of correlation of P-glycoprotein expression with response to MIC chemotherapy in oesophageal cancer. Journal of clinical pathology, 1997, Volume: 50, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Membe	1997
Combined effects of ionizing radiation and 4-hydroperoxyfosfamide in vitro. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1998, Volume: 46, Issue:3 Topics: Animals; Carcinoma, Squamous Cell; Cell Cycle; Cell Survival; Colonic Neoplasms; Combined Modality T	1998
[Neoadjuvant chemotherapy for advanced cervical cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou	1999
[Effect of combined carboplatin and ifosfamide with local hyperthermia on human mouth carcinoma in the animal model]. Mund-, Kiefer- und Gesichtschirurgie : MKG, 1999, Volume: 3 Suppl 1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Comb	1999
Tumor oxygenation after radiotherapy, chemotherapy, and/or hyperthermia predicts tumor free survival. International journal of radiation oncology, biology, physics, 2001, Mar-15, Volume: 49, Issue:4 Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dise	2001
A preclinical model for experimental chemotherapy of human head and neck cancer. International journal of oncology, 2001, Volume: 18, Issue:6 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Body Weight; Carboplatin;	2001
[The value of qualitative regression grading as a prognostic factor for survival after preoperative radiochemotherapy in patients with advanced head and neck cancer]. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2001, Volume: 177, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuv	2001
Ifosfamide in the treatment of recurrent or disseminated lung cancer: a phase II study of two dose schedules. Cancer, 1978, Volume: 41, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Bone Marrow; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cyclophos	1978
Combined chemotherapy using cisplatin, ifosfamide and bleomycin (PIB) in the treatment of advanced and recurrent cervical carcinoma. The Australian & New Zealand journal of obstetrics & gynaecology, 1992, Volume: 32, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, S	1992
Phase II study of cisplatin, ifosfamide with mesna, and etoposide (PIE) chemotherapy for advanced non-small cell lung cancer. Seminars in oncology, 1992, Volume: 19, Issue:1 Suppl 1 Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcin	1992
[Combination chemotherapy with 254-S, ifosfamide and peplomycin for advanced or recurrent cervical cancer]. Nihon Sanka Fujinka Gakkai zasshi, 1992, Volume: 44, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents;	1992
[Elderly non-Hodgkin's lymphoma presenting with pulmonary squamous cell carcinoma as a complication of chemotherapy for malignant lymphoma]. Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, 1992, Volume: 29, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cyclophosphamide; Hu	1992
The potential for adjuvant therapy in early-stage cervical cancer. Cancer chemotherapy and pharmacology, 1990, Volume: 26 Suppl Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; B	1990
Chemotherapy in recurrent and advanced cervical cancer. Gynecologic oncology, 1991, Volume: 40, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplati	1991
Ifosfamide with mesna in squamous carcinoma of the cervix: phase II results in patients with advanced or recurrent disease. Gynecologic oncology, 1991, Volume: 43, Issue:2 Topics: Adult; Aged; Carcinoma, Squamous Cell; Drug Evaluation; Drug Therapy, Combination; Female; Hematolog	1991
[Cisplatin, ifosfamide and vindesine in the chemotherapy of squamous cell carcinoma of the lung]. Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:13 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Squamous Cell; Cisplatin; Dr	1991
Ifosfamide and mesna at high doses for the treatment of cancer of the cervix: a GETLAC study. Cancer chemotherapy and pharmacology, 1990, Volume: 26 Suppl Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Humans; Ifo	1990
[Phase II study of ifosfamide and vindesine combination of non-small cell lung cancer in elderly patients and patients with reduced renal function]. Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:5 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung	1990
Cisplatin, ifosfamide and vindesine in the chemotherapy of non-small-cell lung cancer: a combination phase II study. Cancer chemotherapy and pharmacology, 1990, Volume: 26, Issue:5 Topics: Acute Kidney Injury; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Sma	1990
A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix. Cancer chemotherapy and pharmacology, 1990, Volume: 27, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr	1990
Cisplatin-ifosfamide as neoadjuvant chemotherapy in stage IIIB cervical uterine squamous-cell carcinoma. Cancer chemotherapy and pharmacology, 1990, Volume: 26 Suppl Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe	1990
A phase II study of ifosfamide in endometrial cancer. Cancer chemotherapy and pharmacology, 1990, Volume: 26 Suppl Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Drug Evaluation; Female; Humans; Ifosfamide;	1990
Ifosfamide, adriamycin and cisplatin (IAP) plus bleomycin (B) combination chemotherapy in patients with recurrent cancer of the uterine cervix. Nihon Sanka Fujinka Gakkai zasshi, 1989, Volume: 41, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, S	1989
Ifosfamide in advanced carcinoma of the esophagus: a phase II trial with severe toxicity. American journal of clinical oncology, 1989, Volume: 12, Issue:3 Topics: Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Evaluation; Esophageal Neoplasms; Femal	1989
Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix. A Gynecologic Oncology Group study. Investigational new drugs, 1989, Volume: 7, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Evaluati	1989
Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies. Seminars in oncology, 1989, Volume: 16, Issue:1 Suppl 3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Ci	1989
[The course of squamous cell carcinoma antigen and CEA as prognostic criteria for response to chemotherapy in cervix cancer]. Geburtshilfe und Frauenheilkunde, 1989, Volume: 49, Issue:12 Topics: Adenocarcinoma; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumo	1989
Etoposide, ifosfamide, and cisplatin in the treatment of advanced non-small cell lung cancer. Cancer treatment reports, 1987, Volume: 71, Issue:12 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce	1987
[Phase II study of a three-drug combination of ifosfamide, cisplatin and vindesine in non-small-cell lung cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 1988, Volume: 15, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce	1988
[Chemotherapy of non-small cell bronchial cancer with ifosfamide in combination with cisplatin, etoposide or vindesine]. Onkologie, 1988, Volume: 11 Suppl 2 Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun	1988
[Hepatotoxicity with etoposide-ifosfamide combination therapy]. Onkologie, 1988, Volume: 11, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Carcinoma, Squamous Cel	1988
Failure of response to ifosfamide in squamous cell bronchogenic carcinoma. Cancer chemotherapy and pharmacology, 1989, Volume: 23, Issue:2 Topics: Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Drug Resistance; Humans; Ifosfamide; Lung Neoplas	1989
[Treatment of non-small-cell bronchial carcinoma with cisplatin, ifosfamide, vindesine and VP 16]. Strahlentherapie, 1985, Volume: 161, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic	1985
[Chemotherapy with mitomycin C, vindesine and ifosfamide in the treatment of inoperable non-small cell bronchial carcinoma]. Onkologie, 1985, Volume: 8, Issue:4 Topics: Adenocarcinoma; Aged; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug	1985
Experience with ifosfamide combinations (etoposide or DDP) in non-small cell lung cancer. Cancer chemotherapy and pharmacology, 1986, Volume: 18 Suppl 2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell;	1986
Phase II study of ifosfamide in cervical cancer. Cancer treatment reports, 1986, Volume: 70, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Central Nervo	1986
Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpectant severe toxicity. Investigational new drugs, 1988, Volume: 6, Issue:3 Topics: Adult; Aged; Carcinoma, Squamous Cell; Drug Evaluation; Esophageal Neoplasms; Female; Hematologic Te	1988
Ifosfamide in advanced head and neck cancer. A phase II study of the Rotterdam Cooperative Head and Neck Cancer Study Group. European journal of cancer & clinical oncology, 1988, Volume: 24, Issue:4 Topics: Adult; Aged; Carcinoma, Squamous Cell; Drug Evaluation; Head and Neck Neoplasms; Humans; Ifosfamide;	1988
A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix. Cancer chemotherapy and pharmacology, 1986, Volume: 18, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Drug Evaluation; Female; Humans; Ifosfamide;	1986

chemdatabank.com

ifosfamide and Carcinoma, Epidermoid

Research Excerpts

Research

Studies (173)

Authors

Clinical Trials (8)

Trial Overview

Trial Outcomes

Apparent Terminal Phase Elimination Rate Constant (Lambda z) for GSK525762-Besylate Sub-study

Maximum Observed Concentration (Cmax) of GSK525762-Besylate Sub-study

Number of Participants With Dose Reductions or Delays-Besylate Sub-study

Number of Participants With Dose Reductions or Delays-Part 1 BID

Number of Participants With Dose Reductions or Delays-Part 1 QD

Number of Participants With Dose Reductions or Delays-Part 2

Number of Participants With Prostate Specific Antigen (PSA)50 Response-Part 1 QD

Number of Participants With PSA50 Response Rate-Part 1 BID

Number of Participants With PSA50 Response-Besylate Sub-study

Number of Participants With PSA50 Response-Part 2

Number of Participants Withdrawn Due to Toxicities-Besylate Sub-study

Number of Participants Withdrawn Due to Toxicities-Part 1 BID

Number of Participants Withdrawn Due to Toxicities-Part 1 QD

Number of Participants Withdrawn Due to Toxicities-Part 2

Overall Response Rate-Besylate Sub-study

Overall Response Rate-Part 1 BID

Overall Response Rate-Part 1 QD

Overall Response Rate-Part 2

Overall Survival-Besylate Sub-study

Overall Survival-Part 1 BID

Overall Survival-Part 1 QD

Overall Survival-Part 2

Progression Free Survival-Besylate Sub-study

Progression Free Survival-Part 1 BID

Progression Free Survival-Part 1 QD

Progression Free Survival-Part 2

Time to Reach Cmax (Tmax) for GSK525762-Besylate Sub-study

Apparent Clearance of GSK525762-Part 1 BID

Apparent Clearance of GSK525762-Part 1 QD

Area Under the Concentration-time Curve (AUC) From Time Zero to 24 Hours(AUC[0 to 24]); AUC From Time 0 to Last Quantifiable Concentration (AUC [0 to t]) and AUC Extrapolated to Infinity (AUC[0 to Inf]) of GSK525762-Besylate Sub-study

AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID

AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD

Lambda z for GSK525762-Part 1 BID

Lambda z for GSK525762-Part 1 QD

Maximum Observed Concentration for GSK525762-Part 1 QD

Maximum Observed Concentration of GSK525762-Part 1 BID

Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QD

Number of Participants With AEs and SAEs-Part 1 BID

Number of Participants With AEs and SAEs-Part 2

Number of Participants With Changes in Blood Pressure From Baseline-Part 2

Number of Participants With Changes in Pulse Rate From Baseline-Besylate Sub-study

Number of Participants With Changes in Pulse Rate From Baseline-Part 1 BID

Number of Participants With Changes in Pulse Rate From Baseline-Part 1 QD

Number of Participants With Changes in Pulse Rate From Baseline-Part 2

Number of Participants With Changes in Temperature From Baseline-Besylate Sub-study

Number of Participants With Changes in Temperature From Baseline-Part 1 BID

Number of Participants With Changes in Temperature From Baseline-Part 1 QD

Number of Participants With Changes in Temperature From Baseline-Part 2

Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study

Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study

Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID

Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD

Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD

Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD

Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD

Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2

Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study

Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID

Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD

Number of Participants With Grade Change From Baseline in Hematology Data-Part 2

Number of Participants With Increase in Blood Pressure From Baseline-Besylate Sub-study

Number of Participants With Increase in Blood Pressure From Baseline-Part 1 BID

Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD

Number of Participants With Increase in QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)-Part 1 QD

Number of Participants With Increase in QTcF-Besylate Sub-study

Number of Participants With Increase in QTcF-Part 1 BID

Number of Participants With Increase in QTcF-Part 2

Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID

Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID

Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID

Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study